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Abstract 
The incidence of type 1 diabetes (T1DM) is increasing annually and the 
disease pathophysiology remains to be completely understood. The current 
understanding suggests a complex interplay of genetic factors, environmental 
factors and the immune system that ultimately converge to cause selective 
destruction of the pancreatic beta cells. As part of this process immune cells 
(e.g. cytotoxic T-cells), infiltrate the islets and release pro-inflammatory 
cytokines (e.g. IL-1, TNF- and IFN-) which cause beta cell dysfunction and 
cell death. Increasing evidence suggests that there is an imbalance between 
the levels of pro-inflammatory and anti-inflammatory cytokines at the islet site 
in T1DM and this may contribute to beta cell death. Anti-inflammatory 
cytokines (e.g. IL-4, IL-13 and IL-10) are reported to be protective in certain 
animal models of the disease, but their roles in pancreatic beta cells have been 
less extensively studied.  
The work in this thesis primarily examines the pathway stimulated by the anti-
inflammatory cytokines IL-13 and IL-4 and its role in mediating the 
cytoprotectivity in beta cells. Particularly, we examine whether STAT6 is 
central to these protective effects.  
It was confirmed that STAT6 plays a crucial role in IL-4 and IL-13 mediated 
protection of beta cells against a range of cytotoxic stimuli (pro-inflammatory 
cytokines, palmitate and serum withdrawal). Additionally, It was shown that IL-
13 and IL-4 induce the upregulation of anti-apoptotic genes such as MCL1, 
BCLXL and SOCS1, in a STAT6 regulated manner in beta cells. Surprisingly, 
we observed the STAT6-dependent upregulation of a gene not previously 
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associated with this pathway, SIRPThis was further investigated as a 
regulator of beta cell viability and the results revealed that knockdown of 
SIRP resulted in beta cell apoptosis, implicating this protein as a novel 
regulator of beta cell viability.  
Taken together, this work shows that loss of STAT6 renders beta cells 
vulnerable to cell death and suggest that therapeutic targeting of this pathway 
may offer a potential treatment for T1DM.  
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1.0 Introduction 
1.1 Diabetes Mellitus 
The word “diabetes” was first used in 250 BC by a Greek physician, Aretaeus. 
Diabetes is a Greek word, which means 'syphon' because the disease usually 
causes fluid to drain from patients. In this context, Aretaeus noticed that the 
disease caused patients to pass excessive amounts of urine but It was not until 
1674 that Thomas Willis, personal physician to King Charles I, completed the 
term 'Diabetes Mellitus'; imbued with the Latin word “mellitus” meaning honey 
(Dean and McEntyre, 2004).  
Diabetes mellitus describes an assemblage of metabolic disorders arising from 
defects in the control of insulin secretion or in responses to the hormone 
causing hyperglycaemia (American Diabetes Association, 2010). Two distinct 
forms of the disease have been resolved and were initially accredited to a 
French scientist, Lancereaux, although this distinction was earlier recognised 
by a British scientist, called Harley (1866). In one of the subtypes, it was 
observed that patients were obese and in the other, patients were lean 
(Lancereaux, 1880). These have since been named type 1 (occurring in lean 
persons) and type 2 (typically in obese persons) diabetes mellitus. We know 
now that type 1 diabetes mellitus (T1DM) arises from a significant loss of 
insulin secretion requiring administration of exogenous insulin, whereas type 
2 diabetes mellitus (T2DM) is more prevalent and, arises from a complex 
combination of insufficient insulin secretion by beta cells and peripheral insulin 
resistance. T2DM in some individuals can be reversed by lifestyle changes 
such as exercise and reducing intake of glucose-rich meals, without a 
requirement for exogenous insulin. Recent findings suggest that the 
28 
 
classification of diabetes needs to be more complex although the vast majority 
of the pathology falls in these two broad groups (American Diabetes 
Association, 2010). Other forms of diabetes have been established and will be 
discussed later in the chapter. 
According to the World Health Organisation (WHO, 2016 global report on 
diabetes), an estimated 422 million adults were living with diabetes in 2014 
and the number is estimated to rise to 642 million by 2040. Diabetes UK 
estimates that approximately 4.7 million people live with diabetes in the UK 
(Diabetes, 2019) (https://www.diabetes.org.uk/about_us/news/new-stats-
people-living-with-diabetes). It is suggested that the increase in the global 
diabetes burden will mostly affect countries experiencing the economic 
transition from low to middle-income levels and that the prevalence is 
underreported in these settings (Yach et al., 2004). T2DM makes up 90% of 
all diabetes and type 1 diabetes mellitus with other forms of diabetes make up 
the remaining 10% (Zheng et al., 2017).  
1.1.1 Type 2 Diabetes Mellitus (T2DM) 
T2DM (formally referred to as non-insulin dependent diabetes mellitus) is the 
most common form of diabetes, and is usually associated with hyperglycaemia 
due to insulin resistance and may require insulin therapy as a last resort. 
Insulin resistance is defined as the inability of target tissues such as liver and 
muscle to respond appropriately to insulin stimulation (Freeman and Pennings, 
2018). The rise in the number of people with T2DM is largely attributed to the 
increase in the numbers of obese people worldwide including children and is 
suggested to be the main cause that is driving the increased incidence of 
T2DM. The disease is diagnosed using serological techniques in which either 
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random plasma glucose, fasting blood glucose or oral glucose tolerance tests 
are measured from blood samples. In these tests a random blood sample, a 
fasting blood sample (12h fasting) or blood sample after a 2h glucose 
challenge administered orally or intravenously, is used to measure blood 
glucose levels. Alternatively, glycated haemoglobin measurements can be 
used to indicate the average blood glucose over the previous three months. 
Glycated or glycosylated haemoglobin is formed by a non-enzymatic reaction 
between glucose and haemoglobin at the N-terminal valine of  either the beta 
chain or alpha chain of the haemoglobin molecule (Makris and Spanou, 2011). 
A random blood glucose test which detects ≥7mmol/L (normal values 5.6-
6.9mmol/L), a fasting blood glucose test of ≥7mmol/L or a 2h glucose tolerance 
test (following either oral or intravenous administration of 75g glucose) 
reporting values of ≥11.1mmol/L supports the diagnosis of diabetes (Kahn et 
al., 2014). Additionally, a glycated haemoglobin concentration ≥48mmol/mol 
(or ≥6.5%) may also indicate that an individual is diabetic, however this is not 
a strict rule since certain individuals from South East Asian or African 
background differ greatly in their values of glycated haemoglobin due to 
genetic factors enriched in these populations (Canadian Diabetes Association, 
2013).  
 The combined effects of insulin resistance in target tissues and beta cell 
dysfunction result in beta cells being unable to match the metabolic demand 
of the body for appropriate levels of insulin in response to rising blood glucose 
(Kahn et al., 2014). Beta cell dysfunction in T2DM follows from a plethora of 
factors, which include obesity, an individual’s genetic susceptibility and 
epigenetics, environmental factors and alterations within the immune system. 
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1.1.1.1 Lifestyle and obesity 
Obesity is said to be the most blamed factor responsible for insulin resistance 
but a combination of genetic, and environmental factors also play a role 
(Eguchi and Manabe, 2013). Obesity is a disease that can be defined as the 
excess accumulation of fat or adipose tissue leading to an increased in body 
weight (≥ 20% of the ideal weight) (Hruby and Hu, 2015). The body mass index 
(BMI) is commonly used to determine obesity in an individual; it is a ratio of the 
weight in kilograms and the square of the height in metres. An individual is 
classed obese if they have a BMI of ≥30kg/m2 (Ofei, 2005). Lifestyle factors 
that have been implicated in the development of obesity or overweight include 
excessive consumption of alcohol, physical inactivity, and high calorific intake. 
Nutritional factors or dietary risk factors for T2DM include processed foods, 
potatoes, trans-fatty acids, irregular eating habits, consumption of white rice, 
beverages with high sugar content and unsaturated fats (Ayala et al., 2008, 
McNaughton et al., 2008). On the contrary, brown rice, zinc, vitamin D, dietary 
fibre, dairy produce, vegetables, peanut butter and healthy food habits appear 
to reduce the risk of T2DM (Steyn et al., 2004). Being obese contributes about 
55% to the disease aetiology, although a proportion of lean people develop 
diabetes and many obese people do not. Currently, about 80-95% of white 
Europeans with type 2 diabetes are obese and clinical trial interventions to 
reduce obesity through weight loss or dieting and exercise can reverse 
diabetes (Franks, 2012, Lean et al., 2018, Steven et al., 2016). Obesity 
induces a chronic low-grade inflammation in tissues, which can lead to the 
increased release of adipokines and pro-inflammatory cytokines such as TNF-
 and IL-1. These cytokines affect lipid metabolism detrimentally leading to 
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an increase in circulating free fatty acids and a decrease in overall insulin 
sensitivity (Boden, 2008). 
Aside from these, an age-associated decrease in beta cell response, insulin 
sensitivity, and glucose intolerance have also been established (Karakelides 
et al., 2010). This age-association might be attributed to sarcopenia since older 
people tend to be less active (Kirkman et al., 2012). Additionally, there is 
decreased islet proliferation and increased sensitivity of beta cells to apoptosis 
with age due to an increase in the expression of the death receptor Fas 
(Maedler et al., 2006).  All of the above probably contribute to beta cell 
dysfunction and a reduction in beta cell mass. 
The emphasis on lifestyle cannot be overstated (Kolb and Martin, 2017), 
however, there are also genetic and environmental components that cumulate 
in the dysfunctional beta cells. For example, beta cell dysfunction has been 
suggested to be caused by glucolipotoxicity and amyloid deposition in the islet 
(Porte and Diabetes, 2001).  
1.1.1.2 Genetic and epigenetic factors associated with T2DM 
More than 175 genetic loci have been associated with T2DM most of which 
are highly linked to beta cell function (Grarup et al., 2014). It is estimated that 
an individual’s risk of developing diabetes (if one parent is diabetic) is 40% and 
this risk increases to 70% if both parents have T2DM (Ali, 2013). In support of 
this, twin studies have shown a concordance rate of 70% in monozygotic twins 
and 20-30% in dizygotic twins (Kaprio et al., 1992). Single-nucleotide 
polymorphisms (SNPs) in genes controlling insulin synthesis and secretion 
(such as transcription factor 7-like 2 (TCF7L2) which was discovered by 
linkage studies and GWAS) have been reported to increase the susceptibility 
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of an individual to T2DM. TCF7L2 is a transcription factor that influences Wnt 
signalling which is known to modulate proinsulin synthesis and glucose 
stimulated insulin secretion in beta cells (Zhou et al., 2014). Other genes 
associated with T2DM include peroxisome proliferator-activated receptor 
(PPARG), insulin receptor substrate 1 and 2 (IRS1 and IRS2), inwardly-
rectifying potassium voltage-gated channel subfamily J 11 (KCNJ11), hepatic 
nuclear factor 1 alpha (HNF1A),hepatocyte nuclear factor 1-beta (HNF1B) and 
hepatocyte nuclear factor 4 alpha (HNF4A) and Wolfram syndrome 1 (WFS1), 
fat-mass and obesity-associated gene (FTO) (Ali, 2013). Although these genes 
have been identified, not everyone with the susceptibility alleles develops 
diabetes and only about 20% of diabetes is linked directly to heritability (Prasad 
and Groop, 2015).  
T2DM risk can also be conveyed by epigenetic changes caused predominantly 
by environmental factors such as intrauterine malnutrition or intrauterine 
hyperglycaemia (Kwak and Park, 2016). Epigenetic changes refer to changes 
in gene function (upregulation or silencing of a gene) without nucleotide 
alterations usually due to methylation of specific bases, and histone 
modifications (Halban et al., 2014, Kwak and Park, 2016).  
 Evidence of epigenetic changes have been found in T2DM including in genes 
influencing beta cell function and survival such as peroxisome proliferator-
activated receptor gamma coactivator 1 alpha (PPARGC1), insulin (INS), 
pancreatic and duodenal homebox 1 (PDX1), suppressor of cytokine signalling 
2 (SOCS2), aristaless related homebox1 (ARX), and histone deacetylase 7 
(HDAC7) (Davegårdh et al., 2018). In a study using islets from individuals with 
T2DM, hyper DNA methylation of the insulin promoter negatively regulated the 
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INS gene expression and glucose stimulated insulin secretion compared to 
control donors (Yang et al., 2011). Similarly, islets from individuals with T2DM 
have been reported (Yang et al., 2012) to have methylation at CpG sites of the 
PDX1 promoter and enhancer regions which correlated with PDX1 expression. 
Pdx1 is a key transcription factor that is essential for beta cell development, 
function and survival. Loss of this transcription factor has been shown in pdx1 
null mice to cause pancreatic agenesis (Fujimoto and Polonsky, 2009).  
In some studies, researchers found differences in DNA methylation levels in 
the islet beta cells when compared to peripheral blood cells. Most of these 
studies could not be replicated in vitro by stimulating beta cells with high 
glucose (Yang et al., 2011, Yang et al., 2012), raising the question as to 
whether DNA methylation is a cause or consequence of hyperglycaemia. 
1.1.1.3 Environmental factors in T2DM 
It is now established that certain environmental factors can induce epigenetic 
changes linked to diseases, implying that the environmental effects interact to 
regulate cellular responses.  Exposure to land and air pollutants such as 
exhaust fumes and herbicides have been associated with up to a 20% 
increased risk of developing T2DM (Dendup et al., 2018). Many pollutants are 
lipophilic and thus obese individuals tend to store more toxic pollutants in their 
adipose tissue (Zeliger, 2013). An example of one such pollutant is atrazine 
(2-chloro-4-ethylamino-6-isopropylamino-1,3,5-triazine) a herbicide, which 
has been shown to promote mitochondrial dysfunction, insulin resistance and 
obesity (Murea et al., 2012). Atrazine was shown to change mitochondria 
structure and function by decreasing the oxygen consumption rate through the 
inhibition of a key mitochondria complex I & II enzymes (Lim et al., 2009). In 
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this same study, mice exposed to atrazine significantly gained visceral fat 
irrespective of whether or not they were on a high fat diet. Insulin resistance 
was induced in these mice through inhibition of the insulin-Akt signalling 
pathway (Lim et al., 2009).  In this context, a recent systematic review 
associated higher levels of walkability (a measure of how friendly an area is to 
walk) and green space with a lower risk of developing T2DM. This same review 
showed that increased levels of noise pollution and air pollution were 
associated with a greater risk of developing T2DM (Dendup et al., 2018).  
1.1.1.4 Immune system 
The involvement of the immune system in T2DM almost always comes as a 
complication arising from hyperglycaemia or obesity (Spranger et al., 2003). A 
number of studies have shown an increase in the levels of circulating TNF- 
in the blood of persons with T2DM compared to controls (Spranger et al., 2003, 
Chen et al., 2013). It has also been shown that increased glucose and TNF- 
have an additive effect by amplifying NF-kB activation and hence exacerbating 
inflammation through the generation of reactive oxygen species (Iwasaki et al., 
2007). Other cytokines that are dysregulated in T2DM include IL-1 and IL-6 
(Spranger et al., 2003). The increase in cytokine release seems to be a 
consequence of oxidative stress resulting from hyperglycaemia and the 
release of obesity-induced adipokines. This however, is more likely to be a 
consequence for the complications in the disease rather than being the main 
cause of the disease (Graves and Kayal, 2008).  
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1.1.2 Other forms of Diabetes 
1.1.2.1 Gestational diabetes 
Glucose intolerance can arise during pregnancy, in which case it is termed 
gestational diabetes and occurs in 5% of women during the second or third 
trimester of pregnancy. Although it resolves immediately after delivery in most 
cases, the development of gestational diabetes increases the risk of 
developing T2DM later in life, especially in obese women (Gilmartin et al., 
2008). Up to 40% of women who were diagnosed with gestational diabetes 
develop T2DM after 10years of follow-up (Kaaja and Rönnemaa, 2008).  The 
disease may stem from a variety of factors such as increases in placental 
lactogen secretion, insulin secretion, and growth hormone and insulin 
resistance (Kampmann, 2015, Kaaja and Rönnemaa, 2008). Together these 
re-orient maternal metabolism towards a lipid dependent metabolism in order 
to favour glucose reaching the foetus. Consequently, the profile of maternal 
inflammatory cytokines (TNF-, IL-1, and IL-6) increases and together with 
increased blood glucose can cause further deterioration of insulin sensitivity 
(Baz et al., 2016). Gestational diabetes is tested by performing an oral glucose 
tolerance test at the beginning of the third trimester (24-28 weeks) at least 
twice and is positive if the results are ≥7.2mmol/L in both tests (Kampmann, 
2015, Rani, 2016). Gestational diabetes can be managed by pre-conception 
counselling, exercise and diet (reduction in daily caloric intake) during 
pregnancy, as well as the use of oral hypoglycaemics such as metformin, and 
Glibenclamide (Anwar et al., 2018).  
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1.1.2.2 Maturity Onset Diabetes of the Young (MODY) 
Another form of diabetes that is non-insulin dependent but differs from T2DM, 
is Maturity Onset Diabetes of the Young (MODY) which is reported to make up 
approximately 1.2-3% of diabetes diagnosed in children (Hattersley and Patel, 
2017). However, MODY is often misdiagnosed as T1DM thus the prevalence 
may be under represented (Ledermann, 1995). MODY is a group of 
heterogeneous monogenic inheritable diabetes that result from mutations in 
transcription factors and enzymes that modulate beta cell maturation and 
function (Anık et al., 2015). Most patients present with autosomal dominant 
inheritance by the age of 25. The clinical features of these patients are variable 
depending on the mutation causing the disease. At least 13 gene mutations 
have been associated with the disease (Chambers et al., 2016). The most 
common mutations described lie in the coding regions of genes encoding 
hepatocyte nuclear factor 1 (HNF1), hepatocyte nuclear factor 4 (HNF4) 
and glucokinase (GCK), and these account for 52%, 10% and 32% of MODY 
cases in the UK respectively (Thanabalasingham and Owen, 2011). Other 
genes include HNF1B, INS, PDX1, paired box 4 (PAX4), neuronal 
differentiation 1 (NEUROD1),  KCNJ11 and ATP binding cassette subfamily C 
member 8 (ABCC8), but their incidence is less common (Thanabalasingham 
and Owen, 2011, Gardner and Tai, 2012). The misdiagnosis of MODY as 
T1DM has a massive impact on treatment. Given the correct diagnosis, MODY 
patients can often be effectively treated with anti-hyperglycaemic drugs which 
are preferable to exogenous insulin administration (Boyd and Byrne, 2018).  
1.1.2.3 Latent Autoimmune Diabetes of Adulthood (LADA)  
Latent autoimmune diabetes of adulthood (LADA) was first reported in 1986 in 
a group of individuals previously diagnosed with T2DM. These persons 
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present with more typical features of T1DM such as the production of islet 
autoantibodies but they also had preserved beta cell function (Groop et al., 
1986). Due to the challenges of classifying LADA, there is controversy over its 
existence: the only difference between LADA and T1DM is the dependence on 
insulin in T1DM individuals (Laugesen et al., 2015).  Since in the past T1DM 
was mostly diagnosed in the young, and now at any age, it is argued that LADA 
is simply T1DM of the old (Thomas et al., 2018). LADA makes up 
approximately 10% of type 2 diabetes individuals between the ages of 35-75 
years. Individuals diagnosed with LADA and with autoantibodies experience 
beta cell failure within 5 years and those without autoantibodies after around 
12 years. LADA patients have dietary treatment similar to those of T1DM 
individuals as well as Metformin. The use of exogenous insulin typically follows 
beta cell dysfunction (Stenström et al., 2005).  
1.1.2.4 Neonatal Diabetes Mellitus (NDM) 
Neonatal diabetes mellitus (NDM) is a rare genetic form of diabetes that occurs 
in children below the age of 6 months and with incidence rates of 1 in 100 000 
(Hattersley and Patel, 2017). There exist two clinical forms of NDM, permanent 
NDM (PNDM) which requires lifelong exogenous administration of insulin, and 
transient NDM (TNDM) which is sporadic sometimes recurring in an 
individual’s twenties or thirties (Marin et al., 2016, Aguilar-Bryan and Bryan, 
2008).  These two forms can only be distinguished by genetic analysis. The 
genetic causes of more than 90% of TNDM are now known and over 68% of 
these cases are due to abnormalities in the imprinted region of chromosome 
6q24. The rest are due to mutations in the KCNJ11 and ABCC8 genes (Sood 
et al., 2017, Marin et al., 2016). PNDM is mostly due to  mutations in the 
KCNJ11, ABCC8 and the INS genes (Marin et al., 2016), with KCNJ11 and 
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ACC8 accounting for 50% of cases (Hattersley and Patel, 2017). NDMs are 
generally managed by the use of exogenous insulin and sulfonylurea in order 
to improve neurodevelopment (Marin et al., 2016). 
1.1.3 Type 1 Diabetes Mellitus (T1DM) 
The main focus of this thesis relates to type 1 diabetes mellitus (T1DM) rather 
than the other types described above. T1DM is an autoimmune disease in 
which there is selective destruction of the pancreatic beta cells of the islets of 
Langerhans. This leads to lifelong exogenous insulin dependence to control 
blood glucose (Insel et al., 2015). Beta cell destruction usually occurs during a 
subclinical period in which insulin-containing beta cells are selectively 
destroyed by the immune system in persons that are genetically susceptible. 
In the past, T1DM was mainly diagnosed in children hence it acquired the 
name Juvenile-onset diabetes although it can be diagnosed at any age 
(Atkinson et al., 2013, Thomas et al., 2018).  
It is estimated that approximately 1,106,500 children under the age of 20 live 
with type 1 diabetes worldwide (Snouffer, 2018).  More than 30 000 children in 
the UK live with the disorder and  trends suggest that the disease incidence is 
steadily increasing in many European countries and the world at large 
(Patterson et al., 2009, Patterson et al., 2018). However, the reason for this 
increase in T1DM incidence is not clear. 
In a similar manner to T2DM, the disease is diagnosed serologically by 
measuring fasting blood glucose concentration (≥7.0mmol/L positive), random 
blood glucose (≥11.1mmol/L means diabetic) or oral glucose tolerance tests. 
Glycated haemoglobin levels above 48mmol/mol can be used but this test is 
usually less sensitive since dysglycemia is rapid in T1DM (DiMeglio et al., 
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2018). A combination of the serological tests above, and the clinical symptoms 
are most commonly used for diagnosis, hence 50% of adults with new-onset 
T1DM tend to be misdiagnosed as T2DM (DiMeglio et al., 2018). This has 
important implications since the treatments used for these two diseases are 
different. During insulin biosynthesis insulin is first synthesized as 
preproinsulin. A signal peptide is cleaved in the ER to give proinsulin. 
Proinsulin is then cleaved to yield active insulin in vesicles from where it is 
released with the other cleaved component, c-peptide in equimolar quantities. 
C-peptide levels can be useful for disease diagnosis; since very low 
concentrations indicate severe beta cell assault. C-peptide concentrations 
(normal range: 0.26-1.03nmol/L) can be a sensitive measure of beta cell 
function but should be used for definitive diagnosis in  combination with other 
tests (Yi et al., 2018). The gold standard for distinguishing type 1 diabetes from 
the others, is a serological measurement of two or more auto-antibodies (which 
recognise beta cell specific proteins). These are normally present in more than 
90% of  patients at diagnosis and indicate ongoing disease pathophysiology.  
There are five main islet autoantibodies which have been identified to date, 
these are Islet cell autoantibodies (ICA), Insulin autoantibodies (IAA), 
antibodies raised against glutamic acid decarboxylase 65 (GAD65), protein 
tyrosine phosphatase related antigen 2 molecule (IA-2A) and zinc transporter 
8 autoantibody (ZnT8) (Törn et al., 2008, Lampasona et al., 2011, Schlosser 
et al., 2011). Recently, a 38kDa glycoprotein autoantigen was identified as 
tetraspanin-7 was also shown to be a target of islet autoantibodies in T1DM 
(McLaughlin et al., 2016).The functions of these antigens are on Table 1. 
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Table 1: Functions of autoantigens in T1DM 
Antigen Function Reference 
GAD65 An enzyme essential in gamma-
aminobutyric acid (GABA) 
biosynthesis which is an inhibitor of 
neurotransmission in the central 
nervous system with paracrine 
functions. Its function in the islet is not 
known but local paracrine effects on 
glucagon secretion are suggested 
(Lampasona 
and Liberati, 
2016, Wendt et 
al., 2004) 
IA-2A A protein tyrosine phosphatase-like 
protein promotes mobilisation of 
secretory granules to the plasma 
membrane  
(Mziaut et al., 
2008) 
ZnT8 Regulates Zinc content in beta cells.  
Stabilizes insulin crystals in secretory 
vesicles 
(Lemaire et al., 
2012) 
IAA Insulin is triggers glycogenesis hence 
responsible for glucose homoeostasis  
(Lampasona 
and Liberati, 
2016) 
ICA Non-specific antigens on the islets (Lampasona 
and Liberati, 
2016) 
Tetraspanin 7 Function as a molecular scaffold and 
facilitate signalling on receptors such 
as EGFR 
(Termini and 
Gillette, 2017) 
 
A number of factors have been identified that may promote the development 
of T1DM, although the explanation as to how they lead to the disease remains 
a conundrum. Both genetic and environmental factors have been implicated 
and possibly combine to provoke the immune system into attacking pancreatic 
beta cells in a selective manner (Roep and Tree, 2014, Russell and Morgan, 
2014). In the subsequent sections, various factors associated with the 
development of T1DM will be examined. 
1.1.3.1 Genetic factors 
The evidence that genetic factors play a role in T1DM arises from the 
observation that a significant number of individuals with the disorder have 
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close relatives with T1DM. There is a 15 fold higher risk of developing T1DM 
among siblings of a person with T1DM compared to the general population. 
Additionally, the risk is 3% if the mother has T1DM individual and 5% if the 
father has T1DM (Pociot and Lernmark, 2016). There is also a greater than 
50% chance of concordant development of T1DM in monozygotic twins (Steck 
and Rewers, 2011). Together, these data reveal a significant genetic 
component to the disease.  
The human leukocyte antigen- DQ (HLA-DQ) locus accounts for about a half 
of the most important susceptibility genes in T1DM, however, an additional 50 
non-HLA genes also contribute to the risk of T1DM (Knip and Simell, 2012).  
The HLA class II region on chromosome 6p21 (precisely loci HLA-DRB1 and 
HLA-DQB1) is known to exert the highest T1DM risk, with the alleles DR3-
DQA1*0501-DQB1*0201 (DR3) and DR4-DQA1*0301-DQB1*0302 (DR4) 
accounting for 30-50% of the genetic T1DM risk (Steck and Rewers, 2011). At 
least one of these alleles is present in 95% of all T1DM patients in the US (Aly 
et al., 2006). Although the HLA-DR/DQ locus confers a high risk of developing 
T1DM, some haplotypes of these have been reported to be protective such as 
HLA-DQA1*0102, DQB1*0602 (Steck and Rewers, 2011). Other HLAs 
associated with T1DM include alleles A24, A30 and HLA I. HLA-B18, B39, 
B44, C3, C8, and C16. There also exist non-HLA gene markers and currently, 
more than 50 such markers have been confirmed with the most significant 
being in INS (11q15), interferon induced with helicase C domain 1 (IFIH1) 
(2q24), cytotoxic T-lymphocytes associated protein 4 (CTLA-4), protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22) and IL2RA (Eizirik et 
al., 2012).  
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To understand the genetics of T1DM, two main approaches have been 
employed. In the first, children born of a first-degree family history of T1DM 
have been monitored for development the disease. And in the other, new-
borns are screened to identify children at increased genetic risk. They are then 
followed up to detect autoantibodies known to be associated with increased 
risk for T1DM (Størling and Pociot, 2017, Pociot and Lernmark, 2016). These 
approaches have helped to record the natural history of T1DM and to 
categorise the alleles with various risk levels. 
There is only a 33% chance of developing the disease in individuals with the 
highest genetic susceptibility and in conjunction with evidence from pair-wise 
twin studies, it is acceptable to argue that genetic susceptibility alone is not 
sufficient to develop T1DM and additional environmental factors are required 
to trigger  the disease (Barnett et al., 1981). 
1.1.3.2 Environmental factors as triggers of T1D  
A growing number of potential environmental factors have been reported which 
may act as triggers for T1DM (or at least influence this process). These include 
demographic, viral infection, early introduction of cow’s milk, vitamin D, and 
the intestinal microbiome. Evidence for each of these factors has been 
generated to support their involvement (Knip and Simell, 2012). A study by 
Barnett et al. (1981)  and another by Kaprio et al. (1992) suggested that only 
about 13%-33% of paired monozygotic twins concordantly develop T1DM 
indicating that other factors influencing the disease exist.  
The Geography of T1DM is also an indicator of a possible environmental factor 
with the highest number of cases recorded in northern Europe. Also, the rate 
of increase in T1DM over 15 years cannot be explained by genetic factors 
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alone and points to contributions from the environmental changes (Patterson 
et al., 2009). In the subsequent sections, the various environmental factors 
associated with the development of T1DM will be examined. 
Viruses  
The involvement of viruses in the pathogenesis of T1DM was first suggested 
over a century ago by Harris (1899). Recently the evidence has become more 
compelling, with certain enterovirus serotypes receiving the most attention 
(Morgan and Richardson, 2014, Harris, 1899, Richardson and Morgan, 2018).  
A number of viruses have been implicated in T1DM including, mumps, 
cytomegalovirus (CMV), rotavirus, enteroviruses particularly coxsackie virus B 
(CVB), herpesvirus and rubella virus (Filippi and von Herrath, 2008, 
Richardson and Horwitz, 2014).  
The link between enteroviruses and T1DM have been established by meta-
analysis suggesting a clinically significant association (Yeung et al., 2011). 
Enteroviruses are a group of non-enveloped RNA viruses from the 
picornavirus family which induce mainly mild and asymptomatic infections in 
infants and newborns (Knip and Simell, 2012). There are over 100 different 
serotypes of enteroviruses but the most commonly implicated in T1DM is 
Coxsackie virus B4 (although B1 to B6 have also been implicated) (Filippi and 
von Herrath, 2008). Coxsackie B3 has been shown to infect and accelerate 
insulitis in NOD mice at 8 weeks (Drescher et al., 2004). In the Finnish diabetes 
protective study, investigators showed that enteroviral infection occurred in 
susceptible children prior to the appearance of islet auto-antibodies (Lönnrot 
et al., 2000). This appearance  has been deemed seasonal with the highest 
infections occurring between autumn and winter (Kimpimäki et al., 2001). 
Evidence of enteroviral infection in the pancreas has been obtained by staining 
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tissue sections for the viral capsid protein VP1 in children and young adults 
soon after the diagnosis of T1DM (Richardson et al., 2013, Richardson et al., 
2009). It is proposed that the virus gets to the pancreas through the blood (or 
via the pancreatic duct), and that beta cells are targeted by these viruses 
because they express an isoform of the Coxsackie-adenovirus receptor (CAR) 
(Ifie et al., 2018), which enteroviruses can use to gain entry into the cells. The 
virus might induce beta cell death by cytolysis after replication, although very 
little evidence of large scale islet cell lysis has been reported in T1DM. Rather, 
It has been suggested that a persistent form of infection might develop and 
affect the immune system by upregulation of MHC I or through molecular 
mimicry (Knip and Simell, 2012, Richardson and Horwitz, 2014).  
Other viruses have been implicated in the pathoaetiology of T1DM with the first 
report dating back to 1899; a case of T1DM after mumps infection (Harris, 
1899). An Australian study showed an association of rotavirus infection and 
the beta cell autoimmunity in T1DM susceptible children (Honeyman et al., 
2000), but another Finnish study did not support the same conclusion 
(Blomqvist et al., 2002). A strong correlation has also been reported between 
CMV and islet cell autoantibodies in individuals with T1DM implicating 
persistent CMV infections in T1DM (Pak et al., 1988).  
Bacteria 
Emerging evidence suggests that the microbiome homeostasis may play a 
crucial role in the development of metabolic disorders such as type 2 diabetes, 
dyslipidaemia, non-alcoholic fatty liver disease (Fabbiano et al., 2017), and 
T1DM. In a report on NOD mice that lacked the Myeloid differentiation primary 
response 88 (MYD88), (a toll-like receptor adaptor protein) developed diabetes 
according to the microbial constituents of the intestine (Wen et al., 2008). A 
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comparative study on the oral microbiota and faecal microbiota of T1DM 
persons versus controls showed a significant difference in certain species (e.g. 
Chirstensenella) associated with T1DM (de Groot et al., 2017). However, these 
changes in microbiota seem to be largely due to a change in metabolism and 
not the cause of the disease. In one report, to illustrate this bariatric surgery to 
induce weight loss was performed and the gut microbiota of the individuals 
studied. The results revealed rapid changes in the gut microbiota as an 
adaptation to a starvation-like situation (Furet et al., 2010).  
Dietary factors 
A variation in exposure to complex diets at different stages in life such as the 
early introduction of cow milk, vitamin D, cereals (gluten) and short-term 
breastfeeding have been implicated in T1DM (Antvorskov et al., 2016). In a 
breastfeeding study performed involving T1DM susceptible infants, it was 
observed that infants breastfed for a minimum of 4 months had a lower risk of 
developing IA-2A autoantibodies when compared to infants breastfed for  ≤2 
months (Kimpimäki et al., 2001). In another study by the same group, early 
introduction of cow’s milk to T1DM susceptible children was associated with 
increased risk of seroconversion (Kimpimäki et al., 2001) although others did 
not find any association in children under the age of 5 (Wadsworth et al., 1997). 
Two recently published case reports of T1DM susceptible children have 
reported remission from T1DM with the use of high doses of vitamin D 
(1000IU/day) and omega 3 fatty acids (50-60mg/kg/day) (Cadario et al., 2018). 
Additionally, taking high concentrations of vitamin D in the last trimester of 
pregnancy was associated with a decreased risk of developing T1DM in 
susceptible offspring (Virtanen, 2016).  
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Studies using wheat based feed and gluten free diet performed with NOD mice 
have suggested a role for gluten in the development of diabetes. NOD mice 
on a gluten free diet had a reduced incidence of diabetes (15%) when 
compared to those fed a gluten containing diet (64%) (Funda et al., 1999). In 
humans, first-degree relatives of T1DM individuals put on a gluten free diet for 
6 months followed by a gluten containing diet for a further 6 months had a 
significantly better insulin response to glucose during the gluten free period 
compared to when fed the gluten containing diet. This decreased with a return 
to a gluten containing diet (Pastore et al., 2003). Furthermore, the case study 
of a 6 year old boy diagnosed with T1DM who was then placed on a gluten 
free diet revealed better fasting blood glucose levels and no change in GAD65 
autoantibody titres providing anecdotal evidence that such a diet might 
preserve beta cells (Sildorf et al., 2012). 
1.1.3.3 The immune system involvement in T1DM 
It is established that the immune system plays a key role in T1DM 
pathogenesis since autoantibodies against beta cell proteins can be readily 
detected in the blood of patients, and thus are generally used as biomarkers 
of the disease (Yi et al., 2018). However, studying the pancreas provides much 
more direct evidence for the role of the immune system in the disease. 
Unfortunately, studies on the human pancreas are limited by the lack of access 
to the pancreas due to its retroperitoneal location thus making it hard to study 
the disease pathogenesis completely (Morgan, 2017).  
The NOD mouse model has been used to gain an improved understanding of 
the disease pathogenesis in T1DM. Pancreatic sections reveal the infiltration 
of various immune cell subsets (DC, macrophages, natural killer cells, CD4+ 
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and CD8+ T-cells) with similar phenotypes to those found in humans (Pearson 
et al., 2016). Examination of the human pancreas from patients with T1DM 
reveals the presence of various immune cells associated with and infiltrating 
into the islets of Langerhans, termed ‘insulitis’. Recently a consensus view was 
generated on the definition of insulitis which states that three or more islets 
contain greater than or equal to fifteen CD45+ cells/islet  (Vecchio et al., 2018, 
Leete et al., 2016, Willcox et al., 2009b, Campbell-Thompson et al., 2013). A 
more detailed assessment of the immune cell subtypes present in insulitic 
pancreatic islets revealed that CD8+ cytotoxic T-cells were  predominant, with 
lower numbers of CD4+ and CD20+ B-cells. Other studies also noted the 
occasional presence of macrophages, natural killer cells, dendritic cells and 
FoxP3 positive cells at the islet site (Willcox et al., 2009b, Rodriguez-Calvo et 
al., 2014). The infiltrating immune cells are likely mediators of beta cell death 
in T1DM primarily mediated through the secretion of protein factors from the 
influent T-cells ( cytokines, perforins, granzymes) (Pirot et al., 2008).   
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1.2 The Pancreas; its Architecture and function 
The pancreas is a hammer-shaped organ that lies beneath the stomach, 
measuring between 14-20cm in length in adult humans and with an average 
weight of 100g. It develops from the foregut endoderm and appears by the end 
of the seventh week of gestation. Functionally, the pancreas is responsible for 
the maintenance of glucose homeostasis and the secretion of pancreatic 
enzymes (e.g. amylase) for digestion. The pancreas connects to the 
duodenum via the Ampulla of Vater, which is a duct formed by the union of the 
bile duct and the pancreatic duct. The pancreas is anatomically divided into 
the head, which links to the digestive system, the body and the tail which are 
closest to the spleen (Fig. 1.1). The bulk of the pancreas (85%) is made up of 
acinar cells responsible for the exocrine functions of the organ with only 
approximately 2% responsible for the endocrine function (Campbell and 
Verbeke, 2013, Longnecker, 2014). Blood flows through the portal system first 
from the endocrine pancreas then into the exocrine capillaries with a high 
concentration of islet hormones which may exert trophic effects since 
pancreatic exocrine cells have receptors for hormones such as insulin (Pandol, 
2010).  
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Figure 1. 1: The pancreas and surrounding organs 
The pancreas is divided into the pancreatic head (H), body (B) and the tail (T) 
Courtesy of Mrs Nikki Archer 
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1.2.1 The Exocrine Pancreas 
The exocrine pancreas makes up about 85% of the whole pancreas and is 
responsible for secretion of digestive enzymes through its ductal system into 
the duodenum. These enzymes flow with water and ions also secreted by the 
exocrine cells. The exocrine pancreas is composed mainly of the ductal 
system, and the lumen which extends from the duodenum to the acinus made 
up of acinar cells (exocrine cells)  which are in berry-shaped clusters (Pandol, 
2010). Acinar cells through this ductal system secrete over 20 different 
enzymes involved in chemical digestion. These include proteases, amylases, 
hydrolases, lipases, and ribonucleases and each is normally stored in 
zymogen granules in their proenzymes forms. The enzymes are activated 
once in the duodenum by an enterokinase, which cleaves a peptide from the 
N-terminal of the proenzyme. Activated trypsin is a primary target, which then 
activates other pro-enzymes (-Amylase, procarboxypeptidase, proelastase, 
phospholipase, mesotrypsin).  
The existence of the exocrine and endocrine pancreas in one organ usually 
means that inflammatory damage to the exocrine compartment could result in 
collateral damage to the endocrine compartment and vice versa. In this 
context, 30% of people with acute pancreatitis display glycosuria and 50% of 
these have elevated blood glucose although their symptoms resolve upon 
resolution of pancreatitis. Chronic pancreatitis, however, depending on the 
pathology can lead to overt diabetes (Gorelick, 1993). Endocrine malfunction 
can also lead to a pancreatic exocrine insufficiency in more than 50% of T1DM 
cases (Campbell-Thompson et al., 2015). 
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1.2.2 The Endocrine pancreas  
The endocrine pancreas is made up of the pancreatic islets of Langerhans; 
these structures are disseminated throughout the pancreas and makeup about 
2% of the pancreas volume (105-106 islets) in a human pancreas. Each 
pancreatic islet consists of various cell types (endocrine, endothelial, nerve, 
fibroblast) and is usually about 40-107µm in diameter (Seino and Bell, 2008, 
Komatsu et al., 2017). Pancreatic islets contain five different endocrine cell 
types: insulin-secreting beta cells, glucagon-producing alpha cells, pancreatic 
polypeptide-secreting PP cells, somatostatin secreting delta cells and ghrelin-
secreting epsilon cells (Figure 1.2, PP and  cells have not been stained).  
 
Figure 1.2: Representative image of human pancreas showing 
immunofluorescent stained alpha (red), beta (cyan) and delta cells (green). 
Human FFPE section was cut, placed on a slide, cleared, rehydrated and 
probed with antisera against insulin (cyan), glucagon (red) and somatostatin 
(green). Islets were observed under the fluorescent microscope at 20X 
magnification. Scale bar 550m.  
Courtesy: Dr Sarah Richardson 
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Alpha cells ( cells) 
The alpha cells makeup about 30% of the islet cell mass in humans and are 
responsible for the secretion of glucagon, a hormone which promotes the 
release of glucose into the blood. Glucagon protects the body against 
hypoglycaemia by stimulating hepatocytes to produce glucose by initiating 
glycogenolysis and gluconeogenesis. Glucagon is synthesized from a large 
precursor proglucagon, which is 178 amino acids in length and is cleaved by 
prohormone convertase 2 to yield active glucagon (29 amino acids) in alpha 
cells. The control of glucagon secretion is thought to be both intrinsic (by 
glucose) and paracrine (somatostatin, insulin and neuronal) although the exact 
mechanisms are still under debate.  
It has been shown that glucagon secretion is predominantly modulated by the 
prevailing glucose concentration, but it can also be affected by somatostatin 
and insulin. Briefly, at low glucose concentrations (hypoglycaemia, glucose 
≤3.3mmol/L), alpha cell plasma membrane depolarisation as T-type channels 
open, leading to the activation of voltage-gated Na+ and  calcium channels. 
The Ca2+ channels open leading to an increase in intracellular Ca2+. The 
Increase in intracellular Ca2+ causes the migration of secretory granules and 
their fusion to the cell membrane, and thus the exocytosis of glucagon (Briant 
et al., 2016, Quesada et al., 2008). It is also suggested that incretins, such as 
glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) can 
suppress glucagon secretion (Xavier, 2018). Furthermore, under certain 
circumstances, alpha cells may secrete GLP-1, an alternative cleavage 
product of proglucagon. Under such conditions, this may lead to autocrine 
effects on glucagon release (Marchetti et al., 2012). 
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Delta cells ( cells) 
Somatostatin is secreted by delta cells and these cells make up roughly 11% 
of the human islet (Seino and Bell, 2008). Delta cells are not only present in 
the pancreatic islet, but in the gastrointestinal tract and, the central nervous 
system. Somatostatin has a broad inhibitory effect on the secretion of many 
hormones, including glucagon, and insulin. Somatostatin is synthesized as 
preprosomatostatin (116 amino acids) which is cleaved into prosomatostatin 
(92 amino acids) by proconvertase 1. Prosomatostatin is then enzymatically 
cleaved by proconvertase 2 to yield somatostatin-14(14 amino acids) and 
somatostatin-28 (28 amino acids) both of which are biologically active. 
Somatostatin receptors are present on both beta cells and alpha cells hence 
its actions directly affect these two cell types. Furthermore, somatostatin has 
been suggested to inhibit PP secretion in addition to its own secretion 
(Brereton et al., 2015).  
Pancreatic Polypeptide-producing (PP) cells 
Pancreatic polypeptide-producing cells (PP) also called F-cells were thought 
to be the smallest population of cells in the human islets (<2%) prior to the 
discovery of epsilon cells. More than 90% of PP cells are located at the head 
of the pancreas (Rahier et al., 1983). These cells produce a 36-amino acid 
peptide pancreatic polypeptide, which is released postprandially upon 
stimulation by the vagus nerve. Alternatively, secretion can be stimulated by 
other factors such as arginine. Pancreatic polypeptide is known to act directly 
in the gut where it reduces gastric secretion and the motor activities of the 
intestines. Surprisingly, our current understanding suggests that this hormone 
has a limited impact on other islet cells. That said, It has been shown to inhibit 
glucagon secretion at low glucose concentrations but no effects on insulin 
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release have been reported (Xavier, 2018). These cells have received limited 
attention compared to pancreatic beta cells. 
Epsilon cells ( cells) 
Epsilon cells make up the smallest population of islet cells (about 1% in adult 
human islet) and secrete the hormone ghrelin. Ghrelin is known to inhibit 
insulin secretion from rat, mouse and human beta cells and hence it acts as a 
paracrine inhibitor of insulin in the islet, similar to somatostatin. The major 
sources of ghrelin are the pancreas and stomach (Wierup et al., 2014). Ghrelin 
has been identified in the hypothalamus precisely in the arcuate nucleus where 
it is suggested to regulate appetite leading to increases in food intake, a 
decrease in energy use, all this cumulating to body weight gain (Sato et al., 
2012). 
In diabetes research, the central focus has been on the beta cell due to the 
obvious dysregulation in insulin function and action, however, other islet cells 
have been implicated in the disease pathogenesis. For example, it has been 
reported that alpha cells increase in mass in T1DM and hyper secretion of 
glucagon (hyperglucagonemia) is a common feature of T1DM. Similar to alpha 
cells, the number of delta and PP cells have also been shown to increase in 
both T1DM and T2DM (Brereton et al., 2015). The potential sources of these 
endocrine cell types in diabetes are neogenesis of progenitor cells, self-
replication to replenish the pancreatic islet volume,  and transdifferentiation 
from other endocrine cells or exocrine acinar cells (Corritore et al., 2016). 
Beta cells (cell) 
The beta cells are the most abundant and the most studied of all the islet cells 
and makeup about 60% of the islet population in human. By three weeks of 
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gestation, the first endocrine cells to appear are the beta cells, these are then 
followed by the alpha cells (at 8weeks), then the delta cells and then the 
epsilon cells (at week 9). PP cells begin to appear at about week 17 (Jeon et 
al., 2009). The primary function of beta cells is the synthesis and secretion of 
insulin (Xavier, 2018, Seino and Bell, 2008). Many metabolites (amino acids, 
free fatty acids, and ketones), neurotransmitters (acetylcholine and 
norepinephrine) and hormones (GLP-1, GIP, Glucagon, Gastrin, Secretin, 
CCK and PACAP) induce insulin secretion but the most important is glucose. 
Glucose induces and amplifies insulin secretion.  
The secreted form of insulin has 51aa, although insulin is initially translated as 
a 110aa protein known as preproinsulin. Preproinsulin has a hydrophobic N-
terminal 24aa residue signal peptide which interacts with a signal recognition 
particle (ribonucleoprotein particle) in the cytosol. The nascent preproinsulin is 
translocated into the lumen of the rough endoplasmic reticulum (RER). Signal 
peptidases on the inner surface of the RER then cleave the signal sequence 
to form proinsulin. Following this event, the signal sequence is degraded 
rapidly. Under the catalysis of enzymes and associated chaperone proteins 
such as protein-thiol reductase, proinsulin is folded and three disulphide bonds 
are formed within the molecule. In a rate-limiting step, proinsulin is transported 
to the Golgi apparatus where it is packaged into immature secretory vesicles. 
In these vesicles, proinsulin is cleaved by trypsin-like enzymes PC1/3  and 
PC2 into mature insulin and a 31aa residue connecting peptide (C-peptide) 
(Seino and Bell, 2008, Fu et al., 2013).  
Glucose enters the beta cells through a facilitated form of transport via the 
glucose transporters, GLUT1 and GLUT2. Once glucose enters it becomes 
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phosphorylated by glucokinase to form glucose-6-phosphate (G6P) to initiate 
glycolysis. Metabolism via glycolysis yields pyruvate which is converted to 
acetyl-CoA catalysed by pyruvate dehydrogenase. Acetyl-CoA then enters the 
tricarboxylic acid cycle in which ATP is produced and transported to the 
cytoplasm. An increase in cytoplasmic ATP causes the closure of ATP 
sensitive potassium channels, which prevents K+ efflux from the cell and 
induces depolarisation of the plasma membrane. This event promotes the 
opening of the L-type voltage-dependent Ca2+ channels leading to an influx of 
Ca2+ into the cytosol. Ca2+ influx causes insulin secretory granules to move 
towards the plasma membrane where they dock and fuse for exocytosis of 
insulin to occur (Marchetti et al., 2017b).  
Since the thesis focuses on the role of STAT6 in beta cells, I will expand more 
on beta cell models and some advantages and disadvantages. 
Beta cell study models 
The study of beta cells has been limited by the accessibility and availability of 
pancreatic tissue (Morgan, 2017). Primary beta cells obtained from individuals 
are rare to find and usually undergo various treatments to isolate beta cells, 
which changes their functionality and potentially skew experiments. 
Additionally, maintaining these primary cells out of their in vivo habitat can be 
laborious and will require the technical expertise, hence research on beta cells 
is mostly dependent on cell lines and animal models (Skelin et al., 2010).  
The use of cell lines is advantageous in that experiments performed with these 
are generally reproducible over a limited number of passages. Cell lines can 
also be transfected and manipulated to investigate gene expression or the 
cytotoxicity of different agents (Ulrich et al., 2002). Many different rodent cell 
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lines derived from virus or radiation induced insulinomas. The rat insulinoma 
cell line (RIN) and inulinoma cell line (INS-1E) were both derived by x-ray 
irradiation of rat insulinomas (Asfari et al., 1992, Skelin et al., 2010). RIN cells 
differ in their glucose response (insulin decreases with passages) and 
transport compared to the native beta cells and hence not appropriate for 
glucose stimulated insulin secretion assays (Halban et al., 1983). The INS-1E 
cells respond to glucose stimulated insulin secretion within physiological range 
but differ in total insulin content (about 20% compared to 60% in the native 
beta cell of which 10% can be released) and require the use of toxic beta 
mercaptoethanol to culture (Asfari et al., 1992). The mouse insulinoma (MIN6) 
cell line are derived from neoplastic islet cells transduced with SV40 under the 
insulin promoter. These cell response to glucose stimulated insulin secretion 
within physiological ranges in the presence of nicotinamide and sometimes 
this response is lost between passages (Miyazaki et al., 1990). Other cell lines 
have been reported but disadvantaged by their relatively low response to 
glucose stimulated insulin secretion or no insulin content (Skelin et al., 2010). 
Some human derived beta cell lines have been developed, for example, the 
Flatt lab through electrofusion of isolated human pancreatic beta cells and 
immortalised human ductal PanC-1 epithelial cell line developed the 1.1B4, 
1.4E7, and 1.1E7 (McCluskey et al., 2011). Although these cells have been 
reported to respond to glucose stimulation within physiological ranges, in our 
hands these cells have produced inconsistent results. Another human cell line 
developed is the EndoC H1 which is herein detailed in materials and methods 
(section 2.2.1.2).  
The rationale for the use of animal models in research lies in the similarities 
between the pathologies in humans, dogs, cats, monkey, pigs, mice and rats 
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(O’Kell et al., 2017). Animal models provide information on the various 
pathways and their possible role in T1DM. For instance, poor antigen 
presenting cell maturation reported in both NOD mice and humans was a head 
start to beta cell auto-antibodies (Serreze and Chen, 2005). Several animal 
models for T1DM have been reported and are generated by either chemically 
inducing insulin deficiency (Streptozotocin-induced), genetic induction (AKITA 
mice), virally induced (using coxsackie B, encephalomyocarditis, Kilham rat or 
LCMV virus) and spontaneous autoimmune (NOD mice and BB rats) (King, 
2012). The difficulty with the use of animal models in T1DM research comes 
from the heterogeneity of the disease and the fact that the pathogenesis of the 
human T1DM is not completely understood. T1DM heterogeneity arises from 
ages of onset, differences in the genetics and differences between individuals 
(von Herrath and Nepom, 2009). A few translating successes and failures have 
been reported in animal models. For example, the use of anti-CD20 in NOD 
mice has now been reported in humans to have a considerable success in 
subjects with high C-peptide (Herold et al., 2011). The Finish trial  in which oral 
insulin was administered to children was first established in NOD mice before 
translating to human failed to have an effect in children as recorded in mice 
(https://clinicaltrials.gov/ct2/show/NCT00336674) (Funda et al., 2014). The 
differences in T1DM between mice, rats and humans possibly account for most 
of the failed translations. The heterogeneous nature of T1DM in humans with 
varying in age of onset and different genetics (Leete et al., 2016) and hence 
the choice of the animal model should be representative of the type of T1DM 
one seeks to understand (von Herrath and Nepom, 2009). The 
pathophysiology in mice and rat models differs from humans in terms of the 
autoantibodies detected, mice and rats mostly have the ICA autoantibody (with 
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the exception of NOD mice which can also have IAA and GAD) while humans 
have 7 types of antibodies (CHATZIGEORGIOU et al., 2009). Additionally, the 
pancreatic architecture and insulin levels differ between humans and animals. 
The rat and mouse islets are reported to have alpha cells on the outside 
surrounding a core of beta cells (homotypic contact) while human beta cells 
and alpha cell intermingle in no particular pattern (heterotypic contact) 
(Abdulreda et al., 2013). The human islet has more alpha cells (35%) when 
compared to the rodent models (18%) (Seino and Bell, 2008). Physiological 
differences have been reported such as the effect of ATP on human islets, 
which leads to insulin release, but in rodents have had conflicting reports 
(Abdulreda et al., 2013). Additionally, mice have a higher fasting blood glucose 
compared to humans, while rats show a closer figure to humans. Rats have a 
fasting blood glucose of about 5.65 mmol/L (Wang et al., 2010), mice 6.1 
mmol/L (Sun et al., 2016) and humans 5.6 mmol/L (Kahn et al., 2014). 
Although differences exist between animal models, these models have 
contributed extensively to the understanding of beta cell pathophysiology.  
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1.3 Mechanisms of beta cell death in Type 1 diabetes 
Gaining a full understanding of the mechanisms of beta cell death in T1DM 
has been complicated by many factors including the limited access to the 
whole pancreas from human donors (and thus an over-reliance on rodent 
data). When human samples are available there is variability between donors, 
fixation methods and autolysis occurring during the time of death that can 
obscure the disease pathology (Morgan et al., 2014). Therefore, the precise 
mechanisms involved in beta cell death remain uncertain but are probably 
varied and depend on a myriad of factors including both the underlying cause 
of diabetes, genetic factors and the extent of immune system activation. In the 
two main forms of diabetes (T1DM and T2DM), there is beta cell death, with 
the key difference being that there is an autoimmune attack of beta cells in 
type I which is not seen in T2DM (Cnop et al., 2005). For the purpose of this 
thesis, I will expand more on the mechanisms of beta cell death in T1DM.  
1.3.1 Genetic susceptibility 
HLA 
As already described, polymorphisms within the HLA class lI gene family have 
the strongest association with T1DM, and these genes are found in the human 
leukocyte antigen region on chromosome 6p21.3. The HLA region codes for 
homologous cell-surface proteins that are known to be the most polymorphic 
in the human genome. Their polymorphic nature gives the immune system an 
advantage against a wide range of microorganisms, allowing them to present 
a large diversity of peptides to T-cells (Janeway et al., 2001).  HLA II is 
expressed on specialised antigen presenting cells and is made up of  and  
chains, which together are used to present antigens to CD4+ T-cells (Nerup et 
al., 1974). Alleles that confer genetic risk of T1DM are structurally different at 
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the molecular level. A well-known example is the replacement of aspartic acid 
residue at position 57 of the beta chain of the DQ molecule by either valine, 
alanine or serine in people with T1DM. This modification causes a change in 
electric charge within the peptide-binding groove of HLA-DQ8 and changes its 
ability to bind insulin epitopes (Todd et al., 1987). It is suggested that the weak 
binding of some auto-epitopes by diabetogenic class II alleles fails to generate 
tolerance at the thymus or peripherally leading to the perpetuation of self-
recognising immune cells (Wong and Li, 2003).  
HLA class I, on the other hand, is expressed by all nucleated cells and presents 
intracellular antigens to CD8+ T-cells. HLA class I has been associated with 
T1DM independent of the HLA class II DR/DQ allele after adjusting analysis 
for linkage equilibrium (Noble et al., 2002).  
NON HLA loci 
In humans, the expression of insulin is modulated by the transcription of a 
highly polymorphic insulin gene variable number tandem repeat associated 
with a proinsulin promoter. One such polymorphism is in the VNTR I which 
causes a peripheral increase in INS mRNA but a much lower expression in the 
thymus (Durinovic-Belló et al., 2010). Low expression of INS mRNA in the 
thymus affects the negative selection process in which less bound T-cells  are 
not destroyed creating insulin autoreactive T-cells. Cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) is another T1DM candidate gene which 
encodes for the T-cell receptor which is expressed on T-cells 48h after their 
activation. Although the exact mechanism by which polymorphisms in this 
gene contribute to T1DM is unclear, it is suggested that mechanism might 
involve alternative spliced variants of the gene. Targeted disruption of PTPN22 
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another candidate gene has been shown to lead to an increase in the number 
of memory T-cells although the mechanism remains elusive (Kim and 
Polychronakos, 2005). It is reported that the SNP R620W in PTPN22 causes 
a decrease in the B and T cell receptors, hence preventing the removal of 
autoreactive cells in the thymus (Sharp et al., 2015). At least 8 IL-4R SNPs 
have been reported and together with IL-4 and IL-13 haplotypes have been 
suggested to be involved in persistent islet autoimmunity and T1DM (Mirel et 
al., 2002, Erlich et al., 2009)  although the precise mechanism is not completely 
understood (Steck et al., 2005). Others have not found an association between 
these SNPs and T1DM (Maier et al., 2003). 
Conversely, other SNPs in the IL-4R, IL-4 and IL-13 lead to protection from 
T1DM (Bugawan et al., 2003). 
1.3.2 Apoptosis 
Apoptosis is a form of programmed cell death in which somatic cells die in a 
genetically controlled fashion without damaging neighbouring cells. In this form 
of cell death, the cell shrinks, undergoes pyknosis, the nuclear envelope 
collapses and DNA fragmentation occurs (Prause et al., 2016). The cell 
membrane integrity is altered to display properties that allow them to be 
phagocytosed easily. Apoptosis differs from necrosis, a process in which cells 
are lysed in an unregulated manner causing collateral damage to neighbouring 
cells (Alberts et al., 2002b). Apoptosis serves as a homeostatic process to 
maintain cell numbers and it is also used by the immune system to eliminate 
infected or damaged cells.  T1DM is a chronic slowly-progressing autoimmune 
destruction of beta cells, which presents clinically after about 70% ablation of 
the beta cells. It has been suggested that most probable cause of beta cell 
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death is due to apoptosis although evidence for this is limited in tissue (Pirot 
et al., 2008, Cnop et al., 2005). 
Apoptosis is the most studied form of beta cell death and can be ‘extrinsic’ (via 
death receptors) or ‘intrinsic’ (BCL-2- mediated or mitochondrial). There is an 
additional pathway that is T-cell mediated through perforins and granzyme-
dependent killing of the cell.  This perforin/granzyme pathway induces 
apoptosis through granzyme A or granzyme B (Thomas et al., 2009b).  
The extrinsic pathway of apoptosis 
The extrinsic pathway is regulated by the activation of TNF receptor 
superfamily members including FasL/FasR, and TNF-TNFR1 that are 
transmembrane receptors whose extracellular domains are rich in cysteine 
residues. The intracellular domain is made up of about 80amino acids and 
termed the death domain. Activation of FasR by the binding of its ligand (FasL) 
leads to the formation of a trimer which induces the formation of a Fas-
associated death domain (FADD) complex. This event leads to the recruitment 
of procaspase-8 to FADD to form the death-inducing complex (DISC). 
Procaspase-8 undergoes autocatalysis to form active caspase 8 and this 
activated form induces the cleavage of procaspase 3 to active caspase 3. 
Alternatively, caspase 8 can activate mitochondrial death signalling through 
the cleavage of the BH3-interacting domain death agonist (BID)  to a truncated 
bid (tBID)(Kawasaki et al., 2004). This process can be inhibited by a protein 
called c-FLIP that binds to FADD and caspase 8 making them ineffective 
(Elmore, 2007). The truncated tBID then activates BCL2 antagonist/killer 1 
(Bak) and BCL2 associated X, apoptosis regulator (Bax) activation. Activated 
Bax and Bak form pores within the mitochondria membrane leading to 
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cytochrome c release. Cytochrome c reacts with Apaf1 forming an 
apoptosome, leading to the activation of caspase 9 which in turn activates the 
execution caspases 3,6 and 7 induction of apoptosis (Dewson and Kluck, 
2009). Execution caspases translocate to the nucleus and trigger proteolysis 
and fragmentation of DNA through the activation of caspase activated DNase 
(CAD) (Liu et al., 1998b) (Fig 1.3). 
The intrinsic pathway of apoptosis 
The intrinsic pathway, on the contrary, is activated by withdrawal of growth 
factors, hormones and cytokines that suppress death signals. Importantly, it is 
non-receptor mediated but can also be activated by viral infections, radiation, 
toxins, and  free radicals (Elmore, 2007). The intrinsic pathway relies on the 
delicate balance between the pro-apoptotic BCL-2 members Bax, Bak, (BCL2 
interacting mediator of cell death (Bim), BCL2 associated agonist of cell death 
(Bad), BID,  and Egl-1 and anti-apoptotic BCL-2 members; Bcl-XL, Mcl-1, and 
Bfl-1 of mitochondrial proteins (Thomas et al., 2009a). BCL-2 proteins reside 
in the outer mitochondrial membrane and regulate mitochondrial membrane 
permeability. A stimulus that promotes intrinsic apoptosis will initiate the loss 
of mitochondrial transmembrane potential, which is irreversible, and thus lead 
to programmed cell death. Transcriptional upregulation of pro-apoptotic BCL-
2 family members leads to the activation of Bax/Bak that diminishes the 
mitochondrial transmembrane potential leading to the release of cytochrome c 
and Smac (also known as Diablo) from the mitochondria into the cytosol. 
Cytochrome c interacts with the adapter protein Apaf1 and together form the 
apoptosome, this once formed recruits and activates procaspase-9. Under 
normal conditions, prosurvival BCL-2 members prevent Bax/Bak activity by 
binding to them (Prause et al., 2016) (Fig 1.3).  
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The perforin/granzyme apoptosis 
The killing of beta cells by CD8+ cytotoxic T-cells is suggested to be mediated 
via perforins and granzymes or through the secretion of pro-inflammatory 
cytokines. Perforins are cytolytic proteins expressed by CD8+ T-cells and are 
localised in granules together with granzymes which are released by 
exocytosis in response to stimulation of T-cells following antigen recognition of 
HLA I molecules. Released perforins form transmembrane pores in a Ca2+ 
dependent manner, this enables the entry of granzymes (serine proteases) 
which activate apoptotic caspases (Thomas et al., 2009b). Interestingly, a 
report on perforin-deficient NOD mice revealed that these mice were delayed 
from developing diabetes, however, they displayed similar levels of insulitis 
compare to wild type mice. These data suggested the killing of beta cells 
mediated by T-cells  does not require perforins but might be propagated by 
other mechanisms  such as FAS ligand binding and cytokine secretion (Kägi 
et al., 1997). 
Granzyme A, activates DNA degradation through a DNAse NM23-H1 which is 
a tumour suppressor gene. The gene is responsible for immune surveillance 
of tumours wherein they induce apoptosis in tumour cells. A nucleosome 
assembly known as SET normally inhibits this gene. Granzyme A acts by 
cleaving the SET complex releasing NM23-H1 which leads to DNA damage 
and inhibition of repairs (Martinvalet et al., 2005). 
The granzyme B pathway activates apoptosis in a caspase-dependent manner 
via a single-stranded DNA damage. Granzyme B like caspases cleaves 
proteins at aspartate residues leading to the activation of procaspase-10 or 
cleavage of inhibitor of caspase-activated DNAse (CAD). It has also been 
shown that granzyme B can cleave BID leading to the subsequent release of 
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cytochrome c (act of intrinsic pathway) or can directly cleave caspase-3 
bypassing the upstream signalling pathway (Martinvalet et al., 2005). The 
protection of beta cells from granzyme induced cell death by IL-13 remains to 
be investigated but it is reported that loss in STAT6 leads to increase in NM23-
H1 mRNA (Li et al., 2012). 
Both extrinsic and intrinsic apoptosis have a common endpoint, the execution 
phase. It involves the execution caspases (caspase 3, 6 and 7). Caspase-3 is 
pivotal to execution as it cleaves endonuclease CAD from its inhibitor. CAD 
degrades chromosomal DNA and causes chromatin condensation (Elmore, 
2007) Fig 1.3.  Caspase 3 has been reported to be the main executioner 
caspase, firstly because it activates other executioner caspases. Secondly, the 
final stages of apoptosis such as nuclear condensation, chromatin margination 
and DNA fragmentation are only performed by caspase 3. Caspase 6 and  7 
seem to have more specialised roles  in apoptosis  upstream of the final stages  
which are, proteolysis of  Lamin A (a supporting scaffolding protein of the 
nuclear envelop) by caspase 6 and proteolysis of poly-ADP ribose polymerase 
(PARP) by caspase 7 (Slee et al., 2001). (Fig 1.3).
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Figure 1. 3: Intrinsic, Extrinsic and perforin granzyme pathways for apoptosis  
Apoptosis can occur by either by 1) extrinsic mechanisms where cytokines and CD8+ T-cells induce death through cell surface receptors,  2) 
intrinsic mechanisms, which is induced by toxins or stress in a mitochondria driven fashion or by 3) perforin/granzyme mechanisms usually 
secreted by CD8+ cells. All of these pathways ultimately converge in some way at the level of the mitochondria. Modified from Pirot et al., (2008) 
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1.3.3 Pro-inflammatory cytokines and beta cells 
Although the mechanism of beta cell death in T1DM is still not completely clear, 
the mechanisms implicated include a) expression of the Fas ligand or death 
receptors on beta cells. b) CD8+ T-cell release of granzymes and perforins. c) 
immune cell secretion of pro-inflammatory cytokines  such as IL-1, TNF-, IFN-
 by CD4+, CD8+ T-cells (Prause et al., 2016). d) auto-antibody mediated cellular 
cytotoxicity (Wong and Wen, 2005).  
Persons with T1DM have a significantly higher proportion of circulating pro-
inflammatory cytokines (IL1, IL-6, and TNF-) than matched healthy controls 
(Chatzigeorgiou et al., 2010, Pham et al., 2011, Thomas et al., 2013, Gouda et 
al., 2018). In in vitro studies, the cytotoxic effects of these cytokines on beta cells 
involves the production of nitric oxide, reactive oxygen species and activation of 
apoptotic pathways (Thomas et al., 2013). 
It is well established that beta cell death can occur due to chronic exposure to 
pro-inflammatory cytokines. Human pancreatic beta cells express the IL-1 
receptor and are reported to secrete IL-1under high glucose (33.3mM) (Maedler 
et al., 2002). Activated macrophages have also been suggested to secrete IL-1 
in the pancreas of T1DM individuals (Eizirik et al., 2009). IL-1 has been shown 
to induce human and rodent beta cell dysfunction (by inhibiting insulin 
biosynthesis) and death in in vitro studies (Russell et al., 2013, Palmer et al., 
1989, Spinas et al., 1987, Cetkovic-Cvrlje and Eizirik, 1994).  Specifically, IL-1 
activates a cascade of signalling processes when it binds to its receptor, leading 
to the formation of multi-protein complex cytoplasmic domain made up of MyD88, 
Tollip, IL-1R, IL-1 receptor associated kinase (IRAK)-1 and IRAK-4. IRAK-4 
activates IRAK-1, which interact with TNF receptor associated factor (TRAF)-6 
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that in turn activates nuclear factor kappa B subunit 1 (NF-B) or mitogen-
activated protein kinase 1 (MAPK) and inhibitor of nuclear factor kappa B kinase 
subunit beta (IKK). IKK then activates inhibitors of NF-B leading to translocation 
of NF-B to the nucleus. Once in the nucleus, it modulates the expression of 
inducible Nitric Oxide (iNOS) which leads to beta cell death through oxidative 
stress and mitochondrial damage (Collier et al., 2011) (Fig 1.3).   
TNF- on its own has a little effect on beta cell cytotoxicity but in combination 
with IL-1 can induce beta cell death and inhibit insulin biosynthesis (Cetkovic-
Cvrlje and Eizirik, 1994). Specifically, TNF- binds to its receptor (TNF-R1) and 
this leads to the formation of trimer with the TNF receptor-associated death 
domain protein (TRADD). TRADD recruits TRAF-2 and then together with TRAF-
6, this protein complex activates NF-B leading to P38 and JNK activation 
(Elmore, 2007). Rodent beta cells express low levels of TNF-R1 but not TNF-R2 
and have been shown to respond to TNF- stimulation accordingly inducing NF-
B (Stephens et al., 1999, Kwon et al., 1999). TNF- has been reported to be 
secreted by human islets (Hanley et al., 2006) and also by NKT cells, CD4+ T-
cells and some neurons (Eizirik et al., 2009). 
IFN- has been reported to inhibit insulin release and to induce beta cell death 
(Cetkovic-Cvrlje and Eizirik, 1994, Laffranchi and Spinas, 1997). IFN- binding to 
its cognate receptor (IFNGR1) leads to the autophosphorylation of a Janus 
Kinase and recruitment and activation of STAT-1 which homodimerizes, migrates 
to the nucleus and modulates the expression of genes such as Myc proto-
oncogene protein (c-Myc), BCL2 and IRF-1, Bak expression which leads to 
mitochondrial permeability and release of cytochrome c eventually leading to cell 
apoptosis (Zhou et al., 2008). Knockdown of STAT-1 and interferon regulatory 
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factor (IRF)-1 in IFN- stimulated INS-1E beta cells protected them from 
apoptosis. Knockdown of STAT1 also downregulated the production of NO. 
Exposure of rodent beta cells to IFN- leads to the downregulation of beta cell 
functional genes glucokinase, Pdx1 and Nkx2.2 that seem to be IRF-1 modulated 
(Moore et al., 2011). It is suggested that dendritic cells and CD4+ and CD8+ T-
cells secrete IFN-gamma (Ablamunits et al., 1998, Eizirik et al., 2009). 
Fas seem to be absent from the normal human islet according to 
immunohistochemistry on pancreatic sections but is upregulated in IL-1 treated 
islets (Loweth et al., 2000). Fas expression has been induced in rodent beta cells 
using IL-1, TNF- and IFN-. Transgenic NOD mice with the dominant negative 
form of Fas were protected from developing diabetes and from cytokine induced 
Fas upregulation (Allison et al., 2005).  
Whilst the roles of IL-1, IFN- and TNF- are well established in inducing beta 
cell death, the role of IL-6 remains somewhat controversial. IL-6 in combination 
with IL-1 has been shown to potentiate beta cell death in response to a variety 
of cytotoxic stimuli (Prause et al., 2016, Russell et al., 2013, Ellingsgaard et al., 
2008), whilst studies by Choi et al. (2004) have shown the reverse suggesting 
that IL-6 reduces the incidence of diabetes in NOD mice (Kristiansen and 
Mandrup-Poulsen, 2005). The source of IL-6 at the islet site is also a matter of 
debate. Many investigators assume that IL-6 will primarily be released by influent 
immune cells, however, it has also been shown that IL-6 is expressed by islet 
endocrine cells and that its release can be stimulated under certain conditions 
(Campbell et al., 1989). 
These are not the only cytokines suggested to induce beta cell death. IL-17A has 
been shown to increase the expression of IL-1, IFN-, and TNF-mRNA and 
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proteins in human pancreatic islets, potentially exacerbating beta cell apoptosis 
(Grieco et al., 2014, Arif et al., 2011). Moreover, IL-12, IL-23, IL-24 and IL-33 
have been studied in pancreatic beta cells and have each shown the capacity to 
induce oxidative and endoplasmic reticulum(ER) stress which eventually leads to 
beta cell dysfunction and death (Taylor-Fishwick et al., 2013, Weaver et al., 2015, 
Prause et al., 2016).  
1.3.4 Anti-inflammatory cytokines and beta cells 
Whilst the actions of pro-inflammatory cytokines are extensively studied, the 
actions of anti-inflammatory cytokines (IL-2, IL-4, IL-10, IL-13 and IL-22) on beta 
cells have received much less attention. Anti-inflammatory cytokines can be 
secreted by a variety of immune cells such as CD4+ T-cells, M2 macrophages 
and regulatory B cells (Russell and Morgan, 2014).  IL-10 and IL-22 have been 
shown to protect beta cells from apoptosis, to suppress ER stress and to promote 
glucose-stimulated insulin secretion (Xu et al., 2010, Hasnain et al., 2014).  
The actions of IL-4 and IL-13 have been reported in vitro to protect human and 
rodent beta cells from cytotoxicity induced by pro-inflammatory cytokines  and in 
vivo to protect NOD mice from developing diabetes (Russell et al., 2013, Manna 
and Aggarwal, 1998, Rutti et al., 2016, Zaccone et al., 1999, Cameron et al., 
1997). Systematically, It is suggested that IL-4 might act by increasing the  
regulatory T-cell population and that IL-13 might act by suppressing NF-B 
activity, while also upregulating beta cell survival genes (Cameron et al., 1997, 
Manna and Aggarwal, 1998, Rütti et al., 2016). 
This thesis is focused on studying the mechanism by which IL-13 (and the related 
cytokine IL-4) protects beta cells from cytotoxicity. Treatment of cells with these 
cytokines is reported to stimulate Jak/STAT signalling pathway. 
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1.4 The Jak/STAT signalling Pathway 
Cells receive external signals from different proteins such as growth factors, 
cytokines and hormones through a myriad of cell surface receptors, which 
connect to different intracellular pathways in order to communicate information to 
the nucleus. The Jak/STAT signalling pathway is one such signalling pathway, 
and it is responsible for signalling in response to different soluble factors such as 
erythropoietin, IL-13 and growth hormone  (Sehgal et al., 2003). The canonical 
pathway is constituted of two key families of proteins; these are the Janus kinase 
(Jak) proteins and the Signal Transducer and Activators of Transcription (STAT) 
protein families. The pathway is negatively regulated by endogenous inhibitors 
including suppressors of cytokine signalling (SOCS), SH2 containing protein 
tyrosine phosphatase (SHP)  1 and 2 proteins and protein inhibitors of activated 
STATs (PIAS) (Liongue and Ward, 2013). 
Janus Kinases 
There exist four members of the mammalian Jak family: Jak1, Jak2, Jak3 and 
Tyrosine Kinase 2 (Tyk2). Jaks are large non-receptor tyrosine kinases ranging 
in size from 120-140kDa (Zouein et al., 2011). Structurally, Jaks are divided into 
seven Jak homology domains (JH1-7) (Fig 1.4). JH1 is the tyrosine kinase 
domain and is responsible for the kinase function of the protein. The JH2 is a 
pseudokinase domain, which has no kinase activity and is reported to play a role 
in the functional regulation of the kinase domain. This structural architecture of 
the kinase domains gave the Jaks their name “Janus” derived from the two-faced 
Roman god of beginnings, endings and duality (Yamaoka et al., 2004). The 
protein also contains an SH2 like domain (between JH3-JH4) whose function 
remains unknown and a FERM domain (JH4 to JH7). The FERM domain 
mediates the binding of Jaks to various cytokine receptors and together with the 
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pseudokinase domains can modulate the activity of the kinase domain (Sehgal 
et al., 2003, Stark and Darnell, 2012, Yamaoka et al., 2004). Jaks are activated 
when associated with various receptors of the cytokine superfamily, or other 
receptors such as certain tyrosine kinases, or G-protein coupled receptors (Table 
2). Canonically, Jaks are mostly associated with receptors, but non-receptor 
associated Jaks exist and have been reported to have other functions such as 
gene regulation (Zouein et al., 2011, Noon-Song et al., 2011). 
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Table 2 : Jaks their associated receptors and growth factors 
Receptors Cytokines and/or growth 
factors 
Associated Jaks Ref 
Type 1 cytokine receptors 
C receptors IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 Jak1, Jak3 1 
gp130 IL-6, IL-11, IL-12, IL-23  Jak1, Jak2 1 
EPOR EPO Jak2 2 
PrlR Prolactin Jak2 3 
OSMR OSM Jak2 4 
LIFR LIF Jak1, Jak2 1 
GHR GH Jak2 5 
Type II cytokine receptors 
IFNGRA IFN- Jak1, Jak2, Tyk2 1 
IFNAR1&2 IFN- Jak1, Tyk2 1 
IL10RA IL-10 Jak1, Tyk2 6 
IL20RA IL-20 Jak1, Jak2 7 
IL22RA1 IL-22 Jak1, Tyk2 8 
Chemokine receptors 
CXCR4 SDF-1 Jak2, Jak3 9 
Seven membrane Receptors 
CCK2R Gastrin Jak2 10 
Angiotensin II 
Receptor 
Angiotensin II Jak2, Tyk2 1 
Receptor Tyrosine Kinases 
VEGF R1, R2, R3 VEGF Jak2 1 
EGFR EGF Jak1, Jak2 11 
PDGFR PDGF Jak2 12 
FGFR FGF Jak2 13 
IGF-1R IGF Jak1, Jak2 14 
TrkBR TrkB Jak2 15 
1(Sehgal et al., 2003) 2. (Choi et al., 2010) 3. (Fujinaka et al., 2007) 4. (Dharminder Chauhan et al., 1995) 
5. (Waters and Brooks, 2015) 6. (Williams et al., 2004) 7. (Lee et al., 2013) 8. (Lejeune et al., 2002) 9. (Vila-
Coro et al., 1999) 10. (Ferrand et al., 2005) 11. (Andl et al., 2004) 12. (Masamune et al., 2005) 13. (Dudka 
et al., 2010) 14. (Gual et al., 1998) 15. (Kim et al., 2015) 
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Every member of the Jak family has been implicated in T1DM and since the thesis 
is centred on the Jak/STAT pathway, the various Jaks have been illustrated on 
table 3 below and their link to T1DM described. 
Table 3: Jaks and beta cell health  
Jak Role in beta cells or T1DM Reference 
Jak1 
 Blockade of Jak1 protected NOD mice from 
rapidly developing T1DM 
(Trivedi et al., 
2017) 
Jak2 
 Blockade  of Jak2 inhibits IFN- signalling 
hence protects NOD mice from diabetes  
 Phosphorylation induced by EPO and 
lactogens protects beta cells from 
cytotoxicity 
 Inhibition reversed IL-13 protection of INS-
1E during serum withdrawal  
(Trivedi et al., 
2017)  
(Fujinaka et al., 
2007) 
 
(Russell et al., 
2013) 
Jak3 
 Inhibition of Jak3 reverses IL-4 protection of 
INS-1E from cytokine-induced death 
 Inhibition of Jak3 protected islets from pro-
inflammatory cytokine mediated cell death 
(Kaminski et al., 
2010) 
(Lv et al., 2009) 
 
Tyk2 
 SNP mutations in Tyk2 are associated with 
T1DM 
 Tyk2 knockdown reduces MHCI expression 
and cell death in human islets induced by 
poly-IC 
 Tyk2 transduces IFN- signals 
 
(Marroqui et al., 
2015) 
(Marroqui et al., 
2017) 
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Figure 1. 4: Janus kinase and STAT domain structures 
a. Domain structure of Janus Kinases b. Domain structure of STAT, C= C-
terminal, N= N-terminal domain, P= phosphorylated tail, T=transactivation 
domain 
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Signal Transducers and Activators of Transcription (STAT) 
The STAT proteins are a family of cytoplasmic transcription factors that are 
activated in response to various latent cytokines and growth factors. There are 
seven identified members of the STAT family in humans; these are STAT1, 
STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. STATs are between 750-
800 amino acids in length (shorter isoforms have been reported that lack a 
functional transcriptional activation domain, although they can bind and occupy 
certain binding sites) (Stark and Darnell, 2012). Each of the STAT proteins has a 
similar structure, containing an N-terminal domain, a coiled-coil domain, a DNA 
binding domain, a Linker domain, an SH2 domain, and a trans activation domain 
(Fig 1.4b).  
The N-terminal domains of the different STAT family proteins vary subtly in length 
(124-145 amino acids). Although most STATs use the SH2 domain for dimer 
formation, STAT4 has been suggested to use the N-terminal domain instead 
(Sehgal et al., 2003, Hossain et al., 2013, Vinkemeier et al., 1998). The N-
terminal domain is also important for post-translational modification of STATs 
(such as FoxP3-STAT3) (Hossain et al., 2013), and may negatively regulate the 
phosphorylation status of STAT1 at Y701 (Shuai and Liu, 2003).  
The coiled-coil domain has been reported to have a series of functions. For 
example, it is the binding site for other proteins including transcription factors (e.g. 
IRF9, or other STATs such as STAT3) (Vogt et al., 2011). Furthermore, the 
coiled-coil domain has been reported to be essential for nuclear translocation of 
STAT proteins (Ma et al., 2003). The C-C domain of STAT3 has been reported 
to be important for its SH2 domain binding to gp130 receptor upon activation by 
EGF or IL-6 (Zhang et al., 2000).  The DNA  binding domain has immunoglobulin 
variable fold structures, and it is through these regions that STAT dimers bind to 
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DNA at palindromic response elements or GAS motifs TTCN3/4GAA (Heim, 
2003).  
The linker domain (LD) is a ridged spacer which connects the DNA binding 
domain and the SH2 domain (Liongue and Ward, 2013). The SH2 domain is 
critical in mediating the binding of STATs to receptors and mediates the homo 
and hetero dimerization of STATs. Specifically, the SH2 domain of an activated 
STAT protein facilitates its binding to other phosphorylated  STAT monomers 
(Heim, 2003).  
The transcriptional activation domain (or trans-activation) can contain conserved 
tyrosine, serine or threonine residues that are phosphorylated at the receptor 
complex depending on the STAT molecule. In STAT6, the tyrosine at position 
641 is essential for transcriptional activity, while Threonine 645 is a negative 
regulator of DNA binding and transcription. The role of serine 756 is not 
completely understood but is suggested to interact with other molecules such as 
PP2A (Wang et al., 2004). The trans-activation domain is the least conserved 
domain and has been reported to interact with many proteins such as BRCA1 
however; its biological significance is not completely understood (Sehgal et al., 
2003, Lim and Cao, 2006). 
The 7 members of the STAT family have in one way or other been implicated in 
T1DM but for the purpose of this thesis, STAT6 will be the main focus. Table 4 
illustrates the 7 STAT members and the literature reporting their potential role in 
type 1 diabetes. 
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Table 4 : Signal Transducers and Activators of Transcription family and beta cell 
function 
 
 
 
STAT Role in T1D References 
STAT1  Knockout of STAT1 protects NOD mice 
from diabetes 
 Upregulated in the insulin containing 
islets of patients with T1DM 
 Drives apoptosis in rat beta cells 
stimulated with pro-inflammatory cytokines 
(Kim et al., 2007) 
 
  (Richardson et al., 
2016) 
(Moore et al., 2011) 
 
STAT2  Propagates IFN- signalling in T1D 
 Induces inflammation and ER stress in 
human beta cells 
(Santin et al., 2012) 
(Marroqui et al., 
2017) 
STAT3  Activating mutations in STAT3 induce an 
autoimmune form of neonatal diabetes 
 Activated in T-cells of T1DM individuals 
 
 Important for pancreatic development 
and insulin secretion 
(Flanagan et al., 
2014) 
(Hundhausen et al., 
2016) 
(Kostromina et al., 
2010) 
STAT4  Enhances IL-12 mediated beta cell death 
 
 SNPs in STAT4 have been suggested to 
be involved in early development of 
T1DM 
(Weaver et al., 
2015) 
 
(Lee et al., 2008) 
STAT5(A 
&B) 
 Important for beta cell insulin secretion 
 Lactogens protect rodent and human 
cells via STAT5 from STZ induced 
cytotoxicity 
 Important for beta cell growth  
(Jackerott et al., 
2006, Lee et al., 
2007) 
STAT6  IL-4 and IL-13 induce STAT6 
phosphorylation and protect rodent beta cells 
but the mechanism is unclear 
 
 Whole body knockout decreases insulin 
action and IL-4 administration improves 
insulin action and prevented autoimmunity  
 
(Russell et al., 2013, 
Kaminski et al., 
2007, Kaminski et 
al., 2010) 
(Ricardo-Gonzalez 
et al., 2010, Lau et 
al., 2012) 
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1.4.1 Central dogma of IL-13 and IL-4 signalling  
Like many cytokines, the actions of IL-13 are dependent on the type of cell being 
stimulated, for example, in B cells it induces the synthesis of IgE and in 
monocytes, it inhibits pro-inflammatory cytokine synthesis (Punnonen et al., 
1998). IL-13 shares similar functions to IL4, although it has only approximately 
25% amino acid sequence homology. Immune cells such as invariant natural 
killer T-cells (iNKT) (Usero et al., 2016) and innate lymphoid type 2 (Hams and 
Fallon, 2012) cells have been shown to secrete IL-4 and IL-13. Although most of 
the secretion of IL-4 and IL-13 is thought to be by infiltrating immune cells, the 
human pancreatic islet has also been shown to express IL-13 mRNA (Olsson et 
al., 2005).  
IL-4 signals by binding either to type I or type II cell surface receptors. Type I 
receptors are comprised of an IL-4R subunit and the common gamma chain 
(C). However, IL-4R dimerises with IL-13Rto generate a   type II receptor. 
IL-13 signals by binding to the type II receptor (made up of IL-13R1 and IL-4R. 
Alternatively, IL-13 can also bind to another receptor IL-13R2 the role of which 
has not been completely elucidated. However, IL-13R2 has a higher affinity for 
IL-13 than the type II receptor; as such, it acts as a negative regulator of the 
canonical IL-13 signalling.  
Unstimulated receptors exist as monomers with their associated Jaks. Binding of 
cytokines leads to receptor dimerization (IL-4R with C or IL-13R), bringing the 
associated receptor Jaks in close proximity leading to trans-phosphorylation of 
each other. Canonically,  It is suggested that IL-4 activates Jak1/Jak3 whereas 
IL-13 activates Jak1, Jak2 or Tyk2 (Jiang et al., 2000). However, the exact 
complement of Jaks activated in response to these cytokines depends on the cell 
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type. Once activated the Jaks phosphorylate the key tyrosine residues on the 
cytoplasmic tail of the cytokine receptor. It is suggested that signalling of both IL-
13 and IL-4 occurs on the IL-4Rwhich contains five tyrosine residues, Y497 for 
the recruitment of the IRS2,  Y575, Y603, and Y631 for STAT6 docking and Y713 
as a negative regulator of signalling (Hershey, 2003).  It is also known that STAT3 
is activated in response to the stimulation of these cytokines by docking on the 
cytoplasmic tail of IL-13R1 (Y402) (Umeshita-Suyama et al., 2000). STAT6 
binding to the receptor leading to its phosphorylation by Jak proteins, which 
induces the dissociation of STAT6 from the receptor and promotes the 
dimerization of phospho-STAT6 proteins and sometimes heterodimerisation with 
STAT3 (Delgoffe and Vignali, 2013). Alternatively, the activation of IRS-2 leads 
to the activation of the PI3-K/AKT pathway (Russell et al., 2013). Homodimers of 
STAT6 are then translocated to the nucleus where gene transcription occurs 
(McCormick and Heller, 2015) Fig. 1.5. 
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Figure 1. 5: IL-13 and IL-4 Signalling pathway 
Schematic representation of Jak/STAT signalling. Cytokine binding leads to receptor dimerization, the activation of receptor-associated 
Jaks, followed by phosphorylation of tyrosine residues on the receptor tail to which STAT6 docks. Following docking STAT6 is 
phosphorylated, detaches from the receptor and dimerizes in the cytosol into the nucleus where it transcribes target genes. 
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Negative regulation of Jak/STAT signalling pathway 
The Jak/STAT pathway can be negatively regulated at two major levels; either at 
the level of the Jaks or at the level of STATs.  
Negative regulation of Jaks 
The most extensively researched negative regulator of Jaks is the suppressor of 
cytokine signalling (SOCS). There are at least 8 members of this family SOCS1-
7 and cytokine-inducible SH2 containing protein (CISH) (Shuai and Liu, 2003). 
The precise mechanism by which SOCS proteins inhibit Jak kinase activity 
remains to be completely understood, however, a number of possibilities have 
been suggested. For example, it is reported that a conserved sequence of SOCS 
called the extended SH2 domain with high affinity  for phosphopeptides might be 
the way the inhibitory mechanism works (Babon et al., 2006). Specifically, 
SOCS1 and SOCS3 have an extended SH2 domain which binds directly to the 
activation loop of Jak2 (Y1007 and Y1008) preventing the phosphorylation of 
tyrosine residues on the cytoplasmic tail of the receptor (Yoshimura and 
Yasukawa, 2012). Additionally, others have suggested that the SH2 domain of 
SOCS3 and CISH can bind directly to tyrosine residues on the cytoplasmic tail of 
the receptor inhibiting the binding of STATs (Nicholson et al., 2000).  
Alternatively, SOCS proteins contain another conserved region of 40 amino acids 
at C-terminus called the SOCS box, this region interacts with molecules that 
recruit ubiquitin transferase and this can lead to the degradation of the SOCS-
Jak complex (Shuai and Liu, 2003). 
Additionally, Jaks are regulated by protein tyrosine phosphatases such as SHP1 
and SHP2. These proteins dephosphorylate Jak2 and Jak1 at their activation 
loops (Alicea-Velázquez et al., 2013, You et al., 1999). SHP1 regulates EPO 
signalling by dephosphorylating any Jak2 which is associated with the EPO 
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receptor (Jiao et al., 1996). SHP1 has also been reported to dephosphorylate 
Jak1 in IFN- signalling in macrophages since SHP1 deficient macrophages 
show an increased Jak1 and STAT1 phosphorylation (David et al., 1995). 
Additional phosphatases have also been shown to interact with Jaks, for 
example, CD45 negatively regulates EPO and IFN signalling by 
dephosphorylating Jak1 and Jak3 (Irie-Sasaki et al., 2001). 
Regulation of STATs 
STAT activity can be regulated by post-translational modifications (e.g. 
phosphorylation, methylation and, ubiquitylation) or through their interaction with 
certain proteins, such as protein inhibitors of activated STATS (PIAS) and protein 
tyrosine phosphatases (PTP) (Shuai and Liu, 2003).  
As already described, the stimulation of cells by certain cytokines induces the 
tyrosine phosphorylation of STAT proteins at the transactivation domain, leading 
to dimerization and subsequent translocation to the nucleus. However, there exist 
threonine and, serine phosphorylation sites in some STATs proteins, which can 
also modify protein activity. For example, STAT1 full transcriptional activity and 
function after IFN activation requires serine phosphorylation (Sadzak et al., 
2008). However, in the context of STAT6, serine phosphorylation at the 
transactivation domain has been suggested to negatively regulate DNA binding 
(Maiti et al., 2005). Methylation also has a role in controlling STAT activity, for 
example, methylation of the Arg31 residue of STAT1 by arginine methyl-
transferase 1 increases DNA binding activity of STAT1 and is suggested to inhibit 
the interaction of PIAS1 with the protein (Shuai and Liu, 2003). This effect was 
independent of tyrosine and serine phosphorylation. Methylation of a similar 
residue (Arg27) in STAT6 has also been reported to enhance STAT activity with 
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increased tyrosine phosphorylation, nuclear translocation and DNA binding all 
observed (Chen et al., 2004). 
There are four members of the protein inhibitors of activated STATs (PIAS) family 
PIAS1, PIAS3, PIASX (PIAS2) and PIASY (PIAS4) and these are constitutively 
expressed within the beta cells (Segerstolpe et al., 2016). PIAS proteins can 
regulate STAT activity by; 1) Blocking DNA binding of STAT molecules, for 
example, STAT1 and STAT3 binding are blocked by PIAS1 and PIAS3 
respectively (Chung et al., 1997, Liu et al., 1998a). 2) PIAS2 and PIAS4 enhance 
the activity of  HDACs to inhibit transcription of STAT2 and STAT4 respectively 
(Arora et al., 2003, Liu et al., 2001) 3) STAT activity can be modulated by 
sumoylation of the STAT proteins, but this binding can either enhance or inhibit 
the activity of STAT molecules (Shuai, 2006).  PIAS proteins contain a 
serine/threonine rich domain suggested to be responsible for targeted binding, 
they include a Zn-binding RING-finger like domain for SUMO transfer, a scaffold 
attachment factor A/B for binding to scaffold and a matrix attachment regions in 
the nuclear matrix. PIAS proteins operate by binding to their STAT dimers thereby 
preventing STATs from interacting with the DNA (Seif et al., 2017). 
The Jak/STAT signalling pathway can also be regulated by cross talk between 
the STATs. For instance, pre-treatment of cells with one cytokine can lead to 
upregulation of genes that negatively regulate pathways induced by a different 
cytokine. For example, pre-treatment with IFN- inhibits IL-4 induced STAT6 
activation through the inhibition of transcription of IL-4R mRNA (So et al., 2000).  
Viruses have also been shown to target STATs for degradation; this is mediated 
through the polyubiquitin-proteasome pathway and provides a method of evading 
the immune system. Specifically, simian virus 5 has been reported to target 
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STAT1, parainfluenza virus targets STAT2 and mumps virus targets STAT1 and 
STAT3 through the assembly of STAT-specific ubiquitin ligase complexes (Ulane 
et al., 2005). These are then degraded by the proteasomal pathway. Additionally, 
enteroviruses have been reported to inhibit the translocation of IFN activated 
STAT1/2 heteromers to the nucleus by downregulating the karyopherin-1, a p-
STAT1 nuclear localisation receptor (Wang et al., 2017).  
In addition to the above mentioned regulations, STAT molecules can be regulated 
at the level of alternative splicing. For instance, alternative splicing of the STAT3 
gene generates two isoforms, STAT3 and STAT3 through a conserved 
acceptor site on exon 23, which leads to the addition of seven amino acids and a 
termination codon (Aigner et al., 2018). These isoforms compared to the wild-
type STAT3 have an altered C-terminal transactivation domain and the serine 
727 phosphorylation site. STAT3 was until recently suggested to be a dominant-
negative regulator of STAT3 but now known to have different transcription and 
regulatory activities (Caldenhoven et al., 1996). STAT3 and STAT3 are not the 
only isoforms, two other STAT3 isoforms exist STAT3 and STAT3 formed by 
proteolytic processing (Nakajima et al., 2003). Proteolytic processing is a post 
translation modification of proteins by protease cleavage of a single of multiple 
peptides leading to the activation or inhibition of the target protein (Neurath, 
1989). In STATs, proteolytic processing usually generates a C-terminally 
truncated STAT protein commonly referred to as STAT (Hendry and John, 
2004). Proteolytic processing of STAT6 has been described in mice to occur 
between amino acid 685-686 (Aspartate and methionine). The forced expression 
of this mutant forms have been reported to prolong the accumulation of STAT6 
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in the nucleus and induce apoptosis and cell growth suggesting a dominant 
negative effect (Hendry and John, 2004). 
1.4.2 The role of IL-13 and Jak/STAT6 in pancreatic beta cell health  
In T1DM IL-13 levels are reduced along with other anti-inflammatory cytokines 
(IL-4, IL-10) (Berman et al., 1996, Rapoport et al., 1998), however pro-
inflammatory cytokines secreted from infiltrating CD4+ and CD8+ lymphocytes or 
macrophages are increased during insulitis (Mandrup-Poulsen, 1996, Eizirik and 
Mandrup-Poulsen, 2001). One possibility is that the reduction in IL-13 secretion 
might be due to a dysfunction in the invariant NKT-cells (Usero et al., 2016).  In 
NOD mice models the cytokine is reported to reduce the incidence of diabetes 
(Zaccone et al., 1999). 
 In vitro studies have shown the expression of IL-13R1 and IL-4R in both 
human and rodent islets (Russell et al., 2013). The precise Jaks associated with 
the IL-4R or IL-13R1 in beta cells are not clearly defined but the involvement 
of Jaks in T1DM has been proposed (see table 2). IL-13 has been shown to 
activate STAT6, STAT3 and IRS2 and to protect rodent and human islets from 
the cytotoxic effects of pro-inflammatory cytokines (Russell et al., 2013, Rütti et 
al., 2016). STAT6 is more highly expressed in beta cells  in the islets  when 
compared to other islet cells  and the exocrine pancreas and its expression 
diminishes in T1DM persons as seen on stained tissue sections (Leslie et al, 
2018). Although IL-13 protects against cytotoxicity the mechanism by which this 
is accomplished is not completely understood. Additionally, the role of STAT6 in 
this pathway has not been reported in beta cells. 
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1.4.3 Therapeutic inhibition of Jak/STAT pathway 
The role of the Jak/STAT pathway in cell communication, growth and survival is 
established, as well as its role in autoimmune diseases and malignancy reported 
(Liu et al., 2015b).  Mutations that lead to inactivation of Jak1 and Jak2 are lethal 
in mice due to neurological and erythropoiesis dysfunction respectively the 
reason why these forms of mutations have not been seen in humans (Sehgal et 
al., 2003). Jak3 and Tyk2 inactivating mutations cause severe immunodeficiency 
disease and viral infections respectively, linking both of these to the immune 
system (Aittomäki and Pesu, 2014). Activating mutations of these pathways on 
the other hand have been reported in malignancies or proliferative disease. For 
instance the change in the amino acid valine to phenylalanine at position 617 in 
Jak2 (pseudokinase domain) leads to a constitutively active Jak2/STAT5 
signalling and heighten haematopoiesis and reported in patients with 
polycythaemia vera (Pesu et al., 2005, James et al., 2005). These gains in 
function indicate that inhibitory therapeutic intervention could play an important 
role in addressing these. Ruxolitinib is a potent Jak1 and Jak2 inhibitor FDA 
approved for the treatment of rheumatoid arthritis and polycythaemia vera 
irrespective of Jak2V617F mutations (Clark et al., 2014). Oclacitinib a pan-Jak 
inhibitor has also been approved for use in the treatment of atopic dermatitis in 
dogs (Cosgrove et al., 2013). Tofacitinib originally designed to specifically inhibit 
Jak3 has been reported to inhibit Jak1, Jak2 and to a lesser extend Tyk2 have 
been approved for the use in the treatment of severe rheumatoid arthritis. It is 
also suggested to be used for immunosuppression in autoimmune diseases and 
transplantations (Changelian et al., 2003).  
STATs are known to also have a gain or loss in function with mutations. For 
example, inactivating mutations in STAT5B  A630P have been reported to cause 
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growth retardation (Kofoed et al., 2003).  STAT3 inhibitory mutations have been 
reported to be important for immune response against bacterial (staphylococcus, 
pneumococcus) and fungal infections (candiditis) and an autosomal dominant 
hyper IgE syndrome (Job’s disease) due to a loss in IL-17 production (Milner et 
al., 2008). Activating mutations in various STATs have been reported in multiple 
leukaemias and lymphomas. For instance it has been shown that STAT6 D419G 
mutation enhances the expression of CD23 in some non-Hodgkin lymphomas 
(Bösl et al., 2015). STAT molecules are non-enzymatic proteins and hence 
therapeutic targeting is challenging, however, theoretically they can be targeted 
by preventing their phosphorylation, disrupting their SH2 domain hence 
preventing dimerization and receptor association and inhibiting DNA binding 
(Aittomäki and Pesu, 2014, O'Shea et al., 2015). One major challenge of 
specifically targeting STAT molecules lies in the similarities in their sequence 
homology. For examples, targeting of STAT1 is likely to interfere with STAT3 
activity which could be severe (O'Shea et al., 2015). A few molecules have been 
developed to target STATs although none has yet been approved for use in 
humans (Furqan et al., 2013).   
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 1.5 Aims 
IL-4 and IL-13 have been shown to protect NOD mice from developing T1DM and 
protect human islets and rodent beta cells from cytotoxic stimuli (Zaccone et al., 
1999, Cameron et al., 1997, Russell et al., 2013). However, the mechanism by 
which this protection is mediated remains undefined and the genes altered 
following stimulation of these cells are unknown. Furthermore, no study has 
clearly defined the complement of Jaks activated by IL-13 and IL-4 in beta cells 
and it is difficult to infer this information from other cell models since this differs 
between cell types. These cytokines signal by activating the transcription factor 
STAT6 and so the goal of this thesis was to investigate to the role of STAT6 in 
beta cell cytoprotection. This has been divided into the following aims; 
1. Assess the protective effect of IL-4 and IL-13 in rodent and human-derived 
beta cell lines (Chapter 3) 
2. Determine the complement of Jaks expressed in beta cells and reveal 
which are activated by IL-13 and IL-4 treatment (Chapter 4) 
3. Investigate the functional consequences of altered STAT6 expression and 
activity in beta cells (Chapter 5) 
4. Study the genes regulated by IL-13 stimulation of rodent and human beta 
cells and to assess whether these changes are dependent on STAT6 
activity (Chapter 4 and 5) 
5. Study the impact of novel genes induced by IL-13 and IL-4 stimulation on 
beta cells viability (Chapter 6). 
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1.6 Study hypothesis 
1. IL-13 protects beta cells from serum withdrawal, palmitic acid and pro-
inflammatory cytokines 
2. Loss of STAT6 attenuates the protection of beta cells by IL-13 from 
cytotoxic stimuli 
3. IL-13 and IL-4 protect beta cells from cytotoxicity by upregulating anti-
apoptotic genes in a STAT6 dependent manner 
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Chapter 2.0: Materials and Methods 
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2.0 Materials and Methods 
This chapter explains in detail the different methods and materials used in the 
various studies reported in this thesis. There are, however, chapters with specific 
methods that are detailed therein.  
2.1 Reagents  
Table 5: Chemicals and reagents 
Reagent Company Catalogue 
number 
2-Mercaptoethanol Fisher(UK) BP176-100 
Attractene Qiagen(USA) 301005 
Bovine Serum Albumin (BSA) Roche (Switzerland) 10775835001 
CDP-Star Sigma(USA) C0712 
Dimethyl sulfoxide Sigma(USA) PH1309 
DMEM Fisher(UK) 12491015 
Extracellular matrix Sigma(USA) E1270 
Fibronectin Sigma(USA) F1141 
Foetal Bovine Serum (FBS) Fisher(UK) 10270 
Glycine Sigma(USA) G8898 
LDS Invitrogen(USA) NP0007 
L-Glutamine 200mM Life Tech (USA) 21051040 
Lipofectamine Ltx Fisher(UK) 100014470 
Lipofectamine RNAi Max Fisher(UK) 13778030 
MOPS SDS running buffer Life Tech (USA) B0001 
Nicotinamide Sigma(USA) N5535 
Optimem Fisher(UK) 31985070 
Palmitic acid Sigma(USA) P0500 
Penicillin/Streptomycin Life Tech(USA) 15140122 
Phosphatase inhibitor cocktail 2 Sigma(Israel) P2850 
Phosphatase inhibitor cocktail 3 Sigma(Israel) P0044 
Phosphate buffered saline Lonza(Switzerland) 10010023 
Propidium iodide Sigma (USA) P4170 
Protease inhibitor cocktail Sigma(Israel) P8340 
Re-blot strong plus Millipore (USA) 2504 
RNeasy mini kit Qiagen(USA) 74104 
RPMI 1640 Lonza (Belgium) 21875034 
RT2 First Strand  Qiagen(USA) 330401 
Skim milk powder Sigma(USA) 70166 
Sodium Selenite Sigma (USA) S5261 
SYBRGreen Master Mix Qiagen (USA) 330500 
Tris-Acetate gels 12% Invitrogen (USA) EA03552BOX 
Trizma base Sigma(USA) T1503 
Trypan blue Sigma(USA) T6146 
Trypsin EDTA Fisher(UK) SM-2003 
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2.2 Cell cultures 
2.2.1 Cell culture conditions 
2.2.1.1 Rat insulinoma -cell line (INS-1E) 
INS-1E cells are a rat cell line derived by X-ray irradiation of rat insulinoma cells 
and respond to glucose stimulation by increased insulin secretion within the 
functional ranges (3-11mM glucose) (Špaček et al., 2008). INS-1E cells possess 
a high insulin content although, they require the use of -mercaptoethanol for 
their proliferation (Skelin et al., 2010, Asfari et al., 1992). Unlike many beta cells, 
INS-1E cells remain close to the parental cell phenotype over at least 116 
passages where they still respond with a glucose-stimulated insulin response 
similar to that of the parent cell (Asfari et al., 1992). The cells were cultured in 
RPMI-1640 medium containing 11mM glucose and supplemented with 10% FBS, 
100U/ml penicillin, 2mM L-glutamine, 100U/ml Streptomycin and 50M -
mercaptoethanol. The cells were plated in 75cm2 flasks, 25cm2 flask, 6well plates 
or 12well plates depending on the experiment and incubated in 5% CO2 in a 
humid incubator at 370C. 
2.2.1.2 Human EndoC H1 beta cell line  
EndoC cells are a human beta cell line generated by transducing foetal 
pancreatic buds with a lentiviral vector expressing SV40LT (simian vacuolating 
virus 40 T antigen) under an insulin promoter (Ravassard et al., 2011). Lentiviral 
vector transduction of cells enables long-term expression of a target gene, herein 
expressing SV40LT under the insulin promoter. SV40LT is an oncoprotein, which 
induces malignancy in cells by binding to tumour suppressor proteins such as 
P53 and P105-Rb causing cells to replicate (promotes cells to leave the G1 phase 
to the S-phase) (Ali and DeCaprio, 2001). Hence, the transducing of foetal 
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pancreas with a lentivirus expressing SV40LT enabled the selective formation of 
insulin positive cells. SCID mice were then grafted with these buds to obtain 
mature pancreatic tissue that differentiated into beta cells expressing SV40LT 
and formed insulinomas. The beta cells were re-grafted into other SCID mice 
after transducing them with a lentiviral vector expressing the human telomerase 
reverse transcriptase (hTERT). The human telomerase reverse transcriptase 
together with the telomerase RNA component form the telomerase complex 
which lengthens telomeres in DNA immortalizing cells by permitting them to 
exceed their dividing thresholds (Hayflick limit). Hence, the lentiviral vector will 
permit long-term expression  of the hTERT hence preventing these cells from 
apoptosis (Weinrich et al., 1997).  The resulting beta cells were then expanded 
in vitro to generate the cell line (Ravassard et al., 2011).  
The use of primary beta cells in research is challenging due to the availability of 
these cells and the labour involved in isolating beta cells from pancreata. Also, 
rodent beta cells experiments do not always translate to humans in several ways. 
For example, humans only have a single gene that encodes for insulin while 
rodents have two. In addition, sensitivity to treatments such as palmitate between 
human beta cells and rodent beta cells is different. EndoC H1 cells are not killed 
by palmitate treatment while rodent beta cells are. These differences and many 
more suggest that we need to use human beta cell lines to fill in the gaps in 
knowledge. EndoC H1 cells have the advantage of expressing insulin and 
responding to glucose stimulated secretion in a dose dependent manner. EndoC 
H1 cells express beta cell specific genes such as MAFA, NKX6-1, PAX6, PDX1, 
NEUROD1, GCK, SLC2A2, KCNJ11, GAD2 and PTPRN. Although EndoC H1 
expressed the right markers for human beta cells, they have a very slow growth 
rate (144h to divide) (Tsonkova et al., 2017), express relatively low insulin per 
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cell compared to humans (0.46 pg in EndoC H1 vs 20pg in humans) (Marchetti 
et al., 2017a). Lastly, EndoC H1 are a recommended cell line but still fall short 
by the fact that, they are a mono-layer cell culture and do not exactly replicate 
the in vivo environment in which beta cells co-exist with other endocrine cell 
types. Furthermore, genetic manipulation of cells by the addition of various 
plasmids alter some functions although only the IAPP protein has been reported 
in EndoC H1 cells at the moment (Skelin et al., 2010, Ravassard et al., 2011). 
EndoC  cells were cultured in plates pre-coated with ECM/fibronectin, 
100U/mL Penicillin, 100U/ML streptomycin and 25mmol/L glucose within 
Dulbecco's Modified Eagle's Medium (DMEM) for at least 1hour. The coating 
medium was then replaced with culture medium which consisted of DMEM 
containing 5.6mmol/L glucose and supplemented with 2mM L-glutamine, 
100U/mL Penicillin, 100U/mL streptomycin, 50M β-2-Mercaptoethanol, 10mM 
Nicotinamide, 5.5g/mL transferrin, 2% fatty acid free albumin power (bovine 
serum albumin) and 6.6ng/mL sodium selenite. The cells were mainly cultured in 
a 25cm2 flask or in 6, 12 or 24 well plates depending on the experiment and 
incubated at 5% CO2 at 370C in a humidified incubator  (Ravassard et al., 2011). 
2.2.1.3 HEK293 cells  
HEK293 cells are a human embryonic kidney cell line developed by exposing 
embryonic kidney cells to an adenovirus type 5 DNA (Graham et al., 1977). These 
cells were cultured as previously described (Graham et al., 1977) with few 
modifications. They were cultured in 11mM glucose RPMI-1640 medium 
supplemented with 10% FBS, 100U/ml penicillin, 2mM L-glutamine, and 100U/ml 
Streptomycin. 
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2.2.2 Passaging cells 
INS-1E and HEK293 cell lines were grown to about 80% confluency before 
passaging. The medium was aspirated and the cells washed with phosphate 
buffered saline (PBS), then incubated in 0.05% trypsin-0.53mM EDTA (Fisher, 
UK) for 5min at 37oC to detach the cells from the plates. The trypsin was 
neutralised with culture medium and then spun (200g, 5min) to pellet the cells. 
Pelleted cells were resuspended in 10mL of fresh medium, counted with a 
haemocytometer and seeded as required per experiment. 
EndoC  cells were seeded at about 60-70% confluency and cultured to a 
confluency of over 90% before passaging them in a similar manner to the INS-1 
with a slight modification of using PBS containing 10% FBS as the neutralising 
medium after trypsinisation. 
2.3 Silencing gene expression with small interference RNA 
Small interference RNAs (siRNA) are small (20-30 nucleotides) noncoding 
double-stranded RNAs that can regulate gene expression by binding to the 
complementary messenger RNAs of the gene of interest. Specifically, the newly 
formed double-stranded RNA is processed into siRNA by RNAse II-like enzymes 
(Dicer). The siRNA then binds to an RNA inducing complex (RISC) where the 
more stable 5’ strand is incorporated into the RISC and separated from the other. 
The single-stranded siRNA then guides the RISC complex to align and bind to its 
target mRNA. A combination of catalytic RISC protein and Argonuate 2 cleaves 
the mRNA (Hassan D. et al., 2017). Knockdown experiments exploited the use 
of small interference RNA (siSTAT6, & siSIRP all from Thermofisher, USA) 
while scrambled siRNA sequences were employed for control treatments 
(Eurofins, Germany). The siRNA transfection was performed with lipofectamine 
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RNAi max (a liposome delivery system) transfection reagent (Invitrogen, USA), 
Optimem (Lifetechnologies, USA) according to the manufacturer’s instructions 
with only slight modifications. siRNA (10nM/well) was diluted in Optimem medium 
(60L/mL culture medium) for 10min followed by the addition of lipofectamine 
(3.4l/mL of culture medium). The solution was then mixed and applied cells in a 
dropwise fashion and then mixed gently by swirling the plate. 
Table 6: siRNA mix for transfection  
Reagent/ml Control Treatment 
Optimem 60l 60l 
siRNA 10nM* 10nM 
Lipofectamine 3.5l 3.5l 
*the scrambled siRNA is used 
2.4 Assessment of cell viability  
2.4.1 Using trypan blue as a vital dye 
Following treatment, medium containing detached cells was collected from 
culture plates into 10mL tubes and this was later supplemented with medium 
containing any remaining adherent cells after these were harvested by 
trypsinisation. The cell suspension was then centrifuged at 188g for 5min and the 
supernatant aspirated. The cell pellet was reconstituted with an equal volume of 
trypan blue (0.4% in PBS) in culture medium. Trypan blue stains dead cells (but 
not live cells) because live cells actively pump it out whereas it is retained in non-
viable cells (Tran et al., 2011). 
2.4.2 Propidium Iodide staining 
Propidium iodide (PI) is a fluorescent DNA intercalating agent which binds to 
short non-specific sequences dsDNA (4-5 DNA base pairs). PI has an excitation 
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wavelength between 491-495nm and a maximum emission wavelength of 
636nm. Unlike trypan blue, PI cannot penetrate an intact plasma membrane, and 
thus can only get into the cell when the plasma membrane has become 
permeable. Once bound to DNA its fluorescence increases by about 30 fold with 
a shift in the excitation maximum and emission maximum in both the red and blue  
respectively. This enables its use for rapid detection of dead cells whose DNA is 
accessible due to a permeable plasma membrane. PI staining was performed as 
previously described (Crowley et al., 2016). Both attached and detached cells 
were harvested as described above (section 2.4.1), centrifuged and re-
suspended in FACS buffer (Table 11). Cells were stained with a solution of 
20g/mL of propidium iodide diluted in FACS buffer and then incubated for 10min 
at 40C (on ice).  Cells were then analysed using a BD AccuriTM C6 flow cytometer 
in which single cells flow through a nozzle and pass a laser beam to detect 
forward and side scatter (FSC and SSC). The extent of forward scatter relates to 
the cell size while the side scatter relates to the granularity of the cell. The 
instrument was calibrated to separate cells according to size and granularity 
which allowed gating to detect both live and dead cells (P1 see fig. 2.1) while 
excluding cellular debris. Cells that were permeable to PI were detected by 
measuring the light emitted at 575nm. By the use of appropriate gating, the 
proportions of live and dead cells were estimated under each incubation condition 
(Fig. 2.1). 
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Figure 2. 1: Flow cytometer gating showing the populations P1 (both live and dead 
cells) and P2 (dead cells).  
INS-1E or EndoCHC1 cells were treated with 20g/mL of PI /Facs buffer for 
10min on Ice and analysed on the flow cytometer. Ungated cells (P1 left panel) 
comprise of two populations, which are resolved as viable, or non-viable cells 
respectively (right panel). 
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2.5 Cell cycle analysis 
Cell cycle analysis at a single time point was performed using a flow cytometer 
as described by Pozarowski & Darzynkiewicz (2014). After treatment, cells were 
trypsinised and pelleted by spinning at 300g for 5min. The pellets were re-
suspended in 250l cold saline GM (Table 11) and then fixed with 750L 95% 
cold ethanol for at least 30min at 40C. The fixative was removed and replaced 
with staining solution (50g/ml of PI and 100g/ml of RNase A in PBS) for at least 
1h at room temperature before 25000 events were counted using the Accuri C6TM 
flow cytometer. The data were analysed graphically (Fig. 2.2) to reveal the 
proportions of apoptotic cells, those in the G0/G1 phase of the cell cycle, the S 
phase and the G2/M phase. 
 
Figure 2. 2: Cell cycle analysis showing the apoptotic cells as M6, synthesis (S), 
G1/G0 and G2/M phases. 
Untreated cells were harvested, fixed and stained to show the apoptotic cells (M6, 
4.6%), Synthesis (S, 16.6%), G0/G1 (73.6%), Gap2 and mitosis phase (M)(G2/M, 
4.5%). 
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2.6 Gene Expression (RT-PCR) studies 
2.6.1 RNA extraction and estimation from cultured cells 
RNA extraction was performed using the RNeasyTM Mini kit by Qiagen. Cells were 
washed with PBS. Then, adherent cells were disrupted using RLT buffer (350L 
for 6well plates). With the help of a scraper, unattached cells were disrupted and 
transferred to a shedding column (QIA ShredderTM) and centrifuged for a 2min at 
13000g. An equivalent amount of ethanol (70%) (350l) was added to the spin-
through and the eluate transferred to an RNeasy Spin column. Ethanol 
precipitates the RNA enabling it to bind to the RNeasy membrane. The samples 
were briefly centrifuged at 8000g, before washing with RPE and RW1 buffers. 
The RNA was eluted from the spin column using 50l DNase/RNase free water 
and stored at -200C until needed for cDNA synthesis.  
RNA quality and quantity were measured using a NanoDrop™ 8000 
Spectrophotometer (Thermo Scientific, UK). The 260/280nm ratio is used to 
assess the quality of the sample and a ratio of greater than or equal to 2.0 was 
regarded as appropriate. Alternatively, the Agilent bioanalyser was used to 
confirm the quality of the RNA by electrophoretically measuring the RNA integrity 
(RIN) of samples. The RNA integrity is a measure of the ratio of 28S to 18S 
ribosomal subunits which indicates the level of RNA degradation in each sample. 
It also can detect the presence of genomic DNA in the samples and compute a 
RIN number to grade the quality of the RNA (from the best quality of 10 to the 
poorest quality 1). 
2.6.2 cDNA synthesis 
cDNA synthesis was performed using the RT2 First Strand kit (Qiagen, USA), 
according to the manufacturer’s instructions. Using 100ng of total RNA, genomic 
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DNA was first eliminated with a DNA elimination buffer. Ten microliters of reverse 
transcription mix (Table 8: Reverse-transcription mix) was added and synthesis 
performed at 420C for 15mins followed by a stop step of 950C for 5mins: 
Table 7: Genomic DNA elimination mix 
Component Amount/reaction 
RNA 100ng 
Buffer GE 2L 
RNase-free water variable 
Total volume 10L 
 5mins at 42oC then placed on ice for 1min 
Table 8: Reverse-transcription mix 
Component Volume/reaction 
5x Buffer BC3 4L 
Control P2 1L 
RE3 Reverse Transcriptase 2L 
RNase-free Water 3L 
Total volume 10L 
2.6.3 Quantitative RT-PCR. 
Relative gene expression was measured by quantitative real-time PCR using RT2 
SYBRGreen master mix (Qiagen, USA) following the manufacturer’s protocol. 
Amplicons were read on the Applied BiosystemTM Quant Studio 12K flex. HPRT1 
and YY1 were used as housekeeping genes for all PCR reactions and were used 
to normalise the data during analysis. Analysis of data was performed using the 
change in cycle threshold (Ct) formula to obtain the fold change in mRNA level. 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = 2−(∆∆𝐶𝑡) 
∆∆𝐶𝑡 = ∆𝐶𝑡𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 − ∆𝐶𝑡𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
∆𝐶𝑡𝑠𝑎𝑚𝑝𝑙𝑒 = 𝐶𝑡(𝐺𝑂𝐼𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) − 𝐶𝑡(𝐻𝐾𝐺𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) 
∆𝐶𝑡𝑐𝑜𝑛𝑡𝑟𝑜𝑙 = 𝐶𝑡(𝐺𝑂𝐼 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) − 𝐶𝑡(𝐻𝐾𝐺 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) 
GOI: gene of interest, HKG: Housekeeping gene. 
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Table 9: PCR mix for one reaction and cycling conditions 
Component Volume 
RT2 SYBR Green Mastermix 12.5L 
cDNA synthesis reaction 1L 
RT2 qPCR Primer Assay (10MStock) 1L 
RNase-free water 10.5L 
Total volume 25L 
Cycling conditions 
 
 
 
2.7 Protein detection by western blotting 
2.7.1 Protein extraction 
In order to study the expression and phosphorylation of proteins, western blotting 
was performed as described by Russell et al. (2013) with some modifications. 
Briefly, after treatment each flash of cells was washed with cold PBS. This was 
removed and replaced with lysis buffer (Table 11) containing Protease and 
Phosphatase inhibitors for 10min on ice. The contents of each flask were scraped 
and transferred into a 1.5mL tube on ice, mixed and then centrifuged for 10min 
at 2500g at 40C. The supernatant was transferred into a new 1.5mL tube and 
stored at -200C until used. 
2.7.2 Protein estimation 
The concentration of protein within samples was estimated using bicinchoninic 
acid (BCA) (ThermoFisher, UK). This test exploits the reduction of Cu2+ to Cu1+ 
by proteins in an alkaline medium resulting in a change in colour from blue to 
purple. The test is made up of a two-step reaction; the first involves chelating of 
Cycles Duration Temperature 
1 10min 950C 
 
40 
15 s 950C 
1min 600C 
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Cu2+ by various amino acid residues (Cysteine or cystine, tyrosine, and 
tryptophan) to form a blue complex in an alkaline environment with sodium 
potassium tartrate. The next step is the colour formation step in which 
bicinchoninic acid (BCA) reacts with Cu1+ to form a BCA/copper complex soluble 
in water with a linear absorbance as protein concentration increases at 562nm 
(Huang et al., 2010). In order to perform the test, 10L of each sample (1:5 and 
1:10 dilutions in lysis buffer) and BSA standards (0, 0.2, 0.4, 0.6, 0.8, 1.0 and 
1.2mg/mL) were pipetted into a 96well plate. This was followed by 200L BCA 
reagent. The BCA reagent was prepared by diluting Reagent A (sodium tartrate) 
with Reagent B (copper (II) sulphate pentahydrate) at 1:50 ratio. The plate was 
then incubated for 15min on a mixer before reading at 562nm on a PheriSTARTM 
instrument. The protein concentration of samples was calculated using from a 
standard curve. 
Preparation of protein samples and running of the gel 
Equal amounts of protein (10-50g/well) were loaded into each well of 
polyacrylamide gel after dilution with lysis buffer. Each sample contained 65% 
protein extract, 25%LDS loading buffer (4 x) and 10% β-mercaptoethanol. Before 
loading the mixture, the samples were heated at 700C for 10min. 20L of each 
sample was loaded into a pre-cast 12% poly-acrylamide Bis-Tris gel (Invitrogen). 
The gel was run at 120V in 1X MOPS (Life Tech, USA) running buffer alongside 
a rainbow molecular marker for 2h. 
Transfer of proteins and blotting. 
PVDF membrane and blotting paper (Millipore, UK) were cut to approximately the 
size of the gel. The PVDF membrane was pre-soaked in methanol; rinsed 3x with 
dH2O, and then placed on the gel. The gel and membrane were sandwiched 
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between pre-soaked (in transfer buffer) blotting paper and two pre-soaked 
blotting pads. The anode core was placed on top and then locked into place. The 
module was filled with transfer buffer (Table 11: Buffers and their Contents1) to 
cover the membrane. The outer chamber was then filled with water to help cool 
the membrane during the transfer process and the module run at 30V, 170mA for 
2h. 
After electrophoresis, the membrane was blocked with 5% milk or BSA diluted in 
TBST for 1h at room temperature, followed by addition of primary antibody in 5% 
milk diluted in TBST at 40C. After incubation, three 15min washes with TBST were 
performed, the membrane was then probed with alkaline phosphatase 
conjugated secondary antibody diluted 1:25000 in TBST containing 1%milk for 
1hour at room temperature. The secondary antibody depended on the species in 
which the primary antibody was raised. Another 3X TBST wash was performed 
followed by incubation of the membrane in chemiluminescent reagent alkaline 
phosphatase substrate (Sigma Aldrich, UK) for 5min at room temperature and 
then detection using the Licor C-Digit blot scanner. In cases where the secondary 
antibody was conjugated to a fluorophore, no detection fluid was used and the 
blots were scanned directly on the Licor clx OdysseyTM instrument.  
Re-probing membranes 
Western blotting membranes were reprobed when two or more proteins of 
interest were to be detected on a single blot. To reprobe, the previously bound 
primary antibody was removed using a stripping buffer (reblot strong plus, Merck 
Millipore, UK) (diluted using dH2O (Promega, UK)). The membrane was 
incubated in reblot strong plus buffer for 13min followed by two 5min washes in 
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TBST. The membrane was then blocked with 5% milk TBST before adding the 
next primary antibody. 
2.8 Protein detection by Immunohistochemistry and 
Immunofluorescence  
2.8.1 Immunohistochemistry 
Immunostaining was performed on human formalin-fixed paraffin embedded 
pancreas samples from the Exeter Archival Diabetes Biobank 
(http://foulis.vub.ac.be/). Serial sections were cut (4m) and mounted on to glass 
slides. Immunohistochemistry was performed as previously described (Arif et al., 
2014, Willcox et al., 2009a). Samples were dewaxed using two changes of 
histoclear (D-limonene) (National Diagnostic, Nottingham UK), then rehydrated 
in decreasing ethanol concentration (from 100% to 50%) before putting the slides 
into ddH20 in 50mL Coplin jars.  
Fixing of tissues with formalin can cause epitope masking hence reducing the 
immunoreactivity of antigens of interest with antibodies. This occurs because 
formalin forms cross-links between proteins and nucleic acids and the formation 
of these bonds lead to steric hindrance of antibody binding sites (Werner et al., 
2000). Heat Induced Epitope retrieval (HIER) was performed to re-expose 
blocked epitopes in a process suggested to break the cross-linking bonds formed 
by formalin fixation. Sections of pancreas on glass slides were placed in a 
pressure cooker containing citrate buffer (pH6, see Table 11: Buffers and their 
Contents) in a microwave (800W) then heated for 20min before cooling for a 
further 20min. Samples were blocked with 5% (v/v) normal goat serum (NGS) 
and then probed with primary antibody diluted in Dako antibody diluent and left 
overnight at 40C. 
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Following primary antibody incubations, slides were given 3 washes in TBS 
before blocking with 300L of Dako Real PeroxidaseTM for 5min in order to arrest 
any endogenous tissue peroxidase activity within the sample. The blocking 
reagent was washed once in TBS, then a relevant secondary antibody added. 
The Dako REAL EnVisionTM HRP conjugated secondary antibody was added for 
1h and unbound antibody removed by three 5min washing in TBS. After washing, 
sections were incubated in 300L of Dako Real EnVisionTM high-sensitivity 
diaminobenzidine (DAB+) chromogenic substrate for 10min followed by a 5min 
wash in ddH20 to stop the reaction. DAB is catabolised by horseradish peroxidase 
(HP) to produce a brown-coloured product at places where secondary antibodies 
are bound to the tissue. The tissue sections were then stained with haematoxylin 
and eosin for 1min and washed with running tap water for 5min. Each tissue 
section was briefly dipped in STWS (40mM NaHCO3, 170mM MgSO4) to “blue” 
the tissue. The sections were then washed in in ddH2O followed by incubation in 
CuSO4 solution (20mM CuSO4/150mM NaCl) for 5min to intensify the 
chromogenic stain (DAB). Sections were given a final wash in ddH2O followed by 
dehydration by dipping slides in increasing concentration of ethanol 50%, 70%, 
90% and twice in 100% (5min each). The sections were then cleared of any 
remaining alcohol and water by 2x5min incubation in histoclear and mounted 
under a coverslip with use of distyrene/xylene (DPX) (Dako, UK) before leaving 
to dry at RT. 
2.8.2 Immunofluorescent staining  
In order to study multiple antigens on a tissue section, slides were sequentially 
probed with the different primary antibodies and fluorescent-tagged secondary 
antibodies. To do this, slides were dewaxed, rehydrated, and blocked as 
described in section 2.8.1. The first antiserum ( diluted in antibody diluent) was 
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put on sections for 1h at room temperature followed by three 5min PBS washes. 
Secondary fluorescent conjugated antibody was applied to the sections in 
opaque staining trays at room temperature for 1h. Secondary antibody was then 
washed 3X with PBS in opaque Coplin jars and the next sequence of stain 
performed. On the last sequence, the secondary antibody was added together 
with a nuclear stain 4′,6-diamidino-2-phenylindole (DAPI). Following the last 
stain, slides were washed and mounted using Dako fluorescent mounting media 
and then left to dry overnight in a dark cupboard. The slides were visualised on a 
fluorescent microscope (Leica Microsystems, Milton Keynes, UK). 
2.9 DNA cloning  
2.9.1 Agar plates, and Broth 
Luria Broth (LB) was used for E.coli amplification and was prepared by weighing 
20g of broth, which was then dissolved in 1L of ddH20; this was autoclaved at 
1210C for 15min and left to cool to a temperature lower than 500C before adding 
an antibiotic (100g/mL ampicillin, 50g/mL kanamycin(Sigma, UK)). LB with 
agar was used for inoculating competent E.coli. It was prepared by weighing 35g 
in 1L of ddH20 then autoclaved. Following autoclaving, the agar was left to cool 
before adding 100g/mL of ampicillin or 50g/mL kanamycin depending on the 
plasmid, mixed and then poured under the biosafety cabinets into 20mL Petri 
dishes.  
Competent E.coli 
Bacteria can obtain genetic information by three mechanisms, conjugation from 
other bacteria, transduction by the help of a bacteriophage and by transformation 
which is uptake of DNA through the cell wall. Bacterial uptake of plasmid or DNA 
(transformation) is possible if the recipient bacteria is made “competent” through 
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heat shock or electroporation both of which precede CaCl2 treatment 
(Rahimzadeh et al., 2016, Bergmans et al., 1981). The mechanism by which 
CaCl2 helps in DNA uptake is still unclear but it is thought to bring the DNA close 
to the bacterial cell wall (Rahimzadeh et al., 2016). 
2.9.2 Bacterial Transformation, amplification and plasmid extraction 
Transformation and expansion 
Following resuspension of each plasmid, it was transformed into competent E.coli 
(New England Biolabs, UK) using a heat shock method as described with some 
modifications by Froger and Hall (2007). Into a 1.5mL Eppendorf 100L of 
competent E.coli was transferred and mixed with 100ng of plasmid by flicking. 
The mixture was then left on ice for 10min prior to being heat shocked at 420C 
for 50s in a water bath, and then incubated on ice for 2min. The transformed 
bacteria were transferred into a universal tube containing 900L LB without 
ampicillin. The LB broth with transformed bacteria was cultured at 370C in a 
shaker for 1h at 150rpm. Fifty microliters of solution were then spread on an LB 
agar plate with ampicillin or kanamycin (in a biosafety cabinet). The plates were 
grown overnight in a non-CO2 incubator at 370C to allow bacterial colonies to 
form.  
Fifty millilitres of LB+ Ampicillin (or Kanamycin) was placed into a universal tube, 
then colonies were picked from the plate and inoculated into the broth and 
incubate for 8h in at 370C shaking incubator. 
Plasmid extraction 
After expansion by overnight liquid culture, the culture was transferred into 50mL 
tubes for extraction. The tubes are spun down at 4000rpm for 15min and the 
supernatant decanted. Extraction was performed using a Midiprep as required by 
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the manufacturer (Qiagen, USA). Briefly, cells were resuspended in 4mL of buffer 
(P1), and then lysed with 4mL of lysis buffer (P2) and mixed by inverting the 
capped tube 4-6times. The mix was then neutralised with 4mL prechilled buffer 
(P3). The solution was transferred to a filter (QIAfilter) and balanced with QBT 
buffer before filtering with the aid of a plunger into a column (Qiagen-Tip). The 
column was washed twice before eluting the plasmid with 5mL of buffer QF. The 
DNA was then precipitated with 3.5mL Isopropanol and spun at 4000rpm for 
45min. The supernatant was discarded before DNA was precipitated with 70% 
ethanol then spun for 4000rpm for 10min. The supernatant was discarded and 
the tubes air dried before dissolving the DNA in 100L DNase free water. DNA 
was then quantified using a Nanodrop instrument (Thermofisher, USA). 
2.9.3 Transfection of INS-1E and HEK293 cells 
Plasmids were then transfected into cells using Attractene (Qiagen, USA) or 
Lipofectamine LTX (Fisher, UK) and Optimem (Fisher, UK) as transfection 
reagents according to table 10: 
Table 10: Plasmid transfection in INS-1E or HEK293 Cells 
Reagent Control Treatment 
Optimem 60l/mL  60l/mL 
DNA (STAT6, CA, DN) 0ng/mL 400ng/mL 
DNA (Reporter firefly 
luciferase)for Dual Luciferase 
experiments 
200ng/mL 200ng/mL 
DNA (Renilla control) for Dual 
luciferase experiments 
200ng/mL 200ng/mL 
eGFP (for viability experiments) 500ng/mL 500ng/mL 
Attractene or 
 
Lipofectamine 
2l/mL 2l/mL 
3.5l/mL 3.5l/mL 
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2.9.4 Dual-Luciferase Reporter assay 
The Dual-Luciferase Reporter Assay (DLR) is an assay system that measures 
the activity of a given promoter for a transcription factor, gene or intracellular 
signal (McNabb et al., 2005). The term ‘Dual’ simple refers to the assay’s capacity 
to measure the expression of two luciferase enzymes at the same time. The 
assay exploits the differences in the biochemistry of two enzymes, a luciferase 
(61kDa) from the firefly (Photinus pyralis) and a (36kDa) luciferase from the sea 
pansy (Renilla reniformis). The enzymes are different in structure and substrate 
requirements permitting measurement of two protein products in the same 
reaction. These two enzymes do not require any post-translational modification 
for their functioning and so act efficiently as reporters. The photon emission 
reaction of the firefly luciferase occurs by the oxidation of beetle luciferin in the 
presence of ATP, Mg2+ and a co-enzyme to increase the speed of reaction. The 
luminescence reaction for the Renilla occurs by the oxidation of coelenterazine 
by Renilla luciferase to coelenteramide and CO2 (Fig. 2.3.). In the DLR, the 
activity of the firefly enzyme is directly proportional to that of the promoter 
(experimental reporter) whilst the Renilla acts as the control and allows the 
number of cells transfected to be controlled for. These activities were measured 
simultaneously from the same lysate, such that as one reaction was quenched 
(Firefly), the other was activated Renilla. The experimental activity (firefly 
luciferase) was then normalised against the control (Renilla) (Sherf et al., 1996).  
DLR was performed following the manufacturer’s instructions. Briefly, 24h after 
STAT6 mutant plasmid transfection alongside the luciferase reporter and Renilla 
plasmids, cells were given two PBS washes before lysing with 100L of 1x 
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passive lysis buffer at room temperature for 15min with gentle shaking. Lysates 
were transferred into 1.5mL Eppendorf tubes and placed on ice. The luciferase 
assay reagent II (LAR II) and the Stop and GloR substrate were reconstituted as 
required and used to prime the plate reader. 20l of each sample was transferred 
into a 96-well white plate and the plate placed into the PHERstar luminometer. 
The instrument was set to inject the LARII reagent at 0s then read for 12s before 
the injection of the STOP and GloR with another 12s there after making a total of 
24s recording. The readings with the Firefly enzyme were normalised to the 
Renilla data and expressed relative to the relevant controls. 
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Figure 2. 3: Reactions of Luciferin and coelenterazine catalysed by firefly and Renilla 
luciferase enzymes 
Source: www.promega.com 
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2.10 Statistical Analysis 
All statistical analyses were performed on GraphPad Prism 7.03 for Windows 
software. To compare two means, a Student’s t-test was performed and when 
more than two means were compared, an ANOVA was used with a Tukey post-
test. ANOVA stands for the analysis of variance and is usually used to compare 
if the means of two or more unrelated data sets are different. It differs from the t-
test in that it examines the variability of between the groups and within the groups. 
Even though the ANOVA test can tell that there is a difference in the means of 
the data set, it is limited by the fact that it cannot tell which group is different or 
how big the difference (Ennos, 2007). To identify which group is different and how 
big the difference is a post-hoc test is performed. There are several post hoc test 
but for the purpose of this thesis the Tukey post-test was used.  The Tukey test 
is used to determine if there is a significant difference between experimental 
group on a studentized range distribution. It compares the mean of each group 
to the mean of every other group within a given data set (Ennos, 2007). Data in 
this thesis is presented as mean values ± standard error of the mean (SEM). 
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Table 11: Buffers and their Contents 
Unless or otherwise stated in text or on table 5, the chemicals on this table were 
acquired from Sigma (USA). 
Buffer Contents 
BCA Protein assay Reagent A: Sodium carbonate, sodium bicarbonate, 
bicinchoninic acid & sodium tartrate in 0.1N sodium 
hydroxide. 
Reagent B: 4% cupric sulphate pentahydrate 
FACS Buffer PBS, 2% FBS 
LDS sample buffer 
(4X) 
4M glycerol, 0.56M Tris Base, 0.42M Tris HCL, 0.3M 
Lithium dodecyl sulphate, 2mM EDTA, 0.075% serva blue 
G250, 0.025% Phenol red 
Lysis Buffer 20mM Tris, 150mM NaCl, 1mM EDTA, 1% Triton-X 
MOPS running 
buffer (20X) 
50 mM MOPS (3-(N-morpholino) propanesulfonic acid), 
50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7 
Saline GM - D-Glucose (Sigma) 6.1mM 
- KCl (Sigma) 5.4mM 
- Na2HPO4 (Sigma) 2.75mM 
- KH2PO4 (Sigma) 1.1mM 
- NaCl (Sigma) 6.9mM 
- 50L 0.5M EDTA (Sigma) 
All into 50mL tube and top up to the mark with ddH2O 
water 
TBS 137mM NaCl, 2.6mM KCl, 49.5mM Tris (pH 7.6) 
TBST TBS+0.05% Tween (pH 7.6) 
Transfer Buffer 25mM Tris, 0.19M Glycine, 20% Methanol (pH 8.3) 
Whole cell lysis 
buffer 
20mM Tris, 0.15M NaCl, 1mM EDTA and 1% Triton-X 100 
(pH 7.4) 
Citrate 
buffer(10mM) 
Citric acid 1.92g, 1L ddH20 and add 2N NaOH to pH6 
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Chapter 3.0: IL-13 and IL-4 protect pancreatic 
beta cells from cytotoxicity 
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3.0 IL-13 and IL-4 protect pancreatic beta cells from cytotoxicity 
3.1 Introduction 
T1DM is a pancreatic islet inflammatory disease in which the insulin-producing 
beta cells of the pancreas are specifically destroyed by autoreactive T-cells. 
Developing therapies to resolve the disease pathology has been unsuccessful 
probably because the pathogenesis of the disease itself remains to be fully 
understood (Grunnet and Mandrup-Poulsen, 2011).  
Cytokines are small protein molecules involved in intercellular communication 
and implicated in almost every biological process in the body. They can be 
secreted by most types of cells (almost every nucleated cell) although immune 
cells are an important source. The actions of cytokines can be anti-inflammatory 
or pro-inflammatory (Charles, 2007).  
 A long list of cytokines have been implicated in the pathogenesis of T1DM and 
in many cases, their effects on beta cells have been extensively studied. For 
instance, IL-1 has been shown to inhibit insulin biosynthesis and induce beta 
cell death by apoptosis through NO production. Cytokines such TNF- and IFN-
 on their own induce very little beta cell death but in combination with IL-1 
exacerbate beta cell death. IFN- inhibits insulin secretion and induces beta cell 
dysfunction independent of NO production. (Eizirik and Mandrup-Poulsen, 2001, 
Rabinovitch and Suarez-Pinzon, 2003, Thomas et al., 2013, Laffranchi and 
Spinas, 1997). Other pro-inflammatory cytokines have been shown to inhibit 
insulin secretion by induction of beta cell ER stress through increased production 
of reactive oxygen species and nitrites include IL-23, IL-24 and IL-33 (Hasnain et 
al., 2014). Circulating levels of these cytokines have been monitored in T1DM 
and their changes studied extensively (He et al., 2014, Alnek et al., 2015). 
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Increasing evidence suggests that in T1DM there is a paradigm shift in the 
Th1/Th2 CD4+ T-cells cytokine secretion to a Th1 secretion model (Walker and 
von Herrath, 2016, He et al., 2014). Other reports show a decrease in circulating 
Th1 cytokines; in one such report, they studied mRNA levels of these cytokines 
which might be different from protein expression levels (Vaseghi and Jadali, 
2016). In another report, wherein T1DM patients were grouped into under 15 
years and over 15 years of age, an initial increase in Th1 cytokines (individuals 
under 15 years) was followed by a decrease (over 15 years individuals) 
suggesting that duration of T1DM might have an influence on serum cytokines 
levels (Fatima et al., 2016). Serum cytokine levels (IL-2, IL-5, IL-10, IL-6, IL-
1IL-8, IL-10, IL-17, IL-23, and GM-CSF) of patients compared to their matched 
controls seem to be elevated irrespective of whether Th1 or Th2 derived (Alnek 
et al., 2015). While many studies have been published on the role of pro-
inflammatory cytokines in beta cell biology (Choi et al., 2010, Collier et al., 2011, 
Stanley et al., 2017, Souza et al., 2008), few have looked at their “anti-
inflammatory” counterparts. The levels of these anti-inflammatory cytokines (IL-4 
and IL-13) have only been studied at a serological level which gives us a picture 
of the alterations in circulating cytokines but does not provide evidence of events 
in the islet environment which could be different (Russell and Morgan, 2014). 
The protective role of IL-13 and related IL-4 have been previously studied in NOD 
mice by treating them with human recombinant IL-13 three times weekly which 
led to a delay in their development of type 1 diabetes. Use of anti-CD3 
monoclonal antibody to induce the release of cytokines (IFN- and TNF-) by T-
cells in these mice was also diminished by IL-13 administration when compared 
to their controls. IL-4 treatment of NOD mice was suggested to protect them from 
diabetes by diminishing insulitis and promoting a Th2 response while decreasing 
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the number of T-cells infiltrating the pancreatic islets (Zaccone et al., 1999, 
Cameron et al., 1997). Similarly, galactosylceramide (-GalCer) treated NOD 
mice were protected from developing T1DM mainly by modulating IL-4 secretion 
by invariant natural killer cells (NKT). NOD mice treated with -GalCer and anti-
IL-4 mAB or NOD IL-4 -/- mice treated with -GalCer still developed T1DM. In 
these experiments, -GalCer was used to activate invariant NKT-cells (shown to 
be deficient in T1DM) which then produce IL-4 and IL-10. The use of NODIL-4 -
/- showed that the protection offered by -GalCer was mainly due to IL-4 (Mi et 
al., 2004). 
We and others, have shown that IL-13 and related IL-4 protect beta cells from 
inflammatory cytokines (IL-1, TNF-, IFN- and IL-6), palmitic acid and serum 
deprivation induced death (Kaminski et al., 2010, Kaminski et al., 2007, Russell 
et al., 2013, Rutti et al., 2016). Human islets stimulated with pro-inflammatory 
cytokines had diminished insulin secretion while their co-incubation with Th2 (IL-
4 and IL-10) and Th3 (TGF-1) cytokines reversed this inhibition. In these 
experiments, cell death was prevented by the addition of Th2, but not Th3 
cytokines (Marselli  L and M, 2001). 
The objectives of this chapter were as follows; 
 To investigate the protection of INS-1E beta cells by IL-13 ( and IL-4), from 
serum withdrawal, pro-inflammatory cytokines, and palmitic acid induce 
cytotoxicity  
 To investigate the effect of IL-6 with and without pro-inflammatory 
cytokines on EndoC H1 beta cells  
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 To investigate the protection of EndoC H1 cells by IL-13 from pro-
inflammatory cytokine induced cytotoxicity 
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3.2 Materials and Methods 
Rat INS-1E and human EndoC HC1 beta cell lines were used in these 
experiments. Culture of these cells has been described in section 2.2.2.1 and 
2.2.2.2. All cytokines (IL-1, IL-6, TNF-, IL-4, IL-13, and IFN-) were purchased 
from R&D systems (Abingdon, Oxford, UK). Palmitic acid and Bovine serum 
albumin were purchased from Sigma (Dorset, UK). The concentrations used in 
these experiments were previously optimised in our group (Russell et al., 2013, 
Kaminski et al., 2007). 
3.2.1 Viability assessment 
Viability of cells was assessed with either trypan blue or propidium iodide as 
described in section 2.4. Cell viability analysis was performed to assess the 
response to various cytotoxic stimuli in this chapter. 
3.2.3 Serum withdrawal assay 
Serum withdrawal experiments were performed according to (Russell et al., 
2013). Briefly, INS-1E cells were seeded at 2.0x105 cells/mL in a 12-well plate 
and complete medium was replaced after 4h with serum free medium in the 
presence or absence of IL-13 or IL-4. Cells were incubated for 96h, with a 
medium change performed after 48h. Cells were then harvested and viability 
measured as described in section 2.4.2. 
3.2.2 Cytokine induced cytotoxicity 
INS-1E or EndoC H1 cells were pre-incubated with 20ng/mL of IL-13, for 
48hours. The medium was then changed and replaced with medium containing 
20ng/mL of each of the following cytokines IL-6, IL-1, TNF and IFN with and 
without IL-13 for 48hours (Russell et al., 2013). Both floating and attached cells 
were then harvested and cell viability measured. 
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3.2.3 Palmitic acid induced cytotoxicity 
Palmitic acid induced cytotoxicity assays were performed as described by 
(Russell et al., 2013). Palmitic acid was prepared in 50% ethanol and dissolved 
by heating for 10min at 700C. The palmitic acid was introduced to INS-1E cells 
by using fatty acid free BSA as a carrier, to which palmitic acid was bound upon 
incubation at 370C for 1h. Prior to palmitic acid treatment of cells, INS-1E were 
stimulated with and without 20ng/mL of IL-13 for 48hours, followed by a further 
48hours of palmitic acid treatment. Cells were then harvested and viability 
measured. 
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3.3 Results 
In order to demonstrate that IL-13 protects beta cells from cytotoxicity, cultured 
beta cells were incubated under cytotoxic conditions comprising of: serum 
withdrawal, palmitic acid or pro-inflammatory cytokines. The cytoprotective 
potential of IL-13 was investigated in rodent INS-1E and human EndoC H1 cells.  
3.3.1 IL-13 partially protects INS-1E beta cells from serum withdrawal 
induced cytotoxicity
Serum withdrawal (sometimes called serum starvation or serum deprivation or 
serum free conditoins) involves the use of cell culture medium without FBS and 
has been used to induce cell death in various cell types including beta cells 
(Higuchi et al., 2006, Charles et al., 2005, Russell et al., 2013). FBS contains 
growth factors and lack of these leads to the activation of intrinsic apoptotic 
pathways, culminating in cell death (Charles et al., 2005).  
Initially, the level of beta cell death induced by serum withdrawal in INS-1E 
cultures was assessed over a 96h to determine a suitable time point at which to 
conduct subsequent experiments. Serum withdrawal for up to 48h did not induce 
significant cell death when compared to serum containing medium (24h Con 
4.1±0.6% cell death, SW 7.7±1.26% p=0.88; 48h Con, 13.3±3.4% SW 21.6±7.8% 
p=0.99). However, there was a significant rise in cell death at 72h and 96h in 
serum free conditions when compared to cells incubated in serum containing 
medium (72h Con 10.16±2.2%, SW 31.8±4.1% cell death p<0.001; 96h Con 
21.1±2.8%, SW 44.5±5.3% cell death). With reference to the previously 
established time point, 96h was chosen for all other serum withdrawal 
experiments (Fig. 3.1) (Russell et al., 2013).   
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IL-13 protected INS-1E cells from serum withdrawal induced cell death at 96h 
(SW, 47.9±1.8%; SW+IL-13, 36.4±2.4% cell death, p<0.001) (Fig. 3.2). IL-4 also 
significantly improved beta cell viability after removal of serum from the culture 
medium (SW, 52.8±1.6%; SW+IL-4, 46.7±1.3% cell death, p<0.01) (Fig.3.3). 
Earlier reports had also shown that IL-13 and related IL-4 can protect pancreatic 
beta cells from cytotoxic effects of serum withdrawal (Kaminski et al., 2007, 
Russell et al., 2013, Sternesjo and Sandler, 1997). 
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Figure 3. 1 Serum withdrawal induces cell death in INS-1E beta cells 
INS-1E cells were incubated in serum withdrawn conditions for 96h and cell 
viability assessed using trypan blue. Data represents mean values ±SEM of three 
replicates in two experiments. ***p<0.001, ns: not significantly different from 
serum containing culture medium determined by student t-test. 
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Figure 3. 2 IL-13 treatment partially protects INS-1E beta cells from serum 
withdrawal induced cell death 
Cell death was induced by incubation of INS-1E beta cells in serum withdrawn media for 
96h. These cells were untreated or treated with 20ng/mL of IL-13 and cell viability 
assessed by trypan blue staining. 
Data represent mean values ±SEM of 6 replicates of three different experiments, 
***p<0.001 determined by student t-test. 
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Figure 3. 3 IL-4 treatment partially protects INS-1E beta cells from serum 
withdrawal induced cell death 
Cell death was induced by incubation of INS-1E beta cells in serum withdrawn media for 
96h. The cells were untreated or treated with 20ng/mL of IL-4 and cell viability assessed 
by trypan blue staining. 
Data represent mean values ±SEM of 6 replicates of three different experiments, 
**p<0.01 determined by student t-test. 
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3.3.2 IL-13 partially protects INS-1E beta from pro-inflammatory cytokines 
induce cell death 
Emerging evidence suggests that an imbalance between pro-inflammatory and 
anti-inflammatory cytokines occurs in T1DM and that this may play an important 
role in modulating the viability of pancreatic beta cells in the disease (Fatima et 
al., 2016, Fitas et al., 2018). Pro-inflammatory cytokines such as IL-1, TNF- 
and IFN- are widely reported to induce beta cell death and dysfunction and these 
effects have been extensively studied in pancreatic islets and beta cells (Rutti et 
al., 2016, Collier et al., 2011, Cetkovic-Cvrlje and Eizirik, 1994, Marselli  L and M, 
2001). IL-1 alone is reported to induce cell death, however, this depends on the 
concentration used and the length of exposure (Spinas et al., 1986, Palmer et al., 
1989). Conversely, TNF-, IFN- and IL-6 do not induce any potent cytotoxic 
effects on their own, but when applied in combination with IL1-, these cytokines 
are cytotoxic (Cetkovic-Cvrlje and Eizirik, 1994).   
Previous experiments by Russell et al. (2013) revealed that pre-incubation of INS-
1E with IL-13 was crucial to its mediated protection from pro-inflammatory 
cytokines induced cell death. This revelation was assessed here and confirmed 
by treatment of INS-1E beta cells with pro-inflammatory cytokines (IL-1, TNF- 
IFN- and IL-6) for 48h simultaneously with IL-13 and following pre-treatments of 
IL-13. INS-1E beta cell treatment with pro-inflammatory cytokines induced 
significant cell death (pro-cytokines (IL-1, TNF- IFN- and IL-6), 64.6±4.3%) 
which was reduced by 48h pre-incubation with IL-13 (pro-cytokines+pre-IL-13: 
47.4±2.2% p<0.001). However, under conditions where IL-13 was added 
concurrently with pro-inflammatory cytokines, there was a less significant 
reduction in cell death (pro-cytokines+pre-IL-13: 47.4±2.2%, pro-cytokines+ IL-
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13: 60.4±3.5%, cell death p<0.05) Fig. 3.4. On the basis of these results, all 
subsequent experiments were performed with a 48h pre-incubation period with 
IL-13. INS-1E cells were then treated with four pro-cytokines (IL-1, TNF- IL-6 
and IFN-) with and without IL-13 for 48h. As expected in experiments with a in 
other experiments, IL-13 significantly reduced cell death induced by these 
cytokines (pro-cytokines: 78.7±2.8%, pro-cytokines+IL-13: 58.1±4.0%, cell death 
p<0.001) Fig 3.5. These results are in agreement with those of Kaminski et al., 
(2007), Russell et al., (2013) who showed that pre-incubation for 48h with IL-4 or 
IL-13 significantly reduced cell death induced by pro-inflammatory cytokines. 
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Figure 3. 4 IL-13 pre-incubation partially protected INS-1E cells from pro-
inflammatory cytokine induced cell death. 
INS-1E beta cell death was induced with pro-inflammatory cytokines, IL-1, IFN-
, TNF- and IL-6 for 48h with and without pre-treatment with IL-13. Cell death 
was assessed by trypan blue. Data represent mean values of ±SEM of three 
technical replicates of experiments repeated thrice. 
*p<0.05, ***p<0.001 determined by student t-test. 
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Figure 3. 5 IL-13 partially protects INS-1E beta cells from pro-inflammatory 
cytokine induced cell death 
INS-1E cells were cultured in the presence of 20ng/mL of IL-1, IFN-, TNF-, & 
IL-6 with and without IL-13. Cell death was assessed by trypan blue. Data 
represent mean values ±SEM of 8 technical replicates of experiments performed 
three times. ***p<0.001 determined by student t-test. 
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3.3.3 IL-13 partially protects beta cells from palmitic acid induced cell death 
Palmitic acid has been shown to induce cell death in various beta cell lines 
(Morgan et al., 2008, Diakogiannaki et al., 2007, Welters et al., 2004, Lenzen, 
2008). The exact way by which this fatty acid induces cell death remains elusive 
but it is an extremely effective cytotoxin. Experiments with palmitic acid were 
performed in serum free medium since FBS contains various fatty acids (Gregory 
et al., 2011) including palmitic acid, that might alter the overall concentration of 
the fatty acid. Initially, two concentrations of the fatty acid were chosen based on 
literature (0.25mM, and 0.5mM) (Maedler et al., 2003, Diakogiannaki et al., 2007) 
to treat INS-1E for 24h and 48h to assess the cell death profile. Incubation of cells 
in 0.5mM palmitic acid for 24h induced significantly more cell death when 
compared to the 0.25mM (control:15.8±1.0%, 0.25mM 24h:24.7±3.2%, 0.5mM 
24h: 64.4±4.0%, cell death p<0.001). Forty-eight hours incubation with palmitic 
acid led to a significant increase in cell death in the 0.25mM treatment when 
compared to 24h (0.25mM 24h: 24.7±3.2%, 0.25mM 48h:79.5±1.6%, cell death 
p<0.001). There was a significant increase in cell death in the 0.5mM 48h 
treatment (0.5mM 24h: 64.4±4.0%, 0.5mM 48h: 83.4±2.7% cell death p<0.01) but 
this was not significantly different from the 0.25mM 48h treatment (79.5±1.6%), 
as previously noted (Diakogiannaki et al., 2007, Russell et al., 2013), Fig. 3.6. 
Experiments with the chosen concentration (0.25mM palmitic acid) were then 
performed after pre-incubation with IL-13 for 48h. As expected palmitic acid 
treatment of INS-1E cells for 48h led to significant cell death (Control: 9.4±1.0, 
PA: 86.18±2.0% cell death, p<0.001) that was significantly reduced by 48h pre-
incubation with IL-13 (PA: 86.2±2.0%, PA+IL-13: 72.9±2.6%, p<0.01) Fig 3.7. 
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Figure 3. 6 Palmitate induces INS-1 cell death at different concentrations and times 
INS-1E beta cells were treated with 0.25mM and 0.5mM palmitic acid for 24h and 
48h and cell viability assessed with trypan blue. Data represent mean values 
±SEM of triplicates of experiments performed twice. ***p<0.001 determined by 
student t-test. 
 
 
 
 
 
P
ro
p
o
rt
io
n
 o
f 
d
e
a
d
 c
e
ll
s
 (
%
)
0
2 0
4 0
6 0
8 0
1 0 0
P a lm it ic  a c id  d u ra tio n
2 4 h 4 8 h
0 .5 m M
0 .2 5 m M
ns
* * *
ns
* * *
c o n tro l
135 
 
 
P
ro
p
o
rt
io
n
 o
f 
d
e
a
d
 c
e
lls
 (
%
)
0
20
40
60
80
100
***
IL-13
Palmitic acid
-
-
-
+
+
+
***
 
Figure 3. 7 IL-13 partially protects INS-1E cells from palmitic acid induced 
cytotoxicity 
Cell death was induced by treating INS-1E beta cells with 0.25mM of palmitic acid 
for 48h with and without IL-13 and cell death assessed by trypan blue.  
Data represent mean values of ±SEM of 6 technical replicates of three 
experimental repeats. **p<0.01, ***p<0.001 determined by student t-test. 
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3.3.4 IL-13 partially protects EndoC H1 from pro-inflammatory cytokines  
Then EndoC H1 cell line has been shown to respond glucose with a rise in 
insulin secretion and respiration in a similar manner to human beta cells 
(Krizhanovskii et al., 2017). It has been shown by others (Cunha et al., 2017, 
Lenzen, 2008) that pro-inflammatory cytokines induce cell death in EndoC H1 
beta cells.  
It is well established that IL-1, IFN- and TNF- are detrimental to beta cell 
survival but the role of IL-6 has been controversial (Eizirik et al., 2009, Prause et 
al., 2016). Whilst some reports show a protective response during inflammation 
(Choi et al., 2004, Kristiansen and Mandrup-Poulsen, 2005), our group and others 
have revealed that it potentiates beta cell death (DiCosmo et al., 1994, Russell 
et al., 2013). Experiments using EndoC H1 cells were performed to understand 
the role of IL-6 in inducing cell death. EndoC H1 cells were cultured in the 
presence of cytokines (IL-1, IFN- and TNF-) with and without IL-6 and with 
and without IL-13. Based on the results from experiments using INS-1E cells, pro-
inflammatory cytokine stimulation of EndoC H1 to show IL-13 protection were 
performed following IL-13 pre-treatment Fig 3.4. As previously shown in rodent 
beta cells by Russell et al. (2013), IL-6 significantly increased cell death by pro-
inflammatory cytokines (pro-cytokines-IL6; 66.1±1.6%, pro-cytokines+IL6; 
74.3±1.0%, cell death p<0.01). Interestingly, IL-13 protected EndoC H1 cells 
from cell death induced by the pro-inflammatory cytokine treatment without IL-6 
(pro-cytokines-IL6; 66.1±1.6%, pro-cytokines-IL6+IL13; 52.9±0.7%, cell death 
p<0.01). Additionally, IL-13 significantly protected Endo H1 cells from pro-
inflammatory cytokine treatment with IL-6 (pro-cytokines+IL6; 74.3±1.0%, pro-
cytokines+IL6+IL-13; 60.3±2.0%, cell death p<0.01) Fig 3.8. 
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Figure 3. 8 IL-13 partially protects EndoC H1 from pro-inflammatory cytokines 
and pro-inflammatory cytokines with IL-6 
EndoC H1 cells were cultured in the presence of 20ng/mL of IL-1, IFN-, TNF-
, ± IL-6, in the presence and absence of IL-13 and cell viability assessed by flow 
cytometry after propidium iodide staining. Data represent mean values ±SEM of 
6 replicates of experiments performed three times. ***p<0.001 determined by 
student t-test. 
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3.4 Discussion 
The data arising from the experiments in this chapter show that IL-13 protects 
INS-1E and EndoC H1 cells against serum withdrawal (IL-4 protects against), 
palmitic acid and pro-inflammatory cytokine induced cell death. The protection of 
beta cells by IL-13 from serum withdrawal is in agreement with previous data 
(Russell et al., 2013, Rütti et al., 2016). The results in this chapter show for the 
first time, that IL-13 can also protect human-derived EndoC H1 cells from pro-
inflammatory cytokines induced cell death. Also, the use of palmitic acid to induce 
beta cell death was reduced by IL-13 as previously reported (Russell et al., 2013).  
In the pancreas, anti-inflammatory cytokines such as IL-4 and IL-13 are likely to 
be secreted by infiltrating immune cells such as invariant natural killer T-cells 
(Usero et al., 2016, Mi et al., 2004) or the islet ductal cells (Prokopchuk et al., 
2005) or pancreatic stellate cells (Xue et al., 2015), although the precise source 
is not entirely clear. Some of these sources have been reported to be 
dysregulated in T1DM leading to decreased availability of these cytokines (Usero 
et al., 2016). 
In this chapter, serum withdrawal was exploited to induce cell death in INS-1E 
cells. Serum withdrawal ultimately induces cell death by apoptosis through the 
activation of caspase 3 and caspase 9 (Higuchi et al., 2006, Goyeneche et al., 
2006). Serum withdrawal conditions have also been shown to induce death 
through the depletion of the pro-survival factor Bcl-2, which in turn caused the 
release of Bak/Bax that change the mitochondrial outer membrane potential by 
forming pores, followed by the discharge of cytochrome C leading to apoptosis in 
RINm5F cell (a rat insulinoma cell line)(Tejedo et al., 2001). We report in our 
experiment, the significant reduction of beta cell death by IL-4 and IL-13 
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stimulation due to serum withdrawal. This protection could be explained by results 
from other cell types wherein, IL-13 is reported to increase the expression of anti-
apoptotic Bcl-2 protein while diminishing the expression of Bax, hence it is likely 
that IL-13 counteracts serum withdrawal depletion of Bcl-2 and increment of Bax 
to sustain the beta cells (Yang et al., 2015, Chand et al., 2018). It has also been 
suggested that serum withdrawal increase superoxide and nitrogen oxide 
production in INS-1 cells (Maestre et al., 2003), although there is controversy 
about the involvement of cytochrome C. Serum withdrawal has been shown to 
induce cell death in other cell types through the activation of P53. P53 is a tumour 
suppressor molecule that is activated during cell stress and trans activates Apaf-
1 which forms a complex with pro-caspase 9 and cytochrome C leading to 
cleavage of caspase 9. Caspase 9 then cleaves caspase 3 that effects DNA 
degradation (Fridman and Lowe, 2003). IL-13 has been show to suppress P53 in 
T-cells, therefore, the protection of INS-1E from serum withdrawal could have 
been through the repression of p53 leading to the inhibition of Apaf-1 and hence 
inhibition of the pro-caspase 9/Apaf complex (Yang et al., 2015).  
The accumulation of lipids in beta cells and other cells can lead to their 
dysfunction and death. This process is known as lipotoxicity. This is primarily 
associated with type 2 diabetes and can consequently lead to reduced insulin 
secretion, and pancreatic beta-cell failure (Kusminski et al., 2009, Robertson et 
al., 2004, DeFronzo, 2010). Palmitate is the most abundant circulating saturated 
fatty acid found in the body and can be acquired through diet or synthesized 
directly when needed (Carta et al., 2017). Palmitate may potentiate beta cell 
death by a variety of mechanisms, such as increased chemokine production 
(CXCL1, CCL2), ER stress leading to unfolded protein response (UPR) but also 
by enhancing the secretion and toxicity of IL-1 and other cytokines such as TNF-
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, IL-6 and IL-8 . (Sharma and Alonso, 2014, Russell et al., 2013, Igoillo-Esteve 
et al., 2010, Song et al., 2014). Palmitate also induces caspase 3 activation and 
other ER stress markers in rodent beta cells (Song et al., 2014). Other 
mechanisms reported include the upregulation of Programme Cell Death 2 Like 
(Pdcd2l), mitochondrial dysfunction, Bcl-2 mRNA downregulation, Caspase-2 
increase in the cytosol, increase superoxide and NO production, increase in Bax 
and the arrest of G0 phase of the cell cycle (Maestre et al., 2003). Taken together, 
it is clear that the precise mode of killing of beta cells by palmitate remains elusive 
but it might be a combination of these mechanisms. From the various reports 
cited above, it is suggestive that palmitate initiates the production of cytokines, 
which together with lipotoxicity lead to beta cell death. IL-13 therefore might be 
counteracting the actions of the pro-inflammatory cytokines either by upregulating 
pro-survival factors such as Bcl-2 or downregulating Bax (Yang et al., 2015). Fatty 
acids like pro-inflammatory cytokines both induce nitrite production which has 
been previous shown to be reduced by IL-4 or IL-13 co-stimulation in INS-1E cells 
(Russell et al., 2013) and suggest that IL-13 might protect against fatty acids in a 
like manner.  
The present results reveal that IL-13 and IL-4 can protect both rat INS-1E cells 
and human-derived EndoC H1 cells from pro-inflammatory cytokine induced 
beta cell death. These results are in agreement with the findings by us and others 
in in vitro experiments which show that IL-13 and IL-4 can act directly on the beta 
cells and protect human islets, rat and human-derived beta cells lines from cell 
death induced by pro-inflammatory cytokines (Rutti et al., 2016, Russell et al., 
2013). The death of beta cells mediated by pro-inflammatory cytokines is one of 
the most researched in the context of type 1 diabetes pathogenesis (Eizirik et al., 
2009, DiCosmo et al., 1994, Choi et al., 2004, Pirot et al., 2008, Souza et al., 
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2008) and low chronic inflammation by cytokines in type 2 diabetes (Eguchi and 
Manabe, 2013).  
TNF-induces beta cell death through the activation of Caspase 8 and IKK 
complex which then leads to the activation of caspase 3 and NF-B leading to 
apoptosis (Tomita, 2017). In immune cells IL-13 has been reported to reduce or 
limit caspase 3 cleavage although the precise mechanism is not known (Yang et 
al., 2015). IL-13 has been shown to inhibit TNF- activities in other cell types by 
inhibiting nuclear translocation of NF-B through decreasing cytoplasmic 
expression of its nuclear translocation protein p65 (Manna and Aggarwal, 1998). 
The reduction in NF-kB activity by IL-13 has been illustrated using clonal beta cell 
lines by Rutti and colleagues who suggest that is the most probably way IL-13 
prevents the action of IL-1 (Rutti et al., 2016). IL-1 increases nitric oxide 
production by beta cells which enhances beta cell death. It has been shown that 
the addition of IL-13 or IL-4 decreases significantly the production of nitric oxide 
in beta cells (Russell et al., 2013). IFN- induces beta cell death through the 
activation of STAT1 that transcribes Interferon regulatory factor 1 (IRF-1) and 
iNOS which together alter the mitochondrial outer membrane permeabilization 
(MOMP) through upregulation of Bak which subsequently leads to caspase 
activation and cell death by apoptosis (Cnop et al., 2005). IRF-1 can also induce 
apoptosis in a p53 dependent manner (Tanaka et al., 1994). IL-13 has been 
shown to regulate BCLXL pro-survival molecule and likely helps maintain the 
balance of these molecules enabling a stable MOMP hence preventing 
cytochrome C release and apoptosis (Wurster et al., 2002). Also, IL-13 can 
probably counteract the action of IRF-1 should the alternative cell death pathway 
be activated by suppression of p53 (Yang et al., 2015). 
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In the present chapter, it was shown that IL-6 enhances the effects of pro-
inflammatory cytokines on EndoC H1 cells. These results are completely in 
accord with previous reports, which were generated using various rodent and 
human beta cell lines (Russell et al., 2013, Wadt et al., 1998, Southern et al., 
1990). However, despite this, others have shown that IL-6 rescues beta cells from 
pro-inflammatory cytokines (Kristiansen and Mandrup-Poulsen, 2005, Choi et al., 
2004). IL-6 signals via Jak/STAT3 and also through the MAPK/mTOR pathway 
and can be secreted by islet beta cells in vivo (Pilström et al., 1995).  
In our experiments, 20ng/mL of IL-6 was used together with pro-inflammatory 
cytokines and this resulted in increased INS-1E and EndoC H1 cell death. 
Similarly, use of 20ng/mL IL-6 on INS-832/13 in the presence of TNF- and IL-
1, increase beta cell death and decreased glucose stimulated insulin secretion 
(Oh et al., 2011). In a recent report the use of 10ng/mL IL-6 to stimulate INS-1 
832/3 cells for 1h did not affect glucose stimulated insulin secretion. Additionally, 
IL-6 did not rescue INS-1 832/3 dysregulation of glucose stimulated insulin 
secretion induced by IL-1 with and without conditioned medium (containing a 
cocktail of myokines, secretions from muscle cells) (Barlow et al., 2018). Contrary 
to these findings In experiments wherein IL-6 is proposed to improve beta cell 
function 1ng/mL of IL-6 was used to show improvement of glucose stimulated 
insulin secretion in MIN6 cells and had to be pre-incubated for 24h to observe 
this effect (Suzuki et al., 2011). Additionally, 24h Pre-incubation with 80g/mL of 
IL-6 or serum from exercised mice (claimed to be rich in IL-6) protected INS-1E 
from cytokine induced cell death (Paula et al., 2015). In all these, IL-6 is 
suggested to protect at concentrations lower than 10ng/mL or greater than 
200ng/mL, also depending on the source of the IL-6, and if pre-incubated 24h 
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before inflammatory stimulations. Pre-incubation of IL-6 in our experiments did 
not result to any improvement in beta cell viability (data not shown). The serum 
used by researchers from exercised mice arguably contains more than just IL-6 
and hence might not be the main protective compound. Taken together, our data 
revealed that, IL-6 enhances beta cell death in pro-inflammatory cytokines, 
conceivably by a STAT3 dependent mechanism that leads to the cleavage of 
caspase 3 as reported by Oh et al. (2011). 
A role for IL-4 and IL-13 in protecting NOD mice (a model for type 1 diabetes), 
from developing autoimmune diabetes has also been reported (Zaccone et al., 
1999, Cameron et al., 1997) with the suggestion that the protection might be due 
to the skewing of CD4+ T-cells response towards a Th2 phenotype (Wong, 2011). 
Contrary to the protection offered by administration of IL-13 or IL-4 NOD mice 
deficient in the IL-4R/IL-13R1 hetero receptor showed resistance to 
developing type 1 diabetes, due to increase T-regs and decreased Th17 cells. 
However, the ablation of the hetero receptor does not take into account the 
circulating levels of the IL-13 neither was a comparison performed for IL-13 
treated NOD mice (Ukah et al., 2017). Also, the role of IL-13 in glucose 
homeostasis has been illustrated using C57BL/6 and BALB/C mice in which IL-
13 was ablated and glucose tolerance test performed with marked increases 
witnessed in IL-13-/- compared to controls. There was an upregulation in 
gluconeogenesis genes, with suggestions that this is possibly through the 
transcription factor STAT3 (Stanya et al., 2013) although a recent study by Rutti 
et al. (2016) suggests that IL-13 does not rescue IL-1 induced loss in glucose-
stimulated insulin response in human islets and rodent cells. 
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The potentiating effect of IL-6 was illustrated using human EndoC H1 cell lines, 
but other works seem to show the opposite effect (Choi et al., 2004). Although, in 
the experiments of Choi and colleagues, rat beta cells were pre-incubated with 
IL-6 for 24h prior to toxicity. Interestingly, the actions of IL-6 seem to depend on 
whether it was pre-cultured with the beta cells, and on the concentration used to 
stimulate the beta cells. We show in our present experiments that IL-13 still 
protects beta cells from pro-inflammatory cytokines with and without IL-6. 
In conclusion, the actions of IL-13 seem to offer a ‘versatile protection’ against a 
variety of cytotoxic stimuli (pro-inflammation, palmitate, and serum withdrawal), 
which initiate beta cell death using different mechanisms but converge in ER 
stress or mitochondrial dysfunction. The underlying mechanism by which IL-13 is 
protecting beta cells still not completely understood. We have shown in our 
previous work that this is potentially through the Jak/STAT6 signalling (Russell et 
al., 2013), but others have suggested that it is potentially though, the PI3Kinase 
signalling pathway (Rutti et al., 2016). In the subsequent chapters, experiments 
seek to explore which signal transduction pathways are involved in the 
cytoprotective actions of IL-13. 
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Chapter 4.0: Characterisation of the IL-13 
Jak/STAT6 Signalling Pathway in beta cells 
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4.0 Characterisation of the IL-13 Jak/STAT6 Signalling Pathway in 
beta cells  
4.1 Introduction 
In the previous chapter, it was shown that both IL-13 and IL-4 protect beta cells 
from various cytotoxic stimuli (cytokines, serum withdrawal and palmitic acid). In 
other published work it has been suggested that this protection is likely to be 
mediated by the Jak/STAT signalling pathway (Russell et al., 2013). The role of 
Jak/STAT has been studied in the context of various important aspects of 
pancreatic beta cell biology, for example with reference to the actions of insulin, 
growth factors, erythropoietin, cytokines, prolactin and other hormones (Choi et 
al., 2010, Fujinaka et al., 2007, Shen et al., 2010). 
Upon cytokine binding to a cognate receptor, a conformational change occurs 
allowing the receptor to dimerize and bringing Jak proteins into close proximity 
with each other leading to their trans phosphorylation. Jaks phosphorylate 
specific tyrosine residues within the cytoplasmic tail of the receptor creating 
docking sites for the STAT proteins. Importantly, Jaks also activate bound STAT 
molecules (by phosphorylation) that then dissociate from the receptor and homo-
or heterodimerize and migrate to the nucleus to induce the transcription of target 
genes (Dodington et al., 2018, Shuai and Liu, 2003). 
4.1.1 Jak1 
The roles for Jak1 and Jak2 in T1DM have been investigated recently by Trivedi 
and colleagues in experiments wherein they used a Jak1/Jak2 inhibitor 
(AZD1480) in NOD mice and on isolated human islets. The results showed a 
reduction in various hallmarks of T1DM in the mice, including IFN- signalling, 
MHC class I expression, and islet T-cell accumulation. Altogether the data 
147 
 
indicated a reduction in autoimmunity in NOD mice through a reduction in 
phospho-STAT1 (Trivedi et al., 2017). Another drug, Exenatide (Ex-4), a potent 
glucagon-like peptide 1 receptor (GLP-1) agonist, also significantly reduced Jak1 
expression in INS-1E cells and this was associated with a decrease STAT1 
(Couto et al., 2007). Data from these experiments were obtained by real-time 
PCR, but the conclusions support those of Trivedi et al (2017). These results 
implicate Jak1 as a regulator of beta cell viability. 
4.1.2 Jak2 
Atkinson and colleagues, who treated female NOD mice with a potent Jak2 
inhibitor, AG490 (also known to inhibit Jak3), and found a reduced incidence of 
diabetes compared to vehicle treated controls. However, although pancreatic 
leukocyte infiltration was not diminished and euglycemia could only be achieved 
in mice whose initial blood glucose levels were below 17.5mM (Davoodi-
Semiromi et al., 2012). In a separate study, it was found that treatment of 
C57BL/6 mice with recombinant Human (rHu) EPO for one week caused 
activation of Jak2 and STAT5 and that this was associated with a reduction in the 
incidence of diabetes in db/db mice exposed to streptozotocin (STZ). The 
PI3K/Akt pathways was also activated under these conditions and, in order to 
attempt to verify the involvement of Jak2, a knockout approach was taken in 
which RIPcre+Jak2 fl/fl mice were treated with STZ and rHuEPO. There was no 
protection of rHuEPO from STZ induce diabetes in the mutant animals indicating 
that Jak is essential for the ability of rHuEPO to promote beta cell viability (Choi 
et al., 2010). We have shown that Jak2 is activated by IL-13 and have suggested 
that Jak2 could be involved in mediating the protective actions of IL-13 under 
condtions of serum withdrawal-induced cytotoxicity on INS-1E cells. A Jak2 
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inhibitor (hexabromocyclohexane) antagonised this protective response (Russell 
et al., 2013).  
4.1.3 Jak3 
Jak3’s role in T1DM was illustrated by study of the actions of Janex-1, a Jak3 
selective inhibitor, which was administered to NOD mice for 25weeks and the 
extend of insulitis assessed. Janex-1 treatment lowered the proportion of NOD 
mice developing T1DM without affecting their B cell and T-cell splenic populations 
(Cetkovic-Cvrlje et al., 2003). Janex-1 acts by suppressing NF-B and 
upregulating SOCS1 and SOCS3 (Lv et al., 2009) which may account for its 
protective effects. Another Jak3 inhibitor WHI-P154, reversed the cytoprotection 
of IL-4 from pro-inflammatory cytokines in INS-1E (Kaminski et al., 2010). 
Similarly, the islets of C57BL/6J mice in which Jak3 had been knocked out were 
more resistant to cytokine toxicity compared to controls. Thus, Jak3 appears to 
play an important role in mediating beta cell cytotoxicity under certain conditions. 
4.1.4 Tyk2 
The fourth member of the Jak family is Tyk2, a kinase which is activated by IFN-
In human EndoC  cells this leads to upregulation of MHC class I molecules 
in a STAT1 and STAT2 dependent manner. Knockdown of Tyk2 reversed the 
IFN- induced inflammatory response and also attenuated the induction of ER 
stress markers such as CHOP, CXCL10, ATF3, BIP and XBP1s (Marroqui et al., 
2017). Given that loss of Tyk2 seems to reduce ER stress in the beta cells in the 
presence of IFN-, it can be inferred that beta cells might also have an impaired 
antiviral response observed in the absence of Tyk2 (Størling and Pociot, 2017).  
149 
 
4.1.5 IL-4 and IL-13 regulated genes 
The regulation of genes by IL -4 and IL-13 (mediated via Jak/STAT signalling) 
has been extensively studied in other cell types (Ritz et al., 2008, Jiang et al., 
2000, Fichtner-Feigl et al., 2005) but gene regulation in beta cells has received 
limited attention. IL-13 has been shown to upregulate four beta cell genes CISH, 
CD83, Galnt14 and St6galnac3 using rat beta cells (Rütti et al., 2016). CISH is a 
negative regulator of the Jak/STAT signal transduction regulatory pathway 
belonging to SOCS family of proteins and binds phosphorylated tyrosine 
residues. CD83 is an antigen presentation protein, while Galnt14 and St6galnac3 
encode for N-acetylgalactosaminyltransferase and sialyltransferases 
respectively (Rütti et al., 2016, Trengove and Ward, 2013). IL-4 and IL-13 are 
known to upregulate anti-apoptotic genes such as BCLXL, MCL1 and SOCS1 in 
other cell types (Ritz et al., 2008, Dunkle et al., 2011).  
Our group has shown that IL-13 activates Jak2, STAT3, STAT6, and the PI3-AKT 
pathways in beta cells but have argued that the inhibition of the PI3-AKT pathway 
does not alter IL-13-induced cytoprotection in INS-1E cells (Russell et al., 2013). 
By contrast a study by Rutti and colleagues suggested that the PI3-AKT is the 
main pathway by which IL-13 protects beta cells (Rutti et al., 2016).   
The main objectives of this chapter were as follows;  
 To investigate and identify the Jaks that are activated by IL-4 and IL-13 
stimulation and determine how important they are to IL-13 mediated 
protection of beta cells 
 To investigate and identify the genes regulated by IL-13 and IL-4 using a 
Jak/STAT qPCR array system.  
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4.2 Materials and Methods 
4.2.1 Cytokine Stimulation 
20ng/ml of IL-4 and IL-13 were used to stimulate INS-1E cells for the desired time 
according to each experiment. 
4.2.2 Gene expression studies using RT2 Profiler PCR array 
Gene expression studies were performed as described in section 2.6. At the 
conclusion of the incubation periods, cells were lysed and RNA extracted 
according to the manufacturer’s protocol, before being reverse transcribed to 
form cDNA. SYBRGreen was used in the qPCR protocol designed to amplify the 
cDNA using commercially synthesised primers targeted to the genes of interest. 
4.2.3 Western blotting 
Western blotting and small interference RNA studies were performed as 
previously described in section 2.7 and section 2.3 respectively. INS-1E and 
EndoC HC1 were cultured as described in section 2.2.    
Table 12: List of antibodies and dilutions 
ANTIBODY COMPANY CATALOGUE NUMBER DILUTION 
STAT6 Cell signalling  5397 1:1000 
Phospho STAT6 Santa Cruz Sc-11762 1:200 
JAK1 St John’s Labs STJ113441 1:500 
JAK2 Santa Cruz Sc-294 1:500 
JAK3 Santa Cruz  Sc-6932 1:1000 
TYK2 Fisher 720124 1:1000 
PHOSPHO JAK1 St John’s labs STJ90314 1:500 
PHOSPHO JAK2 Abcam Ab219728 1:1000 
PHOSPHO JAK3 St John’s labs STJ98188 1:500 
PHOSPHO TYK2 Cell signalling 68790s 1:1000 
SIRPA Cell signalling 13379s 1:1000 
GAPDH Proteintech 60004-1 1:10000 
MCL-1 Cell signalling  94296s 1:1000 
BCLXL Biolegend 633902 1:1000 
BETA ACTIN Sigma A5316 1:25000 
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4.3 Results 
4.3.1 INS-1E express all four Janus kinases 
In order to reveal which Jak proteins are involved in IL-13 signalling in INS-1E 
cells, it was important to study the complement of Jaks expressed in these cells. 
INS-1E cells were cultured, lysed and protein extracted as in section 2.7. A series 
of western blot analyses were then performed, probing with antisera directed 
against the different Jaks (see Table 12: List of antibodies and dilutions).  
Western blotting analysis of INS-1E cells showed the presence of Jak1 with a 
molecular weight of about 130kDa (Fig. 4.1) and are in agreement with previous 
data obtained by qPCR in INS-1E and human islet beta cells (Couto et al., 2007). 
Immunohistochemical staining of INS-1E cells has also revealed the presence of 
Jak1 (Stout et al., 1997).  
INS-1E cells also expressed two Jak2 bands at an approximate molecular weight 
of 125kDa and 110kDa respectively (Fig4.1). This confirms earlier data showing 
the expression of Jak2 in INS-1E cells by western blotting (Fujinaka et al., 2007, 
Russell et al., 2013). I also found that Jak3 is expressed in INS-1E beta cells and 
that the antigen appears as three bands with molecular weights of 53kDa, 70kDa 
and 115kDa (Fig. 4.1). Jak3 has previously been observed in INS-1E cells using 
immunohistochemistry by Stout et al., (1997).  
The presence of Tyk2 was observed by western blotting with the band migrating 
at a molecular weight equivalent to about 134kDa (Fig 4.1).Tyk2 has previously 
been observed in INS-1E cells by immunostaining (Stout et al., 1997) and in 
EndoC HC1 beta cells by western blotting (Marroqui et al., 2015).  
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Figure 4. 1: All four Jaks are present in INS-1E beta cells.   
INS-1E cells were lysed and supernatant collected. Western blotting was 
performed and membranes probed for anti-sera for Jak1, Jak2, Jak3 and Tyk2. 
The data represents three independent experiments. 
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4.3.2 Jak1, 2, 3 and Tyk2 are activated by IL-13 and IL-4 with a differing time 
course 
To determine whether Jak1 is activated by IL-13 and IL-4, INS-1E cells were 
stimulated with either IL-4 or IL-13 for periods of 15, 30, 45 and 60min prior to 
cell lysis. Following western blotting, membranes were probed with an anti-serum 
against the activated form of Jak1 (Y1022/1023). The results reveal that IL-4 
induced the phosphorylation of Jak1 but that this was only seen at later points 
during the incubation period (45min and 60min). IL-13, on the other hand, 
stimulated Jak1 phosphorylation at much earlier time (15min), and 
phosphorylation then declined by at 45min and had completely disappeared by 
60min (Fig 4.2). These data suggest a difference in the way these two cytokines 
induce Jak1 signalling.  
Membranes were also probed for phospho-Jak2 (Y1007/1008). Initial results with 
IL-13 treatment showed a somewhat unexpected pattern in that basal levels of 
phospho-Jak2 were high even in the absence of stimulation. Addition of IL-13 
induced an initial decline in phospho-Jak2 before the phosphorylation increased 
once more (Fig. 4.3a). In a repeated set of experiments, the stimulation time was 
expanded, and the data showed a similar initial pattern of Jak2 phosphorylation, 
with an initial decline followed by a later increase (75-120min after initial 
stimulation) exceeding the initial basal levels (Fig. 4.3b). IL-4 treatment induced 
a similar pattern of Jak2 phosphorylation, although there were some subtle 
differences in the kinetics of phosphorylation. In experiments with IL-4, Jak2 
phosphorylation was initially depleted within 15min but then elevated between 
30-75min before declining again (Fig. 4.3c).  
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In similar experiments, INS-1E cells were stimulated with IL-13 and IL-4 for 0-
60min, samples were lysed and a Western blot performed probing for phospho-
Jak3 (Y785). IL-13 induced the phosphorylation of Jak3 within 15min and this 
remained elevated over the rest of the 60min time-course. However, IL-4 
stimulated Jak3 phosphorylation only after 45min treatment (Fig 4.4).  
Probing of Western blot membranes from similar experiments to those described 
above with anti-phospho-Tyk2 (1054/1055), revealed that, IL-4 induced the 
phosphorylation of Tyk2 at 45min and 60min while IL-13 treatment induced the 
phosphorylation of Tyk2 strongly but transiently at 15min (Fig 4.5). IFN- 
treatment of INS-1E for 30min also induced phosphorylation of Tyk2.  The 
phosphorylation patterns of the different Jaks in response to IL-4 and IL-13 
stimulation have been represented in Fig 4.6. 
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Figure 4. 2: Jak1 is activated by both IL-4 and IL-13.  
INS-1E cells were treated with 20ng/mL of either IL-4 or IL-13 for 15-60mins, 
followed by a PBS wash. Cells were lysed and the supernatant collected. a. Western 
blotting was performed and membranes probed with anti-sera for phospho-Jak1. 
GAPDH was used as loading control. b. Densitometry analysis shows the pattern of 
phosphorylation 
The data represents two independent experiments. 
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Figure 4. 3: Jak2 is activated by both IL-4 and IL-13 after initial depletion of phosphor-Jak2. 
 INS-1E cells treated with 20ng/mL of either (a-b) IL-13 or (c) IL-4 for 120min, washed 
with PBS. Cells were lysed and the supernatant collected. Western blotting was 
performed with 50g of protein and membranes probed with anti-sera for phosphor-Jak2. 
Beta-actin was used as loading control. d. shows densitometric representation of Jak2 
phosphorylation. The data represents three independent experiments. 
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Figure 4. 4: IL-4 and IL-13 both activate Jak3 at different time points  
a. INS-1E cells were treated with 20ng/mL of either IL-4 or IL-13 for 15-
60mins, followed by a PBS wash. Cells were lysed and the supernatant 
collected. Western blotting was performed with 50g of protein and 
membranes probed with anti-sera for phospho-Jak3. GAPDH was used as 
loading control. b. Densitometry analysis reveal Jak3 phosphorylation pattern 
upon IL-4 and IL-13 treatments. The data represents two independent 
experiments. 
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Figure 4. 5: IL-4 and IL-13 both activate Tyk2 at different time points  
a. INS-1E cells were treated with 20ng/mL of either IL-4 or IL-13 for 15-60mins, 
followed by a PBS wash. Cells were lysed and the supernatant collected. Western 
blotting was performed on 50g of protein and membranes probed with anti-sera 
for phospho-Tyk2. GAPDH was used as loading control. b. Densitometry analysis 
reveal Tyk2 phosphorylation pattern upon IL-4 and IL-13 treatments.  The data 
represents two independent experiments 
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Figure 4. 6: Heat map highlighting phosphorylation pattern of Jaks upon IL-4 and IL-13 
stimulation 
Western blots probed for the various phospho Jaks and based on the densitometry 
analysis,  the intensity of the band with respect to time graded accordingly from light pink 
to intense red using Microsoft Office PowerPoint. 
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4.3.3 IL-13 and IL-4 both activate STAT6 
It has been shown previously that both IL-13 and IL-4 activate STAT6 in clonal 
pancreatic beta cell lines, human islets (Kaminski et al., 2007) and in monocytes 
(Roy et al., 2002). It was, therefore, important to confirm these data in the current 
study. Experiments were performed by stimulating INS-1E cells with IL-4 and IL-
13 for 0-60min. Western blots were performed with cell lysates and probed with 
anti-phospho-STAT6 (Y641). IL-13 and IL-4 induced the phosphorylation of 
STAT6 at 15min to 60min. Western blotting analysis revealed the appearance of 
three bands, the lowest and expected band at 105kDa, the middle at 150kDa and 
the highest at 200kDa as previously observed in our group (Russell et al., 2013) 
(Fig. 4.7).  
4.3.4 Jak2 knockdown reduced STAT6 phosphorylation 
Since Jak2 has been previously implicated in IL-13 signalling (Russell et al., 
2013), and we report changes in Jak2 phosphorylation in the current study (Fig. 
4.3), we set out to examine whether Jak2 acts upstream of STAT6 in INS-1E 
cells. In order to achieve this goal, we depleted Jak2 expression levels using a 
small interference RNA system (siRNA). It was initially important to optimise the 
use of the siRNA molecules by targeting an abundantly expressed gene. GAPDH 
was chosen to test this. Knockdown was performed as described in section 2.3, 
initially using two transfection reagents, attractene and Lipofectamine, to 
determine which was better for siRNA transfections. A modestly successful 
knockdown of GAPDH was obtained using both attractene and Lipofectamine at 
24h (Fig. 4.8a). An improved knockdown was obtained at 48h using 
Lipofectamine, with GAPDH expression depleted by approximately 75% (Fig 
4.8b) compared to control. Cells transfected using attractene did not show a clear 
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change in GAPDH expression. This optimised protocol was used for experiments 
using STAT6 siRNA described later in chapter 5.  
Following the optimisation of the siRNA protocol, silencing of Jak2 expression 
was attempted using the same approach. Transfection of INS-1E cells with Jak2 
targeting siRNA for 48h successfully depleted Jak2 expression (Fig. 4.9). As 
previously reported a 30min IL-13 treatment induced a robust increased in 
phospho-STAT6 (Y641) expression under control conditions, however, this 
response was partially blocked by Jak2 knockdown (Fig. 4.9). 
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Figure 4. 7: IL-4 and IL-13 induce STAT6 phosphorylation in a similar manner.   
INS-1E cells were treated with 20ng/mL of either IL-4 or IL-13 for 15-60mins, 
followed by a PBS wash. Cells were lysed and the supernatant collected. Western 
blotting was performed using 50g of proteins and membranes probed with anti-
sera for phospho-STAT6. Total STAT6 was used as loading control. The data 
represents three independent experiments. 
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Figure 4. 8: Lipofectamine performed better for long duration transfections.  
INS-1E cells were treated with 10nM small interference RNA targeting (a-b) 
GAPDH using attractene and lipofectamine transfection reagents for 24h and 
48h. Cells were then washed with PBS. Cells were lysed and the supernatant 
collected. Western blots were performed and membranes probed for (a-b) 
GAPDH. Beta-actin was used as the loading control. (c) Densitometry 
analysis reveal the extend of knockdown although no significant difference 
was observed. Data represents two independent experiments. 
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Figure 4. 9: Jak2 knockdown reduced STAT6 induced phosphorylation by IL-13.  
INS-1E cells were transfected with 10nM of siJak2 for 48h followed by IL-13 stimulation for 
30min. Cells were then harvested, lysed, centrifuged and the supernatant collected. Western 
blotting was performed and membranes probed for Jak2, phospho-STAT6 and beta actin as 
loading control.  
Data represents results of experiments performed at least twice.   
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4.3.5 IL-13 stimulation leads to the upregulation of anti-apoptotic genes 
In order to discover genes regulated by IL-13, a rat Jak/STAT targeted PCR array 
was used (RT2 Profiler PCR array from Qiagen). RT2 Profiler PCR arrays are 
pathway focused arrays with a panel of 84 genes, 5 housekeeping genes, 3 
reverse transcription controls, 1 genomic DNA control and 3 positive controls all 
on a 96well plate. In these experiments, INS-1E cells were stimulated with IL-13 
for 48h, RNA extracted, estimated and cDNA synthesized as described in section 
2.6. cDNA was amplified on the Quantstudio 12K flex and analysed using the 
Qiagen online analysis tool which calculates fold change of each gene relative to 
the untreated control.  
The most highly upregulated gene was SIRP, a gene whose protein product is 
known to bind the surface marker CD47 leading to inhibition of phagocytosis in 
macrophages (Willingham et al., 2012). This gene has been studied only rarely 
in beta cells and has not previously been implicated in the response to IL-13 in 
these cells. The anti-apoptotic genes MCL1 and BCL2L1 were also upregulated, 
along with EPOR (erythropoietin receptor), IFNGR1 (interferon gamma receptor), 
SMAD1 (Mothers against decapentaplegic homolog 1), CDKN1a (Cyclin-
dependent kinase inhibitor 1, known for inhibiting apoptosis), SH2B1 (SH2-
domain adapter 1), EGFR (Epidermal growth factor receptor), and SOCS1 a 
negative regulator of the Jak/STAT signalling pathway (amongst others 
represented in Fig. 4.10 & table 12). The RT2 Profiler arrays were used to identify 
the most upregulated genes and the results were then confirmed using specific 
SYBRGreen PCR primer assays in separate experiments. The upregulation of 
most of the genes seen by the array method was confirmed using samples 
obtained after 48h treatment of INS-1E cells followed by qPCR: SIRP (Control: 
1.0, IL-4: 3.0±0.4, IL-13:2.7±0.15, p<0.001), MCL1 (Control: 1.0, IL-4: 1.5±0.12, 
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IL-13:1.46±0.07, p<0.01), and SOCS1 (Control: 1.0, IL-4: 1.5±0.1, 1.7±0.2, 
p<0.001). BCL2L1 was significantly upregulated by IL-4 and not by IL-13 (Control: 
1.0, IL-4: 1.5±0.2 p<0.05, IL-13: 1.15±0.1) as was EPOR (control: 1.0, IL-4: 
2.3±0.6 p<0.05, IL-13: 1.13±0.1). Although strongly upregulated in the PCR array, 
SMAD1 and IFNGR1 were not changed by IL-13 or IL-4 in the specific qPCR 
primer experiments (Fig. 4.11). Protein expression of SIRP, MCL1, and BCLXL 
was determined by western blotting and as expected these proteins were 
upregulated following 48h exposure to IL-4 and IL-13 in INS-1E cells (Fig. 4.12). 
Densitometric analysis of the western blots revealed a significant upregulation of 
SIRP in response to both IL-4 and IL-13 relative to the untreated control (Fig. 
4.13). Densitometric analysis also revealed a significant upregulation of BCLXL 
by IL-4 but not by IL-13 while similar analysis of MCL1 expression showed no 
significant difference between treatments and controls (Fig. 4.13).  
 EndoC H1 cells that were stimulated with IL-13 for 48h were harvested lysed 
and probed with anti-sera against SIRP, MCL1 and BCLXL. SIRP, and MCL1 
showed an upregulation after IL-13 treatment while BCLXL was less affected (Fig. 
4.12c).  
Although qPCR experiments for total STAT6 were not performed, western blot 
experiments revealed that both IL-13 and IL-4 significantly increased STAT6 
levels in INS-1E beta cells after 48h but STAT3, was not altered (Fig 4.14). 
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Figure 4. 10: IL-13 stimulation of INS-1E cells upregulates an array of genes.  
INS-1E cells were stimulated with IL-13 for 48h, harvested and RNA collected using an RNeasy kit. RT-PCR was 
performed using RT2-First Strand from Qiagen. cDNA was then used to perform a qPCR on an RT2 Profiler PCR array. 
Data represents expression relative to unstimulated cells. 
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Figure 4. 11: Specific gene primer qPCR confirmed the upregulation of genes from the array. 
  INS-1E cells were stimulated with 20ng/mL of IL-4(♦) or IL-13(▲) for 48h, harvested and 
RNA extracted with RNeasy. cDNA was synthesized using the RT2 First Strand kit and 
amplicons amplified by SYBRgreen qPCR. a. SIRP, b. EPOR, c. MCL-1 d. BCL2L1 e. 
SOCS-1, f. IFNGR1, g. SMAD1 and h. B2M. Data represents mean of ±SEM of three 
independent experiments each with three replicates *p<0.05, **p<0.01 and ***p<0.001 
relative to control determined by student t-test.  
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Figure 4. 12: IL-4 and IL-13 upregulate SIRP, MCL1 in both INS-1 and EndoC H1 cells 
and BCLXL in INS-1E.  
(a & b) INS-1E and (c) EndoC H1 cells were treated with 20ng/mL for 48h, lysed and 
the supernatant collected. Western blotting was performed with 50g of protein and 
membranes probed with anti-sera against SIRP, MCL-1, BCLXL, with GAPDH as 
loading control. Data represents three independent experiments. 
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c 
Figure 4. 13: Densitometric analysis on INS-1E Western blots revealed persistent 
SIRP upregulation.  
Western blot densitometry analysis were performed with the Licor software 
normalised with loading control and expressed relative to the control. Data 
represent means ±SEM of three independent experiments determined by student 
t-test. 
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Figure 4. 14: IL-4 and IL-13 both upregulate STAT6 expression but not STAT3.  
a. INS-1E cells were stimulated with 20ng/mL of IL-4 or IL-13 for 48h, cells 
harvested, lysed and the supernatant collected. Western blotting was performed 
with 50g of proteins and membranes probed with anti-sera against STAT3, 
STAT6 and loading control GAPDH. b. Densitometry analysis confirm a 
significant  increase in STAT6 upon IL-4 and IL-13 stimulations. Data represents 
three independent experiments 
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4.4 Discussion 
4.4.1 The role of the Jaks 
In the previous chapter, it was revealed that IL-13 and IL-4 protect pancreatic 
beta cells from a range of cytotoxic stimuli, but the protective mechanisms remain 
to be completely understood. IL-4 and IL-13 signal by binding to their cognate 
receptors leading to receptor dimerization and Jak trans-phosphorylation. IL-4 
binds to IL-4R and forms a heterodimer with the common gamma chain (C) 
receptor, while IL-13 binds to IL-13R1 and forms a heterodimer with IL-
4R(Russell and Morgan, 2014). It has previously been shown that the IL-13 and 
IL-4 receptor components are present on both rat clonal beta cell lines and on 
human islet tissue sections (Kaminski et al., 2010). The present chapter sought 
to characterize the key components of the Jak/STAT6 pathway that might be 
involved in the protection of beta cells from cytotoxicity. The impact of IL-13 
signalling on the PI3K/At pathway was not studied here since our previous work 
suggests that, although, this pathway is activated in response to IL-13, it is 
unlikely to be involved in the cytoprotective effects of the cytokine in beta cells 
(Russell et al., 2013). 
In Jak/STAT signalling, the receptor associated Jaks are phosphorylated after 
receptor dimer formation and prior to the recruitment of STATs. However, it is 
unclear which Jak proteins act upstream of STAT6 in response to IL-13 treatment. 
It was shown by western blotting analysis that rat INS-1E beta cells express all 
four known Janus kinases (Jak1, Jak2, Jak3 and Tyk2). These data support initial 
findings by Stout et al. (1997) who also showed by immunohistochemistry that 
INS-1E expressed these proteins. These data are also in accord with other 
studies that show indirectly that Jak1 and Jak2 are expressed in INS-1E and NOD 
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mice using Jak1 and Jak2 inhibitors to influence downstream effects (Trivedi et 
al., 2017, Couto et al., 2007). Jak1 has been implicated in IFN- signalling in both 
beta cells and other cell types. However, a role for Jak1 in IL-4 and IL-13 
mediated Jak/STAT signalling has not been previously reported in beta cells. It 
was shown here that both IL-4 and IL-13 activate Jak1 (Fig. 4.2) but with differing 
kinetics. Research on cytokines that use the common gamma chain, illustrates 
that these cytokines require Jak1 for signal transduction (Haan et al., 2011). IL-4 
has previously been shown to activate Jak1 in a haematopoietic cell line 
(Friedrich et al., 1999) and other cell types through the IL-4R (Chen et al., 1997). 
IL-13 has also been suggested to activate Jak1 in other cell types (Keegan et al., 
1995). Jak1 is known to also be activated by type 1 interferons leading to 
STAT1/STAT2 activation in other cell types (Ahmed et al., 2013). In future 
experiments, it will be important to determine the role of Jak1 is to IL-13 signalling 
by performing knockdown experiments with Jak1. Jak2 knockdown was 
performed instead of Jak1 based on previous experiments by our group 
demonstrating that Jak2 knockdown reversed IL-13 protection (Russell et al., 
2013). It is important to note that the activation of Jak1 can also be induced by 
type 1 interferons (Ahmed et al., 2013). The association of Jaks to receptors is 
not specific as one type of Jak can be found on different receptors. The 
association of Jaks to the receptor is thought to occur after de novo synthesis of 
receptors (Usacheva et al., 2002) and according to the RT2 profiler array, the IL-
4R was upregulated by IL-13 stimulation. It is tempting to speculate that IL-13 
might protect from pro-inflammatory IFN- cytokine by competition for 
cytoplasmic Jak1, although research on receptor association dynamics is still 
needed to confirm this. Alternatively, signalling through Jak1 could lead to the 
upregulation of negative regulators of other signalling pathways such as SOCS1 
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and PIAS1 (Liu et al., 2016, Sun et al., 2013). This suggests that Jak1 might play 
a role in the IL-13 mediated protection of INS-1E from inflammatory cytokines in 
multiple ways. 
Jak2 is known to be activated by IL-4 and IL-13 in vascular endothelial cells 
(Palmer-Crocker et al., 1996). The results in this chapter shows the appearance 
of two Jak2 bands suggested to be isoforms  and have been reported in other 
cell types (Feener et al., 2004, Robertson et al., 2009) although this has not been 
reported in beta cells. In INS-1E beta cells, it has been shown that prolactin 
activates Jak2 in a biphasic manner, with an increase in phosphorylation at 
15mins, then a nadir at 30mins (Brelje et al., 2002). Jak2 has been implicated in 
beta cell proliferation, survival, and protection against beta cell cytotoxicity, and 
can be phosphorylated in response to EPO, Lactogens and prolactin (Choi et al., 
2010, Fujinaka et al., 2007, Yao et al., 2015). Furthermore, Jak2 inhibitors have 
been used to reverse diabetes in NOD mice (Trivedi et al., 2017), where systemic 
delivery was used. Importantly, we have shown that Jak2 is activated upon IL-13 
stimulation and the use of a Jak2 specific inhibitor revealed its role in mediating 
the protective effects of IL-13 (Russell et al., 2013). However, when the time-
course of Jak2 activation was explored in the present work, these data revealed 
a nadir in Jak2 phosphorylation shortly after IL-13 (or IL-4) treatment, but this 
evolved into an elevated level of phosphorylation after 75min of stimulation. It is 
unclear if this initial change is due to enzymatic dephosphorylation of Jak2, as 
this process is known to be performed by a number of protein phosphatases 
including; protein tyrosine phosphatase 1B (PTPN1), Src homology region 2 
domain containing phosphatase (SHP)-1 and SHP2 which can all cause a rapid 
dephosphorylation of the tyrosine 1008 and 1007 on Jak2 (Li et al., 2015a). 
Furthermore, all of these phosphatases have been reported to be present in beta 
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cells (Zhang et al., 2009, Fernandez-Ruiz et al., 2014). The dephosphorylation 
event almost coincides with the activation of STAT6 at 5min and a reported 
increase in the activity of PTPN1 (Li et al., 2015a), which might further implicate 
phosphatases. Building on previous results which had implicated Jak2 in IL-13 
protection of beta cells (Russell et al., 2013), we decided to study Jak2 further. 
Jak2 knockdown reduced the activation of STAT6 by IL-13 (Fig. 4.8) providing 
very strong support for a possible role of this kinase in IL-13 mediated protection 
of beta cells from cytotoxicity.  
The presence of Jak3 in INS-1E beta cells and its activation by both IL-4 and IL-
13 has also been revealed in this chapter. Western blotting showed the presence 
of three bands which represents 3 spliced variants of Jak3 described in other 
cells (Lai et al., 1995). Jak3 phosphorylation is induced by IL-4 and IL-13 via the 
common gamma chain present in their receptors in other cell types (Malar et al., 
1996). Jak3 inhibition using a highly specific inhibitor, WHI-P154 reversed the 
protection induced by IL-4 in rat beta cells cultured in the presence of pro-
inflammatory cytokines (Kaminski et al., 2010). Inhibition of Jak3 using JANEX-1 
in islets and NOD mice reduced NF-B activation by blocking IL-1 and IFN- 
signalling and also reduced iNOS expression by a similar mechanism (Lv et al., 
2009). One possibility is that, IL-4 and IL-13 activation of Jak3 leads to a 
signalling cascade that generates negative feedback molecules (such as 
SOCS1) which then counteract the signalling of pro-inflammatory cytokines such 
as IL-1and IFN-.  
The data presented here and that of others (Marroqui et al., 2015, Stout et al., 
1997) suggest that INS-1E cells express Tyk2. Tyk2 can be activated by both IL-
4 and IL-13 in other cell types (Millward-Sadler et al., 2006), but is also known to 
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be activated by type 1 interferons (Ahmed et al., 2013). More studies are needed 
to confirm which receptor Tyk2 associates with preferentially and whether or not 
it plays a role in IL-13 mediated protection. Tyk2 gene mutations are implicated 
in T1DM and in virus-induced diabetes (Nagafuchi et al., 2015) and knockdown 
of this gene leads to a decrease in MHC I expression and cell death in poly-IC 
stimulated human beta cells (Marroqui et al., 2015).  
Until recently, the role of Jak proteins was understood to be restricted to the 
Jak/STAT signal transduction pathway. However, in the last few years, each of 
the Jak proteins has been shown, unexpectedly, to also translocate to the 
nucleus, where they bind and phosphorylate tyrosine residues on histones 
leading to altered promoter activity. This, in turn, leads to changes in the 
expression of various genes which could potentially be involved in viability, 
survival and other important cell processes. (Zhu et al., 2017, Ahmed et al., 2013, 
Dawson et al., 2009, Landires et al., 2013). This novel insight has however only 
been studied in very few cell types but not in pancreatic beta cells, and may 
illustrate a different but crucial role of the Janus kinases. It is possible that the 
activation of these kinases by different cytokines will lead to differential 
localisation at key nuclear binding sites eventually leading to diverse activities.  
A question that remains unanswered is which receptor (IL-4R, C, IL-13R1) 
mediates the activation of each specific isoform of Jak in beta cells? The present 
understanding indicates a large variation in the cytokine receptor sequence that 
interacts with Jaks (Ferrao and Lupardus, 2017). This suggests that different Jaks 
bind to specific receptors with variable affinities. Immuno-precipitation of the 
receptor components might be one way to define Jak associations. Answering 
this question will give a clearer picture as to which of the Jaks is involved in IL-
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4/IL-13 signalling. Jak proteins use the FERM domain to bind to specific receptor 
components called box1 and box2 (Ferrao and Lupardus, 2017). The IL-4R and 
IL-13R1 have been reported to each have both box1 and box2 and can 
accommodate different Jaks (Usacheva et al., 2002, Ferrao and Lupardus, 2017), 
but whether these are activated simultaneously or in sequence (and which is most 
important) remains to be answered. 
4.4.2 The genes regulated by IL-4 and IL-13 stimulation 
Following the activation of Jaks, the appropriate STAT is recruited to the receptor 
cytoplasmic tail where it becomes activated. In the case of IL-4 and IL-13 
signalling, canonically STAT6 is recruited and phosphorylated, and this model 
was confirmed here using INS-1E cells (and was previously reported in human 
islets (Russell et al., 2013)). However, it is also important to concede that 
additional pathways may be activated independent of STAT6. For example, it was 
previously shown that STAT3 is also phosphorylated in response to IL-13 
treatment of INS-1E (Russell et al., 2013). In addition, activation of PI3K also 
occurs upon IL-4 and IL-13 stimulation (Rutti et al., 2016, Russell et al., 2013). It 
is established that activated STAT6 dimerises with other activated STAT6 
monomers and migrates to the nucleus where it binds to the palindromic 
sequence TTC(N)3 or4 GAA to regulate gene expression (Goenka and Kaplan, 
2011). In trying to understand the genes upregulated by activated by IL-13, a 
qPCR array kit was exploited. 
 Anti-apoptotic molecules such as BCLXL and MCL-1 were upregulated in 
response to IL-4 and IL-13 treatment at both gene and protein levels. These 
results concur with findings in other cell types (Lømo et al., 1997, Wurster et al., 
2002). The importance of both BCLXL and MCL-1 as key anti-apoptotic proteins 
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is well established in beta cell survival, and thus it is likely that the upregulation 
of these proteins may contribute to the protective effects of IL-13 (Carrington et 
al., 2009, Miani et al., 2013). In keeping with this, activated STAT6 dimers have 
been shown to bind to the BCLXL gene promoter region to upregulate BCLXL 
expression (Wurster et al., 2002, Natoli et al., 2013). Data from our group has 
also shown a loss in MCL-1 in certain islets of people with T1DM when compared 
to non-diabetes controls (Richardson et al., 2013). This could imply that 
decreased anti-apoptotic signalling contributes to the death of beta cells in T1DM 
(Usero et al., 2016). 
The results from the gene-specific qPCR assays revealed the dramatic 
upregulation of SIRP (Signal regulatory protein alpha, also known as Src 
Homology domain-containing protein tyrosine phosphatase substrate 1 SHPS-1) 
in response to IL-13 and IL-4. These data were confirmed by qPCR and western 
blotting in EndoC H1 and INS-1E beta cells. SIRP is a transmembrane 
glycoprotein of the Immunoglobulin superfamily involved in cell-cell 
communication through binding to its ligand CD47 (Oshima et al., 2002). CD47 
is a marker of self and is known to inhibit phagocytosis in macrophages through 
its interaction with SIRP (Bian et al., 2016). However, this binding event sends 
a bidirectional signal and as such can have effects on both cells (Oshima et al., 
2002). Results here suggest that CD47 is present in beta cells under control 
conditions and agrees with the results of Kobayashi and colleagues who showed 
the expression of both SIRP and CD47 in the islets of C57BL mice. In that 
report, islet SIRP knockout mice had a reduced ability to secrete insulin 
(Kobayashi et al., 2008). The role of SIRP in beta cell viability remains to be 
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addressed and this is considered in chapter 6 of this thesis. The induction of 
SIRP by IL-13 response has not been documented previously in beta cells.  
Suppressor of cytokine signalling 1 (SOCS1) was also significantly upregulated 
by both IL-4 and IL-13, and a similar effect has been reported in other cell types 
(Hebenstreit et al., 2003). SOCS proteins are the most studied negative 
regulators of the Jak/STAT signalling pathway, wherein they are reported to 
target signalling proteins such as the Jaks for degradation through the ubiquitin 
pathway (Shuai and Liu, 2003). The role of SOCS1 in beta cell health has been 
extensively studied (Martinez-Nunez et al., 2011, Sun et al., 2013, Trengove and 
Ward, 2013, Li et al., 2015b) and may be protective to these cells under certain 
circumstances. Overexpression of SOCS1 protects NOD mice (a T1DM mouse 
model ) from insulitis by preventing both MHCI expression and FASL expression 
and decreasing T-cell proliferation (Chong et al., 2004). Others have shown that 
SOCS1 protected NOD mice from diabetes by blocking IFN- signalling and 
preventing T-cells from attacking the islets (Flodstrom-Tullberg et al., 2003). In 
this context, SOCS1, and other members of the SOCS family (2&3) have been 
shown to be increased at the mRNA level in human islets from people with T1DM, 
possibly as a protective mechanism against inflammatory cytokines (Santangelo 
et al., 2005). Taken together, these data imply that beta cells might be protected 
from cytotoxicity, in part through the upregulation of SOCS1 which can negatively 
regulate pro-inflammatory cytokines signalling.  
The gene-specific qPCR showed an increased expression of the erythropoietin 
receptor (EPOR) by IL-4, but not by IL-13. Little is known about the relationship 
between EPOR and IL-4, except for one report that showing that EPOR signalling 
protects against white adipose tissue inflammation and insulin resistance in a 
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STAT6 dependent on manner (Alnaeeli et al., 2014). Erythropoietin has been 
reported to protect db/db mice from streptozotocin induced diabetes in a beta cell 
specific manner through the upregulation of BCLXL (Choi et al., 2010). 
The RT2 Profiler array also revealed the upregulation other genes such as 
GATA3, PIAS2, SH2B1, PTPN1, GRB2, JUN, PDGFRA, CRK, CRP and MYC 
however, these require further validation with specific primers. Some of these 
genes are known to be STAT6 regulated, such as GATA3, and PIAS2, (Shuai 
and Liu, 2003) and are implicated in diabetes and or IL-13/IL-4 signalling see.  
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Table 13: Other IL-13 regulated genes and their beta cell functions 
Gene Function Reference 
GATA3  Reduced GATA3 upregulation in 
response to type 2 cytokines in cord 
blood T lymphocytes is a genetic risk 
for T1DM 
(Luopajärvi et al., 
2007) 
PIAS2  Upregulated in PBMCs of non-diabetic 
rats stimulated with serum from 
diabetic rats 
 Negative regulator of STAT2 
(Kaldunski et al., 
2010)  
 
(Shuai and Liu, 
2003) 
GRB2  An adaptor protein essential for IGF 
PI3K signalling  
(Hügl et al., 1998) 
PTPN1  Negative regulator of the STATs 
 Its deletion protects mice from T1DM 
(Lu et al., 2008) 
(Herren et al., 
2015) 
cJUN  Helps the beta cell recover from iNOS 
toxicity 
(Scarim et al., 
2003) 
PDGFRA  Essential for PDGF signalling 
important for age dependent 
proliferation of beta cells 
(Chen et al., 2011) 
CRK  An adaptor protein Involved in glucose 
signalling  
(Lee et al., 2004) 
CRP  An acute phase protein secreted in 
response to inflammation and helps in 
phagocytosis. Hence its levels are 
upregulated in T1DM 
(Chase et al., 
2004) 
MYC  Overexpression of the c-MYC in 
streptozotocin induced diabetes mice 
reversed the alter gene expression of 
liver metabolism genes  
(Riu et al., 2002) 
 
Collectively, this chapter set out to study the signalling pathway stimulated by IL-
13 and IL-4 and in beta cells. Whilst a conclusion on which particular Jaks are 
involved in the signalling cannot be drawn pending receptor component 
experiments and viability experiments, the data suggest that all Jaks could 
potentially be involved. The activation of Jak proteins leads to STAT6 recruitment 
and phosphorylation, this in turn increased the expression of various genes, some 
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of which are well known, such as MCL-1 and BCL2L1 and another, not formally 
associated with IL-13, called SIRP And these might be contributing to the 
cytoprotection observed following IL-13 treatment.  
I have confirmed in this chapter, the presence of all four Jaks in INS-1E beta cells 
and illustrated the different activation patterns of these kinases upon IL-4 and IL-
13 stimulation. The dynamics of Jaks and receptors association is still not known 
and might be key to understanding the role of Jaks in beta cells. Importantly, the 
genes regulated by IL-13 were studied in beta cells and revealed the upregulation 
of anti-apoptotic MCL-1 and BCLXL. Additionally, the dramatic upregulation of 
SIRP was observed whose role in beta cells has not been completely defined. 
In the next chapter, the impact of manipulating STAT6 expression by either 
overexpression or knockdown on IL-13 protection in beta cells will be 
investigated. 
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Chapter 5.0: The Impact of STAT6 on beta 
cells 
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5.0 The Impact of STAT6 on beta cells 
5.1 Introduction 
Evidence in the previous chapter demonstrated that the ability of IL-13 to protect 
beta cells involves the upregulation of a variety of gene products. Leading on 
from this, the results described in this chapter establish whether these genes are 
regulated in a STAT6 dependent manner and evaluate the role played by STAT6 
in the cytoprotection afforded by IL-13. Downstream targets of IL-4 and IL-13 
have been extensively studied in immune cells and in other cell types, but 
relatively little is known about their roles in beta cells (Elo et al., 2010, Czimmerer 
et al., 2018, Chen et al., 2003, Szanto et al., 2010).  
IL-13 signals by binding to its cognate receptor leading to receptor dimerization, 
Jak phosphorylation and the recruitment of STAT6. STAT6 is then 
phosphorylated, homo-dimerises and migrates to the nucleus (Jiang et al., 2000). 
According to a GWAS study conducted using human T helper (Th) cells, 80% of 
IL-4 activated genes (453 genes were studied) are regulated by STAT6 over a 
period of 48h. These included genes such as GATA3, GIMAP4, IL-24, LTB, 
SPINT2 and SOCS1 (Elo et al., 2010) but not those found in the present work in 
beta cells. In beta cells, some of the genes regulated by IL-13 have been 
identified by Rütti et al. (2016). In their experiments, INS-1E cells were stimulated 
for 48h and the regulation of 4 genes noted which include CISH, CD83, Galnt14 
and St6galnac3 (a pseudogene). Although CD83 has been linked to T1DM, Rutti 
and colleagues did not go on to confirm whether these genes are directly 
controlled by STAT6 since they concluded that the protection afforded by IL-13 
was PI3 kinase-mediated (Rutti et al., 2016). 
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Whole body knockout of STAT6 in Balb/CJ or C57BL/6j mice led to increases in 
serum cholesterol, triglycerides, and insulin resistance due to an increase in 
PPARwhich caused the activation of fatty acid break down pathways. Hence, 
these mice had lean bodies but high serum fat levels. This suggested that STAT6 
may regulate PPARexpression, hence controlling lipogenesis (Ricardo-
Gonzalez et al., 2010). In another report where Balb/c Lyn knockout mice and 
Lyn knockout STAT6 knockout were used, the absence of STAT6 exacerbated 
autoimmunity by increasing serum auto-antibodies, increasing T-cell activation 
(increase CD69, CD44 and decrease CD62L), and increasing serum cytokines 
such as IFN-, suggesting that polarisation to a more Th1 response occurs in the 
absence of STAT6 to encourage autoimmunity (Lau et al., 2012). 
The aims of this chapter were: 
 To assess the impact of STAT6 on beta cell viability by suppressing its 
expression using small interference RNA. Additionally, to study if loss of 
STAT6 had any influence on IL-13 afforded protection of beta cells from 
cytotoxicity  
 Alternatively, the impact of STAT6 was studied by enhancing its 
expression by transfecting a STAT6 plasmid vector into beta cells and 
performing cytoprotection experiments 
 Gene and protein expression studies were performed after STAT6 
knockdown to determine whether the genes upregulated in chapter three 
are controlled by STAT6. 
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5.2 Materials and methods 
5.2.1 Real-time RT-PCR 
After incubation of cells with relevant test reagents, RNA was extracted as 
described in section 2.6.1, and 500ng used for cDNA synthesis as described in 
section 2.6.2. qPCR was performed accordingly to the methods given in section 
2.6.3.  
5.2.2 Knockdown of STAT6 
Knockdown of STAT6 was performed as described in section 2.3. Briefly, 10nmol 
/mL of STAT6 siRNA (5’ CGAGAUCUUGCUCAAUUAATT, 3’ 
UUAAUUGAGCAAGAUCUGGA from Life technologies, USA) was mixed with 
Optimem, and the transfection reagent Lipofectamine RNAi Max (Thermofisher, 
UK). The mixture was used to transfect plated cells in a dropwise manner, plates 
swirled and incubated at 370C. 
5.2.3 Plasmids  
All plasmids arrived on blotting paper or were lyophilised and were reconstituted 
following the manufacturers’ protocols. Briefly, tubes containing the plasmids 
were centrifuged at 5000g for 5min and DNA suspended in RNAse/DNAse free 
water. The tubes were then left at room temperature for 10min and centrifuged at 
5000g for one minute before storage at -200C or used to transform competent 
Escherichia coli (E.coli). 
STAT6 plasmid 
The rat STAT6 gene ORF cDNA clone expression plasmid was obtained from a 
commercial source (Stratech, UK), (RefSeq NM_001044250.1). The STAT6 
insert was positioned within the multiple cloning site of a pCMV3 vector conferring 
ampicillin resistance. The insert was flanked by various restrictions and two 
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recognised by; KpnI and XbaI, were employed to isolate and sub clone the insert. 
The structure of the STAT6 expression plasmid is shown in figure 5.1 below.  
 
 
 
 
Figure 5. 1:  STAT6 cDNA expression plasmid  
(Courtesy of Sinobiological: http://www.sinobiological.com/Rat-STAT6-Gene-
cDNA-Clone-full-length-ORF-Clone-expression-ready-untagged-
p53097.html#img-1) 
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STAT6 reporters constructs 
The STAT6 reporters plasmids were generously gifted by Mrs Laura Pelletier and 
Prof Karen Leroy of the French National Institute of Health and Medical Research 
(Paris, France). The STAT6 reporters (N3 or N4) were constructed to report the 
binding activity of STAT6 to either an N3 or an N4 GAS domains. The STAT6 
reporters (each containing either an N4 or an N3) are positioned upstream of the 
luciferase gene (Fig. 5.2) thereby allowing their use to monitor promoter activity.  
 
 
 
 
Figure 5. 2: STAT6 reporter construct 
(Courtesy of panomics: www.panomics.com 
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Renilla plasmid 
The renilla plasmid was obtained commercially from Promega, UK. The vector 
encodes a luciferase reporter gene hluc (from Renilla reniformis) with an HSV-
TK promoter which allows constitutive expression in mammalian cells Fig 5.3. 
 
 
 
 
 
 
  
Figure 5. 3: Renilla reporter construct 
Source https://www.promega.co.uk/resources/protocols/product-information-
sheets/a/pgl474-vector-protocol/ 
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GFP plasmid 
In order to monitor the transfection efficiency of our cells, maxGFP was 
employed. This exploits a variant of green fluorescent protein (GFP) from the 
copepod Pontellina plumata (Shagin et al., 2004). The plasmid was commercially 
obtained from Lonza, UK and encodes a kanamycin resistance gene for use in 
selection (Fig.5.4).  
 
 
 
 
 
 
 
  
Figure 5. 4 pmaxGFP plasmid map 
Source: https://bioscience.lonza.com/lonza_bs/US/en/Transfection/ 
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5.2.6 Site-directed Mutagenesis 
Site-directed mutagenesis (SDM) is a protocol performed to create targeted 
changes in DNA by either insertion, deletion or substitution. Such changes in the 
DNA sequence may lead to gain or loss of function in a target protein if designed 
appropriately. SDM was performed following a protocol previously described 
(Bachman, 2013) although pioneered originally by Kunkel (Kunkel, 1985). The 
most important step in carrying out SDM is the design of specific primers that will 
create the change required in the target sequence. The NEBasechanger website 
(www.nebasechanger.neb.com) was used to simulate substitutions in rat STAT6 
cDNA in order to create constitutively active and dominant negative forms. The 
following primers were used to modify the STAT6 sequence; constitutively active 
STAT6 (STAT6CA): forward primer 5’ AAGCAATATGCCGCTAGCCTTCTC3’ 
reverse primer 3’ACTGATAAAGCCGATGATC5’; dominant negative STAT6 
(STAT6DN): primer 5’GGGAGGGGTTCTGTCTCAACTAC3’, reverse 3’ 
GTCCTTTCCCATCTGTTC 5’. At protein level, the constitutively active STAT6 
primer induced a change in the amino acids valine and threonine at position both 
to alanines at position 547 and 548. While the dominant negative primers induced 
a change of the tyrosine 641 to a phenylalanine (Daniel et al., 2000). 
Following the acquisition of the primers, the SDM PCR was performed using a 
Q5® SDM kit (New England Biolabs (NEB), UK). An exponential amplification of 
the plasmid was done using a combination of Q5 master mix, the appropriate 
primers and the template DNA. Denaturation was performed for 30s at 980C 
followed by 25cycles of 980C 10s, 600C 30s, 720C 30s to anneal and a final 
extension step of 720C for 2min. 
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After the SDM, the PCR products were circularised by ligases, and template DNA 
removed by a Dpn1 enzyme (NEB, UK).  
Following this step the plasmids products were sent off for sequencing to confirm 
the successful substitution of the nucleotides.   
5.2.4 Confirming successful insertion or deletion of base pairs 
Five microliters of each sample from the SDM was sent off to Source 
BioScienceTM for sequencing using the appropriate primers depending on the 
vector in which the DNA was inserted. Sequencing results were analysed using 
an online sequence alignment tool (www.expasy.org) in which both the reference 
sequence and mutated sequence are aligned to observe the SDM. 
5.2.5 Bacteria transformation and plasmid purification 
Bacterial transformation to amplify plasmid DNA was performed as detailed in 
section 2.9.2. 
5.2.6 Transfection of cells with plasmid DNA 
Transfection of INS-1E cells or HEK293 cells was performed as detailed in 
section 2.9.3. 
5.2.7 Viability assays 
Cell viability assays were performed as described in section 2.4, using propidium 
iodide staining with some additional modifications. In these experiments, cells 
were transfected with STAT6 constructs prior to the viability assay. Green 
Fluorescent Protein (GFP) construct was co-transfected with STAT6 cDNA in 
order to select only the transfected cells, and thus only the GFP positive cells 
were used for viability counts. After harvesting the cultured cells and staining with 
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PI, the flow cytometer was gated to sort GFP positive cells. From the GFP positive 
gate, PI positive cells were quantified (Fig 5.6). 
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Figure 5. 5: Gating for cell viability read out on the flow cytometer.  
After harvesting cells transfected and treated with various reagents using trypsin, cells 
were stained with 20g/mL PI/Facs buffer and analysed on the flow cytometer. Panel 
a. shows the total population of cells by size (FSC) and granularity (SSC) gated P2. 
Panel b. shows the percentage of the total population P2 that is non-viable labeled P4. 
Panel c. shows the compensation plot of GFP and PI performed according 
manufacturer’s recommendations. Panel d. shows a histogram GFP positive cells 
(M1).  GFP positive cells were then plotted by size and granularity (P1), panel e. and 
on panel f, P1 cells were plotted for PI positive cells P3, which represents the 
percentage non-viable cells positive for GFP. “A” after each acronym on the plots 
stands for Area 
a b c
d e f. 
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5.2.8 Western blotting 
Western blotting was performed to assess protein expression according to the 
protocol in section 2.7. 
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5.3 Results 
5.3.1 STAT6 knockdown abrogated IL-13 protection  
In the previous chapter, a knockdown protocol was established and exploited to 
deplete STAT6 expression in INS-1E cells. A comparison of the different 
transfection reagents revealed that Lipofectamine was more effective than 
attractene (Fig 5.6a). STAT6 levels were significantly reduced (compared to cells 
exposed to scrambled siRNA) in rodent beta cells by approximately 75% within 
48h of introduction of STAT6 siRNA according to densitometric analysis (Fig. 
5.6b). Using the Lipofectamine transfection reagent to monitor the duration of 
knockdown, it was confirmed that STAT6 expression was reduced for at least four 
days (Fig. 5.6c).  
It was important to understand whether STAT6 depletion affected beta cell 
viability in the absence of a cytotoxic stimuli. To asses this, STAT6 knockdown 
was performed in INS-1E cells and cell viability compared with those exposed to 
a scrambled control for a period of 7days. Knockdown of STAT6 did not impact 
the viability of cells for at least six days (Fig.5.7). Observation of the transfected 
cells under the light microscope suggested that, STAT6 knockdown reduced the 
rate of cell growth compared to the scrambled control. Both scramble and 
knockdown treatments witnessed an increase in cell death by day 6 and 7 due to  
increase cell density relative to growth factors in the medium. These lead to cell 
starvation and induction of intrinsic apoptotic pathway and hence increase cell 
death (Alberts et al., 2002b, Alberts et al., 2002a). 
To determine whether the protection offered by IL-13 was mediated via a STAT6-
dependent pathway, IL-13 mediated protection was studied after STAT6 
knockdown. Serum withdrawal was initially exploited to induce beta cell death 
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and was performed as described in section 3.2.3. As already established in 
chapter 3.0 and in other studies (Russell et al., 2013, Charles et al., 2005), serum 
withdrawal from INS-1E cells led to a significant increase in cell death, and this 
was reduced by IL-13 treatment (SW: 46.38±3.5%, SW+IL-13: 27.96±3.3%, 
p<0.001). Importantly, the protection offered by IL-13 was abrogated by STAT6 
KD (SW+STAT6 KD: 48.11±3.6%, SW+STAT6 KD+ IL-13: 42.0±2.6% cell death 
p>0.05) (Fig. 5.8). 
 A similar result was obtained with IL-4 treatment using serum withdrawal to 
induce cell death. Again, SW induced a significant increase in cell death that was 
reduced by IL-4 treatment (SW 53.5±1.5%, SW+IL-4 44.0±1.1% cell death; 
p<0.01). The protection offered by IL-4 was completely reversed by the 
knockdown of STAT6 (SW+KD 58.9±1.8%, SW+KD+IL-4 56.1±2.2% cell death 
p>0.05) (Fig. 5.9).  
To determine whether STAT6 was involved in the IL-13 mediated protection from 
other cytotoxic stimuli, INS-1E cells (with or without STAT6 knockdown) were 
treated with a pro-inflammatory cytokine cocktail (IL-1, TNF-, IFN- and IL-6) 
in the presence or absence of IL-13 and cell viability assessed. As expected, pro-
inflammatory cytokine cocktail treatment led to an increase in cell death that was 
reduced by pre-treatment with IL-13 (Cyt; 92.8±1.3%, Cyt+IL-13; 82.4±1.9%, cell 
death p<0.001). STAT6 knockdown alone had no significant effect relative to the 
scrambled control (control; 15.5±1.4%, Control+KD; 16.9±2.2% cell death). 
Knockdown of STAT6 however, reversed the protection offered by IL-13 
(cytokines: 92.8±1.3%, cyt+KD+IL-13; 94.1±0.8%, cell death p>0.05) (Fig. 5.10).  
As expected 250M palmitic acid (PA) treatment of INS-1E cells for 48h induced 
a large increase in cell death (PA; 91.37±1.49% cell death), and as observed 
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previously this was reduced significantly by IL-13 pre-treatment (PA+ IL-13; 
75.14±3.33%, cell death p<0.001). Strikingly, knockdown (KD) of STAT6 
reversed the protection afforded by IL-13 under conditions of palmitic acid 
treatment (PA+KD+IL-13; 96.16±1.0%, cell death p<0.001). Again, in these 
experiments, knockdown of STAT6 alone did not significantly affect cell viability 
(control; 9.9±1.6%: KD; 15.19±2.1%, cell death p>0.05) Fig. 5.11. Taken together 
these data support the notion that STAT6 is critical in mediating the protective 
effects of IL-13 in pancreatic beta cells. 
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Figure 5. 6: STAT6 was successfully knocked down for four days 
INS-1E cells were treated with 10nM of siSTAT6 for (a-b) 48h and (c) 96h. Cells were 
washed with PBS, lysed and the supernatant harvested for western blotting. (a-b) 
Western blotting was performed with 20g of protein and membranes probed with anti-
sera against STAT6 and control anti-sera against beta-actin. (b) Densitometric analysis 
with Licor software showed a statistically significant decrease in STAT6 expression.  
Western blots results are representative of 3 independent repeats. Data for 
densitometry analysis represent mean ±SEM of triplicate experiments *p<0.05, 
determined by student t-test. 
c 
a 
b 
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Figure 5. 7: STAT6 knockdown does not induce cell death in beta cells 
INS-1E cells were cultured and treated with 10nM of siSTAT6 or scramble siRNA 
and cells harvested at the end of each day for viability studies using trypan blue 
staining.  
Data represent mean values from two independent experiments 
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Figure 5. 8: Depletion of STAT6 reverses the partial protective effects of IL-13 on 
serum withdrawal  
INS-1E cells were transfected with siSTAT6 or scrambled siRNA for 24h prior to 
the addition of 20ng/mL of IL-13 in the absence of serum for 96h. Cells were then 
harvested and viability assessed by trypan blue staining.  
Data represent mean values of 3 independent experiments ±SEM **p<0.01,  
***p<0.001, determined by student t-test. 
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Figure 5. 9: Depletion of STAT6 reverses the partial protective effects of IL-4 on 
serum withdrawal  
INS-1E cells were transfected with siSTAT6 or scrambled siRNA for 24h prior to 
the addition of 20ng/mL of IL-4 in the absence of serum for 96h. Cells were then 
harvested and viability assessed by trypan blue staining.  
Data represent mean values of 3 independent experiments ±SEM **p<0.01 
determined by student t-test. 
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Figure 5. 10: Depletion of STAT6 reverses the partial protective effects of IL-13 on 
pro-inflammatory cytokines treatment 
INS-1E cells were transfected with siSTAT6 or scramble siRNA for 24h prior to 
the addition of 20ng/mL of IL-13 in the presence or absence of 20ng/mL of pro-
inflammatory cytokine cocktail (cytokines) (IL-1, IL-6, TNF- & IFN-). Cells 
were then harvested and viability assessed by trypan blue staining.  
Data represent mean values of 3 independent experiments ±SEM ***p<0.001 
determined by student t-test. 
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Figure 5. 11: Depletion of STAT6 reverses the partial protective effects of IL-13 on 
palmitic acid treatment 
INS-1E cells were transfected with siSTAT6 or scramble siRNA for 24h prior to 
the addition of 20ng/mL of IL-13 in the presence or absence of 250mol/l palmitic 
acid for 48h. Cells were then harvested and viability assessed by trypan blue 
staining.  
Data represent mean values of 3 independent experiments ±SEM ***p<0.001 
determined by student t-test. 
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5.3.2 Knockdown of STAT6 reverses the upregulation of IL-13 responsive 
genes and gene products 
In the previous chapter, it was revealed that IL-13 stimulation of INS-1E cells 
induced the upregulation of several genes (as illustrated in section 4.3.9). To 
understand the role of STAT6 in the regulation of these genes, small interference 
RNA was used to knockdown STAT6, prior to the stimulation of cells with IL-4 
and IL-13. Using gene-specific primers, SYBRGreen qPCR confirmed the 
upregulation of SIRP, BCL2L1, SOCS1, MCL-1 and EPOR in response to IL-4 
and IL-13 stimulation. The fold change was calculated using 2-Ct formula relative 
to levels of the housekeeping genes HPRT1 and YY1.  
As shown previously (Fig. 4.11a), IL-13 and IL-4 stimulation both significantly 
increased the expression of SIRPImportantly, knockdown of STAT6 
completely reversed the IL-13 and IL-4 induced increases in SIRP levels (Fig. 
5.12a). The expression of SOCS1 was similarly elevated by IL-13 and IL-4 
stimulation, and this effect was again abrogated by STAT6 knockdown (Fig. 
5.12b). Although increases in MCL-1 mRNA expression did not achieve statistical 
significance following IL-4 treatment, a significant decrease in MCL-1 mRNA 
levels was noted with STAT6 knockdown when compared to scrambled control. 
Treatment of cells with IL-13 only slightly increased MCL-1 mRNA and this was 
unchanged by STAT6 knockdown (Fig. 5.12c). EPOR was upregulated in 
response to IL-4 stimulation, but not by IL-13. This upregulation by IL-4 was 
reversed by STAT6 knockdown (Fig. 5.12d). IL-4 treatment induced the 
upregulation of BCL2L1 and STAT6 knockdown significantly reduced its 
expression. IL-13 treatment increased BCL2L1 mRNA expression, even though 
this did not attend statistical significance. However, knockdown of STAT6 
significantly reduced BCL2L1 during IL-13 treatment (Fig. 5.12e). IFNGR1 
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expression was unchanged in these experiments and was not affected by 
knockdown (Fig. 5.12f). SMAD1 was reduced under STAT6 knockdown 
conditions but was not directly increased by IL-13 or IL-4 (Fig 5.12h). Initially, 
B2M was used as one of the housekeeping genes, but surprisingly it was noticed 
that its expression was significantly upregulated by knockdown of STAT6 (Fig 
5.12g). 
Western blotting analysis were then performed to determine if these gene 
expression changes led to respective alterations in protein expression. As 
expected and shown in the previous chapter (Fig. 4.10), SIRP expression was 
upregulated by IL-13 and IL-4 stimulation but importantly, this was attenuated by 
STAT6 knockdown. Probing the same membranes using antisera raised against 
BCLXL, the gene product for BCL2L1, or MCL-1 showed an increase in protein 
levels in response to the anti-inflammatory cytokines (IL-4 and IL-13), an effect 
which was blocked by STAT6 knockdown (Fig 5.13) and confirmed by 
densitometry analysis Fig 5.14 although MCL1 levels did not achieve statistical 
significance. 
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Figure 5. 12: IL-13 and IL-4 stimulation of INS-1E cells induces the upregulation of anti-inflammatory and anti-apoptotic genes 
INS-1E cells were stimulated with IL-13 or IL-4 for 48h after STAT6 knockdown, RNA extracted from treated cells and cDNA synthesize. 
Specific primers were generated for qRT-PCR analyses of a selection of genes a. Sirp b. Socs1 c. Mcl1 d. Epor e.Bcl2l1 f. ifngr1 g. B2m 
and h. Smad1 *p<0.05, **p<0.01, ***p<0.001, relative to the control. † †p<0.01, † † †p<0.001, relative to IL-4 treatment. ‡p<0.05, 
‡‡‡p<0.001, relative to IL-13 treatment. The significant differences were determined by the student t-test. 
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Figure 5. 13: SIRP, BCLXL, and MCL-1 are upregulated by IL-4 and IL-13 in 
a STAT6 dependent manner 
STAT6 was depleted by siRNA knockdown followed by 20ng/mL of IL-4 or 
IL-13 for 48h. Cell were lysed, the supernatant collected and western 
blotting performed. Western blots were probed with anti-sera against 
SIRP, BCLXL, MCL-1, and GAPDH. 
Data represent western blot results of experiments that were performed 3 
independent times. 
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Figure 5. 14: Densitometric analysis on Western blots reveals that SIRP and 
BCLXL are upregulated in a STAT6 dependent manner 
Western blot densitometry analysis were performed with the Licor software 
normalised with loading control and expressed relative to the control. Data 
represent means  ±SEM of three independent experiments determined by student 
t-test 
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5.3.3 Construction of constitutively active and dominant negative mutant 
STAT6 
In order to obtain constitutively active STAT6, the wild type STAT6 sequence at 
position 1638-1644 (GTCACT) was changed to GCCGCT hence substituting the 
amino acids valine (547) and Threonine 548 to alanines in these two positions. 
For the dominant negative construct, the STAT6 sequence coding for Tyrosine 
641 (1920-1923) was changed to phenylalanine. Once SDM was performed and 
constructs amplified by E.coli transformation, plasmids were extracted and sent 
for sequencing to confirm the mutagenesis.  
An online alignment tool 
(https://www.expasy.org/genomics/sequence_alignment) was used to confirm 
the changes (Fig. 5.15).   
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Figure 5. 15: Rat STAT6 cDNA sequence (NC_005106.4) alignment with constitutive 
active and dominant negative forms 
Sequence results from sequencing lab were aligned with wild type STAT6 (WT) (a) 
constitutively active STAT6 (CA), GTC ACT codes for Valine and Threonine were 
changed to (↑) GCC (↑) GCT which then codes for two alanines enabling STAT6 to be 
constitutively active. To obtain dominant negative STAT6 (DN), the sequence coding 
for tyrosine 641 TAT was changed to (↑) TTT to code for phenyalanine. 
Y641 
V547 T548 
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The successful insertion was confirmed by sequencing of the plasmid and 
aligning the sequence results with that of the wildtype (Fig 5.15). INS-1E cells 
were transfected with the plasmid for 24h and then stimulated with IL-13 for 
30mins before collecting lysates. A western blot was performed and membranes 
probed with both phospho-STAT6 and total STAT6 anti-sera to monitor 
transfection of the plasmid into INS-1E cells (Fig. 5.16). Expression of STAT6 
was increased in transfected cells. Treatment of INS-1E cells transfected with 
various STAT6 mutant with IL-13 for 30min, caused an increase in 
phosphorylation of STAT6 in cells transfected with (empty vector (EV)), wild type 
(WT), and constitutively active mutant (CA). Dominant negative STAT6 (DN) had 
a slight increase in phosphorylation of STAT6 upon IL-13 stimulation (Fig. 5.16).  
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Figure 5. 16: Mutant STAT6 forms  are activated by IL-13 
INS-1E cells were transfected with a 500ng/mL empty vector (EV), wild type 
(WT), constitutive active (CA), dominant negative (DN) STAT6 plasmid with 
Lipofectamine LTX reagent for 24h followed by treatment in the presence 
and absence of 20ng/mL IL-13 stimulation for 30min. Cells were PBS 
washed, lysed and the supernatant collected and western blotting 
performed. Membranes were probed for phospho-STAT6, total STAT6 and 
a loading control GAPDH. 
Data represent western blots of experiments performed twice 
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5.3.4 Effects of IL-13 on mutant STAT6 variants 
Activated STAT6 dimerizes and migrates to the nucleus to transcribe genes by 
binding to a DNA motif with the consensus sequence TTCN3/4GAA; with N3/4 
representing any three (N3) or four (N4) nucleotides respectively. STAT6 is the 
only member of the STAT family that has a preference for N4 sites (Li et al., 
2016a). The N3 reporter consists of 3 copies of the N3 Gamma Activated Site 
(GAS) in the promoter (TTCtagGAA) while the N4 reporter contains a 3 “N4” 
STAT6 binding sites in the promoter (TTCcgagGAA) upstream of a luciferase 
reporter enzyme (Fig. 5.2).  
The dual luciferase assay simultaneously measures the activity of the firefly 
(reporter) and the amount of Renilla luciferase. While the reporter gives us a 
measure of the activity of the molecule of interest, the Renilla is used to normalise 
the data from the reporter assay. After the measurement of the luciferase activity, 
the firefly reaction is stopped with simultaneous activation of the Renilla luciferase 
which acts as a control reporter (Sherf et al., 1996). In order to evaluate the 
functionality of the various STAT6 forms, HEK293 cells were transfected with an 
expression vector containing WT, CA, or DN STAT6 alongside the N4 luciferase 
reporter and Renilla for 24h before stimulating with IL-4 and IL-13. No activity was 
observed in the empty vector control even with IL-4 and IL-13 stimulation. 
Transfection of WT STAT6 did not yield any activity on its own but the addition of 
IL-4 and IL-13 lead to a nine-fold and 20-fold increase respectively relative to the 
unstimulated control. Transfection with the CA STAT6 showed a 2.8 fold increase 
in activity relative to the control, this increased further to 20 fold, and 27 fold with 
IL-4 and IL-13 stimulation respectively relative to the WT. In contrast, the 
dominant negative form yielded no activity even after the addition of IL-4 and IL-
13. Figure 5.17. 
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After evaluating our STAT6 variants in HEK293 cells, the INS-1E cells were then 
transfected with the N4 luciferase reporter and the Renilla construct to test this 
system. We observed a luciferase reporter activity in IL-13 treated cells samples 
but notice little or no activity with the Renilla reporter. In this context, the Renilla 
response was then tested in a separate experiment in INS-1E. The response 
obtained with the Renilla construct in INS-1E cells was dose-dependent with the 
highest activity realised when 1g per well of the Renilla construct was used (Fig. 
5. 18) in contrast to its activity in HEK293 cells which was greatest with 200ng of 
Renilla. The absolute values were also quite different with a much higher activity 
obtained in the HEK293 cells possibly due to the differences in the cell lines (one 
being human and the other rat). Because the Renilla response was relatively poor 
in INS-1E cells results were expressed our results relative to the empty vector 
control and/ or wild type STAT6.  
Using the N3 and N4 reporters to study the activity of STAT6 by luciferase assay, 
INS-1E cells were transfected with the various STAT6 mutants and reporter 
assays performed as described in section 2.9.4. With the N4 reporter, wild-type 
(WT) STAT6 did not induce any luciferase activity in the absence of cytokine but 
the cells responded well to the addition of IL-13 (31.4 fold change relative to the 
WT unstimulated STAT6). Constitutively active STAT6 (CA) showed an increase 
in activity in the absence of IL-13 (19.5 fold) and this response was tripled by the 
addition of IL-13 (80.6 fold relative to WT STAT6). In contrast, the dominant 
negative STAT6 (DN) showed no activity (Fig 5.19).   
When variant forms of STAT6 were co-transfected with the N3 luciferase reporter, 
only a modest elevation in STAT6 activity was observed in cells transfected with 
the STAT6WT construct in response to IL-13 (5.2 fold relative to the unstimulated 
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control). Surprisingly, transfection with STAT6CA alone did not alter 
transcriptional activity relative to the WT protein (STAT6CA: 1.2 fold), however, 
activity was increased upon stimulation of these cells with IL-13 (STAT6CA + IL-
13: 2.8 fold change). These responses were significantly lower than that of the 
WT activity with IL-13 stimulation in the N4 reporter. The dominant negative 
STAT6 showed no activity with the N3 reporter. (Fig. 5.20). 
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Figure 5. 17: IL-4, IL-13 and STAT6CA induce STAT6 activity as expected.  
HEK293 cells were transfected with an empty vector (EV) or STAT6 variants 
(STAT6WT, STAT6CA, STAT6 DN) with the N4 luciferase reporter and Renilla 
construct for 24h followed by stimulation with 20ng/mL of IL-4 and IL-13 for a 
further 24h. Cells were washed, lysed and dual luciferase assay performed. Data 
was normalised to the Renilla activity and then to the empty vector and 
STAT6WT. 
Data represent fold change mean values from 3 independent experiments ±SEM. 
***p<0.001 relative to STAT6WT: no stimulation, +++p<0.001 relative to 
STAT6WT: no stimulation, &&&p<0.001 relative to STATWT IL-4, ###p<0.001 
relative STAT6WT IL-13, all determined by the student t-test. 
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Figure 5. 18: Renilla plasmid activity was very low in INS-1E cells 
INS-1E cells were transfected with 100ng, 500ng or 1000ng of Renilla cDNA 
construct for 24h. Cells were then harvested and lysed prior to measuring the 
Renilla activity. 
Data represents fold change mean of values of experiments performed twice 
220 
 
  
Figure 5. 19: IL-13 and STAT6VT (CA) mutant induce STAT6 activity at the N4 
domain   
INS-1E cells were transfected with 500ng/mL of STAT6WT, STAT6CA or 
STAT6DN alongside the N4 STAT6 luciferase reporter construct. Cells were 
cultured in the presence of (blue bars) or absence (yellow bars) 20ng/mL of IL-
13, lysed and a luciferase assay performed with 20L of lysates.  
Data represent fold change mean values of experiments performed twice *p<0.05 
relative to STAT6WT: no stimulation, +++p<0.001 relative to STAT6WT: IL-13, 
all determined by the student t-test. 
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Figure 5. 20: IL-13 induces STAT6 activity but not mutant forms at the N3 domain 
INS-1E cells were transfected with 500ng/mL of STAT6WT, STAT6CA or 
STAT6DN alongside N3 STAT6 luciferase reporter construct. Cells were cultured 
in the presence (blue bars) or absence (yellow bars) of 20ng/mL of IL-13, lysed 
and a luciferase assay performed with 20L of lysates.  
Data represent fold change mean values of ±SEM of experiments performed 
twice. ***p<0.001 relative to STAT6WT, +p<0.05 relative to STAT6WT+IL-13, all 
determined by the student t-test. 
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5.3.5 STAT6 mutants reduce beta cell death with IL-13 stimulation 
Data presented in the preceding chapters has revealed that IL-13 protects beta 
cells from the cytotoxic effects of pro-inflammatory cytokines (Figs. 3.4-3.5), and 
in this chapter, the data revealed that this protection is reversed by the 
knockdown of STAT6 (Fig 5.10). An experiment was designed to assess whether 
the expression of constitutively active or dominant negative forms of STAT6 could 
directly impact beta cell viability. 
 For these experiments, the transfection efficiency of INS-1E cells was first 
determined by transfecting with a GFP construct then detecting GFP expression 
using flow cytometry. INS-1E cells showed a transfection efficiency of about 12%. 
For this reason, experiments performed with INS-1E cells that involved 
transfection of variants of STAT6 were performed alongside co-transfection of a 
GFP construct to mark transfected cells for isolation and characterisation in 
viability experiments based on the co-transfection principle. The co-transfection 
principle suggests that if two plasmids are co-transfected into cells, there is a 
positive correlation coefficient of 0.96, which implies that both plasmids are 
almost equivalently delivered into the recipient cells (Xie et al., 2011). Therefore, 
GFP expression served as a transfection control. 
INS-1E cells were transfected with STAT6WT, STAT6CA, or STAT6DN 
constructs alongside a GFP reporter with and without IL-13 stimulation and pro-
inflammatory cytokines. Viability assays were performed using propidium iodide 
staining. In the absence of cytokines, there were no significant increases in cell 
death in the STAT6WT, STATCA when compared to the control. Surprisingly, the 
DN mutant increased cell death in INS-1E cells when compared to the empty 
vector controls (EV control), STAT6CA and STAT6WT (EV: 32.48±2.2%, DN: 
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46.45±2.3%, CA: 30.85±1.6%, WT: 32.21±1.7%, cell death p<0.05). Additionally, 
IL-13 stimulation did not protect from DN mediated cell death (DN: 46.45±2.3, 
DN+IL-13: 53.92±5.5, cell death p>0.05) or improve viability upon transfection 
with other STAT6 variants (Fig 5.21). 
 As previously shown in Chapter 3 and 4, pro-inflammatory cytokines (Pro) 
induced beta cell death in INS-1E cells (Pro: 86.9±2.2% cell death). Similarly, 
pro-inflammatory cytokine stimulation of INS-1E cells transfected with variants of 
STAT6 induced significant cell death (Pro: 86.88±2.2%, Pro+DN: 87.75±1.1%, 
Pro+CA: 85.48±1.4%, and Pro+WT: 82.4±2.9%, p>0.05). As illustrated in section 
3.3.2, IL-13 stimulation protected beta cells from the detrimental effects of pro-
inflammatory cytokines in all treatments including STAT6DN (Pro: 86.9±2.2%, 
Pro+IL-13: 68.3±1.7%, Pro+DN+IL-13: 70.9±2.6%, Pro+WT+IL-13: 67.8±2.4%, 
and Pro+CA+IL-13: 60.9±2.2%, cell death p>0.01). STAT6CA appeared to have 
improved beta cell viability after IL-13 treatment compared to the STAT6WT cells 
treated with pro-inflammatory cytokines although this did not reach significance.  
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Figure 5. 21: STAT6 mutants reduce beta cells death by Pro-inflammatory 
cytokines upon IL-13 treatment 
INS-1E cells were transfected with various STAT6 mutants and GFP to identify 
the transfected cells followed by pro-inflammatory cytokines (Pro) (20ng/mL IL-6, 
IL-1, IFN-, and TNF-) for 48h in the absence and presence of IL-13. Cells 
were harvested with the use of trypsin and cell viability assessed by propidium 
iodide staining. 
Data represents mean values ±SEM of three independent experiments. 
***p<0.001 relative to EV control, ++p<0.01 relative to EV control, $$$p<0.001 
relative to Pro, all determined by the student t-test. 
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5.3.6 STAT6 is lost in cells exposed to pro-inflammatory cytokines and is 
rescued by IL-13 treatment. 
Initial findings using immunohistochemistry suggested that STAT6 is lost from the 
insulin containing islets of individuals with T1DM when compared to age and sex 
matched non-diabetes controls (Leslie et al., 2018). It was not clear what caused 
this change, but we reasoned that it might be due to the release of pro-
inflammatory factors from the influent immune cells. In order to test this, INS-1E 
cells were treated with pro-inflammatory cytokines with and without IL-13. The 
results revealed a significant loss of STAT6 upon treatment with pro-inflammatory 
cytokines Fig. 5.22a. Similarly, treatment of INS-1E cells with 250M palmitate 
for 48h showed a loss in STAT6 by western blotting (Fig 5.22a). Additionally, INS-
1E cells deprived of serum for 96h showed a decrease in STAT6 expression (Fig 
5.22b).  
Treatment of the cells with IL-13 in combination with pro-inflammatory cytokines 
revealed a restoration of STAT6 expression (Fig. 5.22c). A similar response 
occurred in cells incubated in the absence of serum. 
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Figure 5. 22 : STAT6 is ablated by cytotoxicity  
INS-1E cells were cultured in the presence of a. pro-inflammatory cytokines (20ng/mL of 
each IL-1, IL-6, TNF-, and IFN-), 250M palmitic acid or b. 96h serum withdrawn 
conditions c. alternatively, cells were cultured with pro-inflammatory cytokines or serum 
withdrawal conditions in the presence or absence of IL-13. Cell lysates were collected 
and 10g used to perform western blotting and membranes probed with antisera against 
STAT6 and loading control GAPDH. d. Densitometric analysis reveal a significant 
increase in STAT6 relative to respective controls in IL-13 treatments. 
Data are representative of experiments performed 3 times independently. 
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5.4 Discussion 
This chapter provides evidence for the importance of STAT6 in mediating the 
protective effects of IL-13 in pancreatic beta cells. The data suggest that the 
increased expression of anti-apoptotic proteins, including a consistent increase 
in SIRPmight be among the mechanisms by which this protection is facilitated. 
I have shown in this chapter that STAT6 is important in mediating the 
cytoprotection of the beta cell afforded by IL-13. Additionally, it was shown here 
that many of the genes upregulated by IL13 and IL-4 are STAT6 modulated.  
The results are in agreement with those in chapter 3 and with earlier reports on 
the protection of beta cells by IL-13 and IL-4 in a cytotoxic milieu (either serum 
withdrawal, palmitic acid, or pro-inflammatory cytokines) (Kaminski et al., 2010, 
Russell et al., 2013). In contrast, the data presented in this chapter differ from 
those of Rutti et al. (2016) who suggest that the protective effects of IL-13 are 
mediated via a PI3K/Akt signalling route. Although there is activation of the PI3K 
pathway in response to IL-13, a PI3K inhibitor (wortmannin) did not affect the 
protection achieved with IL-13 (Russell et al., 2013). The present data suggest 
that the IL-13 protection primarily works in a STAT6 dependent fashion. 
Additionally, in a study where STAT6 and IRS2 (shown to be the main activation 
route of the PI-3K pathway) deficient mice were employed and their lymphocytes 
cultured overnight in the presence and absence of IL-4, STAT6 was shown to be 
crucial for IL-4 mediated protection whereas IRS2 was dispensable (Wurster et 
al., 2002). The role of STAT6 in beta cell has received limited attention in T1DM, 
but its effect has been documented in other autoimmune diseases. In one such 
disease (systemic lupus erythematosus), a mouse model was used to illustrate 
the importance of STAT6. In Lyn (-/-) mice, a lupus like autoimmune model, 
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depletion of STAT6 (Lyn (-/-) STAT6 (-/-)) exacerbated autoimmunity supporting 
the role of STAT6 as a protective transcription factor (Lau et al., 2012).  
Typically, activated STAT6 dimerises and translocates to the nucleus where it 
transcribes a specific set of genes (Goenka and Kaplan, 2011). Depleting STAT6 
is expected to prevent the upregulation of IL-13/IL-4 induced genes. We identified 
a number of genes which were upregulated in response to IL-13 in the previous 
chapter, and now confirm that many of these changes occurred in a STAT6-
dependent manner. With the use of small interference RNA molecules, it was 
shown that anti-apoptotic genes BCL2L1 and MCL-1 are STAT6 dependent since 
knockdown of STAT6 led to a reduced expression of these genes in INS-1E cells 
(Fig 5.13, 5.14 and 5.15). In immune cells, it is known that IL-4 and IL-13 
modulate both BCLXL and MCL-1 expression in a STAT6 dependent manner 
(Ritz et al., 2008, Steele et al., 2010) but their modulation via STAT6 in pancreatic 
beta cells has not been previously documented. In one example wherein 
lymphocytes from STAT6 deficient and relevant control mice were cultured 
overnight with IL-4, BCLXL expression was significantly upregulated in the wild 
type controls but diminished in STAT6 deficient lymphocytes (Wurster et al., 
2002). Interestingly, loss of STAT6 expression has been observed in tissues from 
individuals with T1DM (Leslie et al. 2018) and MCL-1 expression is reduced in 
some islets of individuals with T1DM (Richardson et al., 2013).  
The findings in this chapter also revealed that SIRP expression is regulated in 
a STAT6 mediated manner in beta cells. This relationship is novel and has not 
been previously reported in any cell type. It was therefore, important to explore 
the role of SIRP in the pancreatic beta cell, and this will be considered further 
in the next chapter.  
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 It was not surprising that IL-13 and IL-4 upregulate the suppressor of cytokine 
signalling 1 (SOCS1) in beta cells, since this phenomenon is established in other 
cell types treated with these cytokines (Hebenstreit et al., 2003, Hebenstreit et 
al., 2005, Ritz et al., 2008). SOCS1 is a negative regulator of Jak/STAT signalling 
and is suggested to regulate the pathway by binding to the activation loop of the 
Jaks (Babon et al., 2006). In this chapter the experiments show that SOCS1 is 
STAT6 regulated. These findings are in agreement with work by Dickensheets 
and colleagues (2006) in which monocytes from STAT6 knockout or control 
animals were stimulated with IL-4 and SOCS1 detected by western blotting. In 
their experiments, SOCS1 was shown to be STAT6 modulated but also a 
negative regulator of the Jak/STAT6 pathway when overexpressed 
(Dickensheets et al., 2006). The role of SOCS1 has been extensively studied in 
beta cells (Sun et al., 2013, Zaitseva et al., 2009, Barral et al., 2006, Chong et 
al., 2004) and it may contribute to cytoprotective effect by negatively regulating 
pro-inflammatory cytokine signalling. In one such study, SOCS1 was shown to 
inhibit IFN-, IL-1 and TNF- induced beta cell death via the downregulation of 
caspase 3 activation through the negative regulation of STAT1 activation 
(Zaitseva et al., 2009). In another study using mice with diabetes that was virally 
induced, overexpression of SOCS1 reduced the incidence of diabetes by over 
90%. In those experiments, it was shown that SOCS1 overexpression rendered 
beta cells resistant to cytotoxic T lymphocyte attack. It is however, not known 
whether SOCS1 can impact the protection against non-cytokine forms of 
cytotoxicity such as serum withdrawal or palmitate. 
SMAD1 (SMAD stands for mothers against decapentaplegic) is an intracellular 
signal transducer of TGF- receptor. SMAD1 has not been extensively studied in 
beta cells, but it is known to be expressed in beta cells which agrees with our 
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qPCR data showing its detection after 23 cycles (Toren-Haritan and Efrat, 2015). 
So although experiments in beta cells revealed that IL-4 and IL-13 stimulation did 
not upregulate SMAD1, research using hepatic cell lines has reported the 
upregulation of SMAD1 by IL-13 in a non-Jak/STAT manner leading to the 
expression of connective tissue growth factor (Liu et al., 2011). In contrast to 
these findings, our data show that knockdown of STAT6 led to a reduced 
expression of SMAD1. Further work will be required better understand the 
relationship between SMAD1 and STAT6 in beta cells. 
Initially, B2M was recommended as the housekeeping gene for qPCR of STAT6 
responsive genes but after performing experiments with STAT6 knockdown it 
was realised that B2M expression may be negatively controlled by STAT6 in beta 
cells. In these experiments, STAT6 knockdown led to upregulation of B2M mRNA 
suggesting that the transcription factor is important for maintaining the levels of 
B2M. B2M is a protein of low molecular weight (11.8kDa) present in all nucleated 
cells and is non-covalently linked with MHCI alpha chain (Li et al., 2016b). Due 
to the changes observed upon STAT6 knockdown I excluded B2M as a house 
keeping gene. Our recently published work suggests that a loss in STAT6 
expression occurs in insulin containing islets of T1DM (Leslie et al., 2018). This 
loss in STAT6 together with evidence of increased in B2M levels in the insulin 
containing islets of subjects with T1DM (Richardson et al., 2016) resonate with 
the present findings suggesting that B2M expression maybe negatively controlled 
by STAT6.  
In dual-luciferase reporter assays, STAT6 showed a preference for the N4 GAS 
domain binding site in beta cells, when compared to the N3 site, this agrees with 
the work of Li et al. (2016a) who showed by x-ray scattering experiments that 
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STAT6 possess a key residue (H415) that gives it the selective ability to bind to 
the N4 site over N3.  
The HEK293 cells are an embryonic kidney cell line with a high transfection 
efficiency (Thomas and Smart, 2005) were transfected with a STAT6 luciferase 
reporter, and the Renilla construct alongside various STAT6 mutants. An 
increased activity was observed with the constitutively active mutant of 
approximately 8 fold after IL-13 stimulation; similar to that reported by Daniel and 
colleagues (Daniel et al., 2000). Also observed, was the inhibition of STAT6 
activity by a dominant negative STAT6, results that were also obtained by Daniel 
et al., 2000 using HEK293 cells (Fig.5.16). In DLR experiments with INS-1E cells, 
the transfection efficiency of the Renilla construct used as a normalisation control 
was poor, and so the data arising from the INS-1E cells experiments could not be 
normalised in the typical way. This meant that interpretation of the results was 
equivocal. The difference in transfection between the INS-1E and HEK293 could 
be due to the differences in the cell lines (one is a human kidney cell lines and 
the order is rat beta cell line).   
Constitutively active STAT6 acts by virtue of an IL-4 or IL-13 independent 
phosphorylation of STAT6 due to a conformational changed induced by two 
amino acids (Fig.5.15). It been suggested that CA STAT6 has a higher binding 
stability than the wild type is and is more resistant to proteolytic degradation. The 
dominant negative STAT6 due to that change in the Tyr641 leads to an inability 
to activate STAT6 with IL-4 or IL-13 and hence no DNA binding activity of STAT6 
(Daniel et al., 2000).  
INS-1E cells transfected with variants of STAT6 showed an increase in total 
STAT6 expression (Fig. 5.16) but this did not seem to directly protect the cells 
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from pro-inflammatory cytokines. Protection was only achieved when IL-13 was 
used in combination with the STAT6 constructs. Cytoprotective experiments with 
STAT6 mutants were performed over a period of five days; plasmid transfection 
for 24h, 48h of IL-13 stimulation and 48h of pro-inflammatory cytokines 
stimulation followed by PI staining and flow cytometry. Loss of plasmid by cells 
over the experimental period (5days) in cell division (Middleton and Sugden, 
1994) could have been a possible reason for the lack of effect of the dominant 
negative and other STAT6 variants but this is unlikely given that the flow 
cytometer gating was performed on transfected cells alone. The mechanism by 
which IL-13 still protected INS-1E against pro-inflammatory cytokines in 
STAT6DN transfections remains unclear. One might be tempted to suggest that 
endogenous STAT6 could have been activated to contribute to this protection. 
Additionally, it is difficult to say if all GFP positive cells also contained the various 
STAT6 mutants. Further research with the use of stably transfected cell lines or 
CRISPR (clustered regularly interspaced short palindromic repeats) modified cell 
lines will be required to uncover the mechanisms. 
Recent findings by our group, suggest that STAT6 is lost from insulin containing 
beta cells of T1DM individuals although the mechanism by which this occurs 
remains to be understood (Leslie et al., 2018). The data in this chapter revealed 
that STAT6 levels might be reduced in response to pro-inflammatory cytokines, 
serum withdrawal or palmitate although the precise mode by which this occurs 
remains to be revealed. IFN- has been shown to inhibit the phosphorylation and 
activity of STAT6 by IL-4 treatment in other cell types. This inhibition was 
achieved by 24h pre-treatment of cells with IFN- followed by IL-4 stimulation. 
STAT6 inhibition was dependent on the concentration of IFN-(Heller et al., 2004, 
Dickensheets et al., 1999). The inhibition of the IL-4 signalling by IFN- might lead 
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to reduced STAT6 expression since it was shown earlier that IL-4 positively 
regulates STAT6 expression (Fig. 4.14). Additionally, pro-inflammatory cytokines 
have been reported to upregulate the expression of some noncoding microRNAs 
(miRs) which negatively regulation the expression of target genes. MiRs achieve 
this by pairing to the 3’-untranslated region of the target mRNA leading to their 
degradation or inhibition of gene expression. Two such miRs, miR-155-5p and 
miR-210, are increased in T1DM, and known to be modulated by inflammatory 
cytokines (TNF-, IFN- and IL-1) in beta cells and other cell types (Grieco et 
al., 2017, Assmann et al., 2017, Huang et al., 2018). These miRs have been 
reported to suppress STAT6 expression and activity in other cell types (Kopriva 
et al., 2013, Matsukura et al., 2016, Martinez-Nunez et al., 2011). It is therefore 
possible that the pro-inflammatory cytokines upregulate these microRNAs 
leading to loss of STAT6 and hence potentiating beta cell death, but this has yet 
to be confirmed in beta cells. 
In previous experiments as well as in the present work, cytoprotection was 
achieved by pre-incubation with IL-13 for 48h prior to addition of cytotoxic stimuli. 
Pre-incubation allows the beta cells to increase the expression of STAT6 and its 
downstream target genes such as, SOCS-1, SIRP and anti-apoptotic proteins 
MCL-1 and BCLXL before subsequent application of the inflammatory cytokine 
mixture.  
This chapter demonstrates the importance of STAT6 for IL-13 protection since 
depletion of STAT6 by knockdown completely prevented IL-13 mediated 
cytoprotection. Furthermore, this work also reveals that many of the IL-13 
regulated genes reported in Chapter 4 were controlled in a STAT6-dependent 
manner. The upregulation of a gene not previously recognised as being 
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transcriptionally regulated by STAT6 (or IL-13), SIRP was identified, and its role 
in beta cell health needs to be investigated further. This will be explored in chapter 
6. 
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Chapter 6.0: Signal Regulatory Protein alpha 
(SIRP) in beta cells 
  
237 
 
6.0 Signal Regulatory Protein alpha (SIRP)/ CD47 in beta cells 
6.1 Introduction 
In the earlier chapters, it was revealed that Signal regulatory protein alpha 
(SIRP) was strongly upregulated in human and rodent beta cell lines stimulated 
with IL-13 and IL-4 in a STAT6 dependent manner. However, the impact of SIRP 
upregulation on beta cells is unknown.  
SIRP (also known as Src homology 2 domain-containing tyrosine phosphatase 
substrate 1(SHPS-1), BIT (Brain Ig-like molecule with tyrosine-based activation 
motifs), P84, MFR (Macrophage fusion receptor) or MyD-1) belongs to the 
superfamily of immunoglobulins and is predominantly expressed in myeloid and 
neuronal cells (Oshima et al., 2002). SIRP is a transmembrane glycoprotein 
whose extracellular region contains 3 immunoglobulin domains whilst its 
cytoplasmic tail contains four tyrosine phosphorylation sites that are typically 
activated following binding to CD47 its cognate ligand (Matozaki et al., 2009) (Fig. 
6.1). The phosphorylation of SIRP can also be stimulated by other mechanisms, 
such as its association with insulin-like growth factor-1 (IGF1) receptor when 
activated by IGF1 (Shen et al., 2009). The activation of SIRP leads to the 
recruitment of Src homology 2 phosphatases such as SHP1, and SHP2 (Takada 
et al., 1998) leading to their activation and interaction with Grb2, and SOS Gab1 
leading to the recruitment of Ras and its activation. Activated Ras then activates 
Raf which in turn phosphorylates and activates MEK which then phosphorylates  
and activates ERK that transcribe genes involved in proliferation or survival 
(Zhang et al., 2015).  
CD47 (also known as integrin associated protein) is the cognate ligand for 
SIRP, which is expressed on most somatic cells. Like SIRPit is a member of 
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the Ig superfamily with an extracellular IgV domain, a five transmembrane-
spanning domain and a short cytoplasmic tail (Per-Arne, 2013). CD47 is also 
recognised as a marker of self (or a “don’t eat me” molecule) and is known to 
inhibit macrophage phagocytosis, promote cell migration, cell-to-cell 
communication, inhibition of apoptosis, cell proliferation, and downregulation of 
cytokine production in dendritic cells (Oshima et al., 2002). Importantly, CD47 
can signal by either a trans (i.e from one cell to another) interaction with SIRP, 
together with SIRPanother member of the SIRP family lacking the cytoplasmic 
tail) and thombospodin-1 or in a cis interaction where it binds to integrins or 
SIRPon the same cell (Soto-Pantoja et al., 2014, Kojima et al., 2016) (Fig 6.1). 
CD47 and SIRP are each expressed in rodent islets and it has been proposed 
that knockout of SIRP alters insulin secretion although the precise mechanism 
is not known (Kobayashi et al., 2008).  
The role of SIRP in beta cells has received limited attention but genome wide 
association studies in diabetic mouse have revealed that the idd13 locus 
(chromosome 2), correlates with the location of SIRP and is involved disease 
pathogenesis. Indeed, high-resolution genomic mapping analysis of the six genes 
in that region, identified Sirp as the causal gene at the Idd13.2 locus which is 
crucial for the regulation of insulitis and the susceptibility of NOD mouse to 
diabetes (Wong et al., 2014). Furthermore, linkage analysis in the Biobreeding 
rat model of T1DM identified the Iddm27 locus (orthologous to Idd13 in mouse) 
as being important in the control of islet integrity and susceptibility to diabetes 
(Wallis et al., 2009). The human chromosome 20p13 includes a SIRP cluster that 
encodes SIRP and has been associated with T1DM (Barrett et al., 2009). A 
report by Takenaka et al. (2007) identified 18 amino acids variations in the 
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extracellular N-terminal variable region of SIRP between mice susceptible to 
diabetes (NOD) and mice protected from diabetes (NOR). These changes in 
amino acids might change the binding dynamics of the SIRP on T-cells 
promoting insulitis (Wong et al., 2014). The role of SIRP in immune cells is 
established as an inhibitor of phagocytosis when it binds to CD47 on the surface 
of other cell types (van Bommel et al., 2017, Nuvolone et al., 2013). C57BL/6N 
mice generated to lack the cytoplasmic region of SIRP in the islets showed 
reduced plasma insulin levels, impaired glucose tolerance, and reduced capacity 
of the beta cells to secrete insulin upon glucose stimulation (Kobayashi et al., 
2008). Wong et al., (2014) showed that a SIRP variant (change in 20 amino 
acids) expressed by NOD mice drives islet inflammation by binding with higher 
affinity to CD47 compared to the diabetes resistant strains. Additionally, transfer 
of this variant SIRP from NOD mice to myeloid cells of NOD.SCID (without 
immune system) mice induced diabetes (Wong et al., 2014).  
The functional role of SIRP in beta cells remains an area of limited research but 
novel data presented in this thesis showing its association with IL-13/IL-4 
signalling and the transcription factor STAT6 makes it in an interesting candidate 
for further study.  
This chapter has several objectives; 
 To investigate the importance of SIRP in beta cells. In particular, I aimed 
to study the role of SIRP in beta cell viability and protection from 
cytotoxicity using rodent beta cell lines, human derived beta cells and 
human islets. 
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 Additionally, expression of the SIRP binding ligand CD47 was studied in 
both human and rodent beta cells.  
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Figure 6. 1: Schematic structure of SIRPand CD47.  
CD47 is the ligand for SIRP. ‘Y’ indicate cytoplasmic tyrosine residues which 
can become phosphorylated upon ligand binding. The arrows indicate the 
direction of signal after interaction. A cis interaction by CD47 and SIRP occurs 
on the same cell while a trans interaction occurs on different cells 
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6.2 Materials and methods 
6.2.1 Western blotting 
Western blotting was performed as described in section 2.7. The antibodies to 
SIRP (catalogue number: 13379, 1:1000 5% BSA TBST) and GAPDH 
(catalogue number: 60004-1, 1:10000 5% milk TBST) were purchased from Cell 
signalling and Proteintech respectively. Human islets were a kind donation from 
the Oxford transplant programme. 
6.2.2 Transfection studies 
Small interference RNA was used to reduce the expression of SIRP in INS-1E 
cells and was performed as described in section 2.3. Increased 
SIRPexpression was achieved by transfecting INS-1E cells with a pCMV6 
vector (catalogue number: RC222380, Origene, USA) containing the human 
SIRP coding sequence (Fig 6.2). Transfections of these constructs (including 
relevant controls) were performed with Lipofectamine LTX reagent (Invitrogen) 
as described in section 2.9.3 and the success of transfection was examined by 
western blotting.  
6.2.3 RT- qPCR 
RT-qPCR was performed as described in section 2.6. Primers were commercially 
obtained from Qiagen, UK. 
6.2.4 Viability studies and cell cycle analysis 
Viability studies were performed using propidium iodide staining as described in 
section 2.4, whilst cell cycle analysis was performed as reported in section 2.5. 
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6.2.5 Immunohistochemistry and immunofluorescent staining  
Immunohistochemical and immunofluorescence staining of FFPE human 
pancreas sections were performed as in section 2.8.2. These samples were 
obtained from the Exeter Archival Diabetes Biobank (http://foulis.vub.ac.be/), a 
collection of post-mortem pancreas samples (Table 15). The list of antibodies 
used and their conditions are described in table 14. Images were captured at the 
same settings on a fluorescent microscope (Leica Microsystem, UK) and the 
mean fluorescent intensity (MFI) of the CD47 containing cells was determined 
using a custom MATLAB script (MATLAB version R2015b) VIOLA (developed by 
Dr Chilton of the University of Exeter Medical School). The script was used to 
determine the MFIs of CD47 in regions of interest in the tissue. DAPI (4',6-
diamidino-2-phenylindole) was used as a nuclear stain (Dako, UK) at 1:1000 
dilution. 
 
Table 14: Antibodies and conditions used in immunostaining  
 
  
Antibody Dilution Source Catalogue number 
CD47 1:1000 RnD systems AF4670 
Insulin 1:300 DAKO A0564 
Glucagon 1:400 Abcam ab92517 
Anti-guinea pig 647 1:400 Invitrogen A21450 
Anti-Goat 555 1:400 Invitrogen A32814 
Anti-Rabbit 488 1:400 Invitrogen A32732 
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Table 15: Tissue samples and patient information  
Case ID Case type Age 
(Years) 
Sex Duration of 
Disease 
146/66 No Diabetes Control 18 F  
21/89 No Diabetes Control 4 F  
PM34/67 No Diabetes control  41 F  
E556 T1DM 18  M 4months 
SC119 T1DM 4 F 2 weeks 
E560 T1DM (organ donor) 42 F 18months 
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Figure 6. 2 Map of the pCMV6 plasmid containing SIRP clone 
Courtesy:https://www.origene.com/catalog/cdna-clones/expression-
plasmids/rc222380/sirp-alpha-sirpa-nm_001040022-human-tagged-orf-clone 
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6.3 Results 
6.3.1 Signal regulatory protein alpha is expressed in human islets and 
upregulated by IL-13 treatment 
In Chapter 4 it was shown by qPCR and western blotting that SIRP is expressed 
in the INS-1E and in human EndoC H1 cells and that its expression was 
increased in response to IL-13 and IL-4 (Fig. 4.12). The expression of SIRPin 
rat beta cells is in agreement with Kobayshi et al. (2008) who showed the 
expression of SIRP in rat pancreatic beta cells by immunohistochemistry. It was 
also important to determine whether a similar pattern could be observed in 
isolated primary human islets. Therefore, isolated humans islets were lysed and 
protein extracted for western blotting with an anti-SIRP antibody (Fig 6.3a). This 
revealed that SIRPis expressed in islet cells. A separate preparation of human 
islets was stimulated with 20ng/mL of IL-13 for 48h prior to western blotting and 
it was found that SIRP expression was increased in response to IL-13 
stimulation (Fig.6.3b). 
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Figure 6. 3: SIRP is present in human islets and is upregulated by IL-13 
stimulation 
Human islets from donors were lysed, a western blot performed, and probed for 
SIRP and GAPDH as loading control. a. unstimulated human islet samples 
express SIRP, b. stimulated human islet samples with 20ng/mL of IL-13 for 
48h prior to lysis for western blotting. IL-13 stimulation upregulated SIRP 
expression  
Data are representative of two independent islet preparations.  
248 
 
6.3.2 SIRP knockdown using siRNA induces cell death in INS-1E cells 
To assess the impact of SIRP on beta cell viability, SIRP expression was 
initially knocked down over a 4 day period in INS-1E cells using specific siRNA 
molecules, then RNA and protein extracted. Quantitative PCR analysis revealed 
that SIRP mRNA was successfully depleted over this 4 day period (Fig 6.4a). 
Western blotting analysis of samples revealed that SIRPprotein levels were 
depleted by approximately 80% during this period. Importantly, the knockdown 
did not affect expression of other proteins such as STAT6 or STAT3 (Fig. 6.4b). 
SIRP expression was also successfully reduced in EndoC H1 cells (Fig 6.4c) 
using siRNA targeting the human sequence. During experiments with INS-1E 
cells, it was unexpectedly observed at later time-points that there were fewer cells 
present after knockdown of SIRP compared to samples transfected with 
scrambled control siRNA. To examine this phenomenon more closely, cell growth 
was assessed by manual counting of cells following trypan blue staining. These 
data confirmed that after three days of SIRP knockdown there was significantly 
lower cell numbers in the knockdown treatments compared to the scrambled 
controls (Day3, control: 83.5±8.6 x104cells/mL, SIRP KD: 51.0±3 x104 cells/mL, 
p<0.05, Day4, control: 137.8±15.2 x104cells/mL, SIRP KD: 84.8±3 x104, 
cells/mL p<0.001) (Fig. 6.7).  
To understand whether SIRP has a role in IL-13 mediated protection of rodent 
beta cells, it was important to assess whether the depletion of SIRP expression 
could alter beta cell viability alone. In initial experiments, cell viability was 
determined by propidium iodide staining in cells incubated in complete medium 
but with SIRP knockdown. This revealed a significant increase in the percentage 
of dead cells after SIRP knockdown when compared to the scrambled controls 
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(Control; 22.5±1.8%, Control + KD; 34.89±2.1%, cell death p<0.001). As 
expected, serum withdrawal increased cell death and this effect was further 
potentiated by SIRP knockdown (serum withdrawal; 49.3±0.9%, SW+KD; 
70.24±1.5%, cell death p<0.001) (Fig. 6.6). Under serum withdrawal conditions 
addition of IL-13 reduced the percentage of dead cells and this was also seen 
under SIRP knockdown conditions (SW; 49.3±0.9%, SW+IL-13; 44.4±0.8%, 
SW+KD; 70.24±1.5%, SW+KD+IL-13; 62.2±2.0% cell death) (Fig 6.6). One 
possible explanation for this observation is that the levels of SIRP were still 
elevated after IL-13 treatment despite the use of siRNA to knockdown the protein. 
To address this possibility, SIRP was knocked down in INS-1E cells 
accompanied by treatment with IL-13. qPCR analysis of these samples revealed 
that IL-13 treatment reversed the depletion in SIRP levels to at least normal 
expression levels (Fig 6.5).  
Since depletion of SIRP slowed the growth beta cells and increased cell death 
when compared to cells treated with a scrambled control siRNA, it was important 
to confirm these findings using a cell cycle analysis protocol. In these 
experiments, SIRP was knocked down for four days (Fig. 6.4), and then cell 
cycle analysis performed as described in section 2.5. The proportion of the cells 
in SubG0/G1 (apoptotic), G0/G1, G2/M+S (proliferating) was calculated after 
analysis by flow cytometry. Cell cycle analysis revealed that SIRP knockdown 
did not alter any phase of the cell cycle, however an increase in the sub G0/G1 
population of apoptotic cells was observed, consistent with our previous findings 
(Control Sub G0G1: 10.3±0.8% of cells, SIRP KD Sub G0G1: 34.5±3.2%, 
p<0.001, Fig 6.8). 
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Figure 6. 4: SIRP was successfully knocked down in beta cells 
Cells were transfected with 10nM of rat SIRP siRNA in a&b INS-1E cells for 96h and c. in human EndoC H1 cells for 48h respectively. 
a. Cells were washed, RNA extracted and RT-qPCR performed or b and c lysed and western blotting performed, membranes were 
probed with anti-sera against SIRP, STAT6, STAT3, and GAPDH.Data represents RT-qPCR results and western blots of experiments 
performed at least twice independently 
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Figure 6. 5: SIRP knockdown reduces the growth of INS-1E cells 
INS-1E cells were cultured and transfected with siRNA SIRP for 96h and cells 
were harvested and live cells counted after staining with trypan blue. 
Data represents mean values of experiments performed three times ±SEM. 
*p<0.05, ***p<0.001, determined by student t-test. 
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Figure 6. 6: SIRP knockdown increases cell death in INS-1E cells 
INS-1E cells were cultured in serum-withdrawn conditions with and without 
SIRP knockdown in the absence and presence of IL-13 for 96h. Cell viability 
was assessed by flow cytometry after propidium iodide staining.  
Data represents mean values of 3 independent experiments ±SEM, ***p<0.001, 
determined by the student t-test. 
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Figure 6. 7: SIRP knockdown is reversed to normal levels by stimulation with  IL-13 
for 48h  
INS-1E cells were depleted of SIRPusing small interference RNA followed by IL-13 
stimulation. RNA was extracted and cDNA synthesized for qPCR using SYBRGreen.  
Data represents mean values of experiments performed twice independently ±SEM.  
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Figure 6. 8: SIRP knockdown induces an increase in DNA fragmentation in beta cells 
Cell cycle analyses were performed on INS-1E cells following SIRP 48h knockdown. Cells 
were fixed with 95% ethanol followed by PI staining after treatment with RNAse A and 
analysed on a flow cytometer. Panel a. shows representative plots of control and SIRP 
cell cycle analysis. There was no significant difference in the G0G1 and G2/M+S (proliferation 
phase) while the M6 (Sub G0G1) was significantly increased in SIRP knockdown 
treatment.  b. is a plot of normalised cell cycle analysis values. 
Data represents mean values from three independent experiments ±SEM. ***p<0.001, 
determined by the student t-test. 
a. 
b. 
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6.3.3 SIRP overexpression protects INS-1E beta cells from serum withdrawal 
induced death 
Since SIRP knockdown causes a clear increase in INS-1E cell death, it was 
assessed whether increasing the expression of SIRP could induce the opposite 
effect. In these experiments, SIRP was overexpressed under conditions of 
serum withdrawal using a commercially obtained construct in which SIRP cDNA 
was placed under the control of a CMV promoter (Origene, UK), and thus 
stimulated a constitutive expression of the protein (Fig. 6.2). Initially, INS-1E cells 
were transfected with this construct, and the over-expression of SIRP was 
confirmed by western blotting after 24h (Fig. 6.9). Cytotoxicity assays were then 
performed by transfecting INS-1E cells with the SIRP plasmid, followed by a 
96h period of serum withdrawal. Overexpression of SIRP in control medium 
significantly reduced cell death compared to the empty vector transfection 
(Control: 12.6±0.9%, Control+SIRP plasmid: 8.5±0.5%, cell death p<0.001). As 
expected serum deprivation enhanced INS-1E cell death (Control: 12.6±0.9%, 
SW: 51.9±2.0% cell death, p<0.001). Importantly, overexpression of SIRP 
strongly reduced the level of cell death in INS-1E cells under these conditions 
(SW: 51.9±0.9%, SW+SIRP plasmid: 38.0±1.1% cell death, p<0.001). Taken 
together, these data suggest that SIRP is a novel regulator of beta cell viability. 
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Figure 6. 9: SIRPwas overexpressed in INS-1E cells 
INS-1E cells were transfected with the SIRPclone for 24h with Lipofectamine LTX 
reagent. Cells were then washed, lysed and western blotting performed. Membranes 
were probed with anti-sera against SIRP and GAPDH for loading control. 
Data represents results of experiments performed twice independently.  
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Figure 6. 10: Overexpression of SIRP protects INS-1E cells from serum withdrawal 
induced death 
INS-1E cells were cultured under serum withdrawn (pink bars) conditions for 96h, 
either untransfected (grey circles) or after transfection (filled hexagons) with a plasmid 
encoding SIRP. Cell viability was assessed by flow cytometry after PI staining.  
Data represents mean values of experiments performed 3 times independently ±SEM 
***p<0.001, determined by the student t-test. 
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6.3.4 INS-1E and human islets cells express the SIRP ligand CD47 and this is 
lost from beta cells of T1DM individuals  
SIRPbecomes activated when it binds to its cognate ligand CD47, and this 
event precipitates the phosphorylation of key tyrosine residues on the 
cytoplasmic tail of SIRP (Matozaki et al., 2009). In macrophages, the binding of 
CD47 to SIRPprevents phagocytosis, and the system thus functions as a “don’t 
eat me” signal (Ayi et al., 2016). Since the expression of CD47 has not been 
examined in pancreatic beta cells we set out to investigate this in beta cell lines, 
isolated human islets and in human pancreas sections. Western blotting analysis 
revealed that both rodent beta cells and human islets express CD47 (Fig.6.11).  
To study the expression of CD47 in situ within the pancreas, 
immunohistochemical staining was performed on FFPE human pancreatic 
sections from non-diabetic individuals using an antiserum raised against CD47. 
This revealed that CD47 is expressed within the islets of Langerhans, with very 
little specific staining observed in the exocrine pancreas. CD47 staining was 
intense in the cytoplasm of the cells, on the plasma membrane but it was not 
found in the nucleus. Within the islets, the staining of some cells was more 
intense than others (Fig.6.12). In order to identify which islet cells express CD47, 
co-immunofluorescence staining of 6 pancreatic sections from 3 individuals with 
T1DM and 3 age and sex matched non-diabetic controls was performed (Table 
15). Insulin was used as a marker of beta cells and glucagon as a marker for 
alpha cells (Richardson et al., 2016, Arif et al., 2014, Leete et al., 2016, 
Kobayashi et al., 2008). Using cyan for insulin, red for glucagon and green for 
CD47 the immunofluorescent staining confirmed our previous observation that 
CD47 is expressed within the islets of individuals without diabetes. Interestingly, 
the expression of CD47 was more intense in the beta cells than the alpha cells 
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within the islets. To quantify this, the mean fluorescence intensity was acquired 
and processed using a MATLAB script (Alpha; 49.79±1.4, beta; 58.3±1.8 MFI 
p<0.001) (Fig.6.14). Sections from individuals with T1DM were then studied using 
the same microscope and camera settings as the non-diabetic control sections. 
As expected, CD47 staining was expressed within the islets, however rather 
surprisingly, the expression of CD47 in insulin containing beta cells was less 
intense than that in alpha cells in the sections from individuals with T1DM. The 
mean fluorescence intensity was evaluated and this confirmed these 
observations (T1D alpha: 60.36 ± 2.7, T1D beta cells: 49±2.2, p<0.01). The mean 
fluorescence intensity results obtained from non-diabetic controls were then 
compared with those of T1DM individuals and revealed a reduction in CD47 
expression in T1DM donor beta cells (control beta cells; 58.3±1.8, T1D beta; 
49±2.2 p<0.001). Interestingly, CD47 was upregulated in the alpha cells of 
individuals with T1D when compared to matched controls (control alpha cells; 
49.8±1.4, 60.4±2.7 p<0.001). 
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Figure 6. 11: Isolated human islets and rat beta cells express CD47 
INS-1E cells  a. and human islets b. were lysed, western blotting performed and probed 
for CD47 expression with GAPDH as loading control.  
Data represents results of experiments performed thrice independently. 
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Figure 6. 12: Human islets express CD47 
Pancreatic tissue section from an individual without diabetes. Formalin-fixed 
paraffin embedded pancreas sections were stained for CD47 using an 
immunoperoxidase approach.  
CD47 is highly expressed in the islets as indicated by the intense brown staining. 
There is some exocrine expression, which on the cell surface membrane.  
 Scale bar 50m  
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Figure 6. 13: CD47 is expressed in beta cells and is diminished in T1D 
Pancreatic tissue section from an individual without diabetes. Formalin-fixed paraffin embedded pancreas sections were stained using 
co-immunofluoresence approach for insulin (blue), glucagon (red), CD47(green) and the nuclear stain DAPI. In control the case, CD47 
is expressed predominantly in the beta cells while in the T1DM case seems to be more expressed in the alpha cells. Scale bar 50m 
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Figure 6. 14: CD47 is reduced in T1DM beta cells and increased in alpha cells 
Identical settings were established to collect images and these images were then 
quantified by measuring the mean fluorescent intensity (MFI) of CD47, insulin, and 
glucagon in insulin containing islets (ICI). The images were then imported into a Matlab 
script, VIOLA, to measure CD47 MFI only in cells containing insulin or only in cells 
containing glucagon. Data was collected from 7 islets/case (3 T1DM individuals and 3  
individuals without diabetes). Data represents mean values ±SEM, **p<0.01 in arbitrary 
units (AU), determined by the student t-test. 
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6.3.5 CD47 is upregulated by IL-13 and IL-4 stimulation 
Next we investigated whether stimulation of INS-1E cells with IL-4 or IL-13 
affected the levels of CD47 using RT-qPCR. CD47 was upregulated 1.5 fold by 
both cytokines when compared to the unstimulated control. In these experiments, 
an additional question was addressed in order to establish whether the 
upregulation was STAT6 dependent. Knock down of STAT6 alone did not affect 
CD47 mRNA levels. However, the addition of IL-13 or IL-4 after STAT6 knock 
down did not lead to any increases in mRNA levels of CD47, indicating STAT6 
knockdown blocks the upregulation of CD47 by IL-4 and IL-13 stimulation (Fig 
6.15). 
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Figure 6. 15: IL-4 and IL-13 upregulated CD47 in INS-1E cells 
INS-1E cells were stimulated for 48h with 20ng/mL of IL-4 (◊) or IL-13 (Δ) after 
48h small interference STAT6 knockdown(filled shapes). RNA was harvested 
and cDNA synthesized. qPCR was performed and results analysed. 
Data represents qPCR fold change means of experiments performed three 
times ±SEM *p<0.05, **p<0.01, determined by the student t-test.  
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6.4 Discussion 
6.4.1 SIRP is important in controlling beta cell viability 
It had been established in the previous chapter that STAT6 controls the 
expression of SIRP, and here it was shown that this response occurs in rodent 
and human clonal beta cells, and also in primary human islets. The regulation of 
SIRP by STAT6 has not previously been reported in beta cells. These data also 
revealed that depletion of SIRP expression results in a significant decrease in 
beta cell viability in the absence of other cytotoxic stimuli. Cell cycle analysis 
confirmed an increase in DNA fragmentation in SIRP knockdown cells indicating 
increased apoptosis. The knockdown of SIRP significantly increased beta cell 
death when cells were incubated under conditions of serum withdrawal. 
Conversely, overexpression of SIRP by transfection, protected beta cells from 
serum withdrawal-induced cell death. Surprisingly, knockdown of SIRP followed 
by IL-13 treatment offered cytoprotection in serum withdrawal conditions albeit 
with lower efficacy. This observation could be explained by the fact that SIRP 
lies downstream of STAT6, hence depletion of SIRPby siRNA was reversed by 
introducing IL-13 and the consequent activation of STAT6 (Fig 6.7).  
Cell death attributed to loss of SIRP has not been studied in beta cells 
previously, however, similar findings have been reported in neutrophils (Stenberg 
et al., 2013) and in fibroblastic reticular cells (Saito et al., 2017). Additionally, 
knockdown of SIRP in neuronal cells of mice has been shown to induce caspase 
3 upregulation and downregulation of BCLXL (Huang et al., 2017), suggesting 
that, loss of SIRPmight induce caspase 3 activity and loss of anti-apoptotic 
BCLXL leading to beta cell death.   
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Taken together, these observations imply that SIRP might be central to the 
protection offered by IL-13 in beta cells and more broadly that SIRP may be a 
novel regulator of beta cell viability.  
6.4.2 The potential mechanism by which SIRP protects beta cells 
In this present work, it was shown that SIRP is important for beta cell survival, 
suggesting that it acts on a signalling cascade to prevent apoptosis. The precise 
mechanism by which SIRP reduces apoptosis is still unclear. However, in 
smooth muscle cells stimulated with IGF, SIRPrecruits PDK1 through Grb2 
leading to the activation of the Akt pathway. The activation of Akt leads to the 
subsequent activation of FOXO1 to prevent it from trans-activating BIM hence 
inhibiting apoptosis in these cells (Shen et al., 2010). IGF1 has been shown to 
protect beta cells from apoptosis, and to be important in beta cell proliferation and 
differentiation (Mallol et al., 2017, George et al., 2002, Maile and Clemmons, 
2002). Alternatively, it was also revealed by the same group that SIRP can 
recruit STAT1, which is known to transduce apoptotic signals mediated by 
interferons (Shen et al., 2009). The binding of SIRP by STAT1 was shown to be 
independent of SIRPphosphorylation. It is conceivable that an increase in the 
level of SIRPmay lead to sequestration of cytoplasmic STAT1, hence depleting 
the availability of STAT1 for interferon activation and in turn inhibit the 
propagation of apoptotic signalling. In this regard, it is unclear if IGF can stimulate 
the activity of SIRP in beta cells and future experiments could usefully examine 
this. 
Growth hormone activation of Jak2 leads to the phosphorylation of SIRPin 
fibroblasts, and this has been shown to enhance its binding to SHP2 suggesting 
an important role in growth hormone signalling and cell proliferation (Stofega et 
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al., 1998). This implies that knockdown of SIRP in INS-1E cells may inhibit 
growth or survival signals initiated by growth factors in culture media. Additionally, 
beta cells are known to express SHP2 which has been shown in knockout mice 
studies to be important in the production and secretion of insulin. In that report, 
the PI3K pathway showed reduced activation in the SHP2 pancreatic knockout 
mice, when compared to controls. Additionally, there was reduced PDX1, GLUT2 
and phospho-FOXO1 activation in SHP2 pancreatic knockout mice(Zhang et al., 
2009). PDX1 is important for beta cell identity, GLUT2 for glucose uptake or 
sensing and FOXO1 to inhibit apoptosis (Fujimoto and Polonsky, 2009). 
Grb2 and HSP70 are also reported to bind to SIRP (Shen et al., 2009) and both 
are present in human beta cells where they are crucial for beta cell survival (Hügl 
et al., 1998, Welsh et al., 1995, Rütti et al., 2016). The majority of these studies 
have been performed in other cell types and the mechanisms by which the growth 
factors activate SIRP are still not known. SIRP has, however, been reported 
to provide a scaffold for multi-protein complexes essential for the transmission of 
signals but these need to be studied in the context of beta cells (Timms et al., 
1999).  
Based on the experiments performed in this chapter using serum withdrawal 
which induces cell death by depletion of the anti-apoptotic protein BCLXL (Tejedo 
et al., 2001, Goyeneche et al., 2006), it can be suggested that SIRP protects 
from cell death by activating the Akt pathway leading to the activation of FOXO1. 
FOXO1 activation inhibits the activation BIM hence preventing mitochondrial 
permeabilisation by the Bak/Bax complex (Fig. 6.16). Future experiments could 
examine the protection of beta cells from pro-inflammatory cytokines by SIRP. 
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Figure 6. 16: Possible mechanisms by which SIRP protects  
STAT6 activation leads to the upregulation of SIRP, which can be activated by binding 
to CD47, PDGFR or IGFR leading to the recruitment of either STAT1, Grb2, SHP1, and 
SHP2. Recruitment of STAT1 could diminish interferon signalling, while Grb2, SHP1 and 
SHP2 can lead to the activation of the Akt and Erk pathways leading to the upregulation 
of anti-apoptotic proteins or cell proliferation.  
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6.4.3 SIRP and beta cell function 
SIRP has rarely been studied in the pancreatic beta cell, with only a single report 
examining its expression in these cells (Kobayashi et al., 2008). In that report, 
the investigators proposed a novel role for SIRP in the regulation of insulin 
secretion. They used mice depleted of SIRP specifically in the pancreas and 
found effects on insulin secretion in animals fed on high-fat diet when compared 
to wild type controls. These data suggest that SIRP plays a role in promoting 
insulin secretion. It was also shown using immunohistochemical staining that 
SIRP was expressed in the islets of Langerhans and within the islets specifically 
in beta cells alone (Kobayashi et al., 2008) and this differed from our findings. 
Kobayashi and colleagues, used rat pancreas tissue while our tissues were of 
human origin and much older than their tissues which could account for the 
differences (Karlsson and Karlsson, 2011). Additionally, rat tissues were 
permeabilised with 0.1% triton X overnight at 40C after antigen retrieval while our 
tissue was permeabilised by use of methanol. In muscle cells, SIRP is able to 
recruit SHP-2 (which we have shown to be expressed in INS-1E beta cells) (Maile 
and Clemmons, 2002) and loss of SHP-2 from beta cells causes a decrease in 
glucose stimulated insulin secretion (Zhang et al., 2009). These data may imply 
that perhaps SIRP and SHP2 could interact to positively regulate insulin 
secretion. This might occur through the maintenance of beta cell identity (PDX1) 
and by maintaining GLUT2 expression as it is important in glucose sensing 
(Zhang et al., 2009). This hypothesis has not been tested in beta cells. 
6.4.4 CD47 and beta cell survival  
The extracellular region of SIRP binds to its ligand CD47 to induce a 
bidirectional signal that has been implicated in migration, cell survival and 
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proliferation (Kobayashi et al., 2008, Matozaki et al., 2009). CD47 is expressed 
on most somatic cells (Ayi et al., 2016, Bian et al., 2016, Per-Arne, 2013), and 
here using immunohistochemistry its expression in pancreatic beta cells was 
revealed. Indeed its expression on these cells was higher than that on other 
pancreatic cell populations. This result agrees with that of Kobayashi and 
colleagues in mice (Kobayashi et al., 2008) and with RNA sequencing data from 
human islets (Segerstolpe et al., 2016). In tissue sections from individuals with 
T1DM, we noticed an unexpected decrease in the expression of CD47 in beta 
cells although the mechanism remains unclear.  
The novel observation of the reduction in CD47 in beta cells may impact on the 
recognition of pancreatic beta cells as “self” (Per-Arne, 2013). Loss of CD47 in 
pancreatic beta cells might make them more vulnerable to immune attack. The 
loss of CD47 has been linked to increased surface expression of calreticulin and 
phosphatidylserine suggesting enhanced phagocytic clearance of CD47 depleted 
cells (Gardai et al., 2005). Additionally, loss of CD47 in TCR transgenic mice has 
been shown to break immune tolerance leading to autoimmune diabetes (Dugas 
et al., 2010). In immune cells such as neutrophils, decreased expression of CD47 
leads to increased phagocytosis by macrophages (Lawrence et al., 2009), 
conversely, overexpression decreased neutrophil apoptosis and phagocytosis 
(Barrera et al., 2017).  
Interestingly, as the expression levels of CD47 diminished in T1DM beta cells, 
expression of this molecule in the alpha cells was increased. One explanation for 
the diminished CD47 expression in beta cells could be that loss of STAT6 (also 
observed in sections from individuals with T1DM), leads to the decreased 
expression. It is not clear why alpha cells in T1DM tissue sections have an 
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increased expression of CD47 but reports from cancer studies (Cook and Soto-
Pantoja, 2017, Jaiswal et al., 2009) suggest that such upregulation enhances the 
proliferation and protects from immune attacking. This could explain why alpha 
cells are spared in T1DM and how they evade the immune attack during insulitis 
(Habener and Stanojevic, 2012). Another intriguing possibility might be a case of 
beta cells transdifferentiating due to inflammation, changing their phenotype to 
alpha cells but still retaining CD47 expression (Nordmann et al., 2017). In support 
of this conclusion, it was observed that not all alpha cells in T1DM have elevated 
CD47 expression and that the number of alpha cells was generally higher in 
T1DM islets when compared to relevant controls. 
Data arising from qPCR analysis suggest that IL-4 and IL-13 can induce 
upregulation of CD47 mRNA in beta cells in a STAT6 dependent manner. Also, 
the data revealed that knockdown of STAT6 did not directly alter the expression 
level, suggesting that other factors regulate CD47 expression under basal 
conditions. Individuals with T1DM have been reported to have reduced levels of 
IL-4 and IL-13 (Kikodze et al., 2013, Alnek et al., 2015) and STAT6 (Leslie et al., 
2018), suggesting that beta cells may not be able to upregulate CD47 during 
inflammation and that this could lead to enhanced phagocytosis and clearance of 
CD47 depleted cells (Lawrence et al., 2009). 
6.4.5 Conclusion 
In summary, SIRP is an IL-13 regulated gene in beta cell lines and human islets 
and might play an important role in beta cell survival. SIRPwas shown to be 
important for beta cell survival as the knockdown of this gene led to significant 
beta cell loss and its overexpression protected beta cells from cytotoxicity. The 
mechanism of protection by SIRP in beta cells remains to be clarified. The 
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binding of SIRP to its cognate receptor CD47 may be one of the ways by which 
this protection is achieved. CD47 expression was significantly decreased in beta 
cells of sections from individuals with T1DM and this could impact the 
phagocytosis of these cells. Additionally, the loss in CD47 could lead to 
upregulation of “eat me” signals such as calreticulin (Gardai et al., 2005).  
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7.0 Discussion  
The incidence of type 1 diabetes is increasing in children below the age of 15 
years and is predicted to double between 2005 and 2020 (Patterson et al., 2009, 
Patterson et al., 2018). It is estimated that approximately 35,000 children under 
the age of 19 live with T1DM in the UK and that the prevalence among children 
under the age of 14 is about 24.5 per 100,000 (Patterson et al., 2009). The 
pathophysiology of type 1 diabetes is not completely understood. Our present 
understanding suggests there is a complex interaction between environmental 
factors, genetic susceptibility and the immune system (Copenhaver and Hoffman, 
2017). GWA studies have identified susceptibility genes that may predispose 
individuals to T1DM yet only about 33% of high-risk carriers develop the disease, 
implicating a role for other factors (Steck and Rewers, 2011). Environmental 
factors implicated include viruses, bacteria, lack of vitamin D, and geographical 
location (Knip and Simell, 2012).  
The involvement of the immune system in T1DM is serologically established by 
the presence of auto-antibodies, generated against particular islet proteins 
(Siljander et al., 2009). Immune cell infiltration of the islets of Langerhans has 
been verified in rare human T1DM pancreatic tissue demonstrates the presence 
of different immune cell subsets (Arif et al., 2014, Morgan et al., 2014). One route 
through which these infiltrating immune cells can impact on beta cell function and 
survival is via the secretion of specific cytokines. There is evidence to suggest 
that beta cell death occurs as a result of an imbalance between the secretion of 
pro-inflammatory and anti-inflammatory cytokines (Souza et al., 2008, Berchtold 
et al., 2016). Work on the detrimental effects of pro-inflammatory cytokines on 
beta cells has been extensive (Moore et al., 2011, Cetkovic-Cvrlje and Eizirik, 
1994, Russell and Morgan, 2014, Pirot et al., 2008, Souza et al., 2008, Collier et 
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al., 2011) but, the action of “anti-inflammatory” cytokines on pancreatic beta cells 
has received far less attention. This thesis sought to investigate the actions of 
two such anti-inflammatory cytokines, IL-13 and IL-4, and examine their role in 
protecting beta cells from cytotoxicity. The role of the transcription factor STAT6, 
activated in response to receptor binding of both these cytokines, was studied in 
detail.  
The first part of the thesis investigated the capacity of IL-13 and IL-4 to protect 
beta cells from cell death induced by exposure to different cytotoxic stimuli (serum 
withdrawal, palmitic acid, and pro-inflammatory cytokines). The second 
component explored the signalling pathways stimulated by IL-13 in beta cells and 
the expression of genes regulated by IL-13. The third part of the work studied the 
impact of manipulating STAT6 levels in the response to IL-13 either by using 
small interference RNA to deplete STAT6 expression or by transfecting an 
expression plasmid to enhance STAT6 levels or to constitutively activate or inhibit 
STAT6 activation. Finally, the genes upregulated by IL-13 stimulation were 
examined to better understand the mechanisms of cytoprotection from 
cytotoxicity in beta cells. 
7.1 Overview of IL-13 cytoprotective phenotype 
IL-13 was shown to exert a potent protective effect against a range of cytotoxic 
stimuli in beta cells (pro-inflammatory cytokines, serum withdrawal and palmitate) 
using rat beta cell lines. IL-13 treatment of human derived beta cell line EndoC 
H1 also protected from pro-inflammatory cytokine induced cell death. The 
precise mode of protection is still not completely known, however, the finding that 
IL-13 can protect against multiple cytotoxic stimuli suggests that several different 
anti-apoptotic pathways may be activated. These multiple cytotoxic stimuli 
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activate apoptotic pathways in beta cells via activation of caspase 3 (serum 
withdrawal, TNF- and palmitate), Caspase 8 (TNF-), Caspase 9 (serum 
withdrawal), depletion of BCLXL and induction of nitric oxide (IL-1IFN-) (Cnop 
et al., 2005, Yang et al., 2015, Tomita, 2017, Eizirik et al., 2009). These results 
are in accord with previous studies (Kaminski et al., 2007, Kaminski et al., 2010, 
Russell et al., 2013, Rütti et al., 2016). Furthermore, the protection may be 
relevant in vivo since treatment of NOD mice with IL13 (or IL-4) reduces the 
incidence and slows the rate of acquisition of diabetes in this mouse model 
(Zaccone et al., 1999, Cameron et al., 1997, Mi et al., 2004). Importantly, 
individuals with T1DM have been shown to have defective invariant natural killer 
T-cells known to secrete IL-13 that can modulate effector T-cells in T1DM (Usero 
et al., 2016). 
7.2 The Jak/STAT6 signalling in the pancreatic beta cell 
Given that IL-13 has a protective effect on pancreatic beta cells, it was important 
to understand the underlying mechanisms by which IL-13 might protect. Typically, 
IL-13 signals by binding to its cognate receptor, IL-13R1 leading to the 
recruitment of a receptor component IL-4Rto form a heterodimerAlternatively 
IL-13 can also bind to IL-13R2 monomer. IL-13 binds to IL-13R2 with a higher 
affinity and although its downstream signalling had initially proved elusive due to 
its short cytoplasmic tail, evidence now suggests that this monomer could be 
involved in inducing TGF-1 production (Fichtner-Feigl et al., 2005). The biology 
of this second receptor has not been studied in the context of beta cells or T1DM. 
However, the receptor expression is thought to be very low since RNAseq failed 
to detect IL-13R2 in beta cells of humans (Segerstolpe et al., 2016). The 
heterodimer formation between IL-4R and IL-13R1 or between IL-4Rand C 
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brings their associated Jak kinases into close proximity leading to trans 
phosphorylation. The activated Jaks, in turn, phosphorylate specific tyrosine 
residues in the receptor leading to the recruitment of STAT6 to the 
phosphorylated docking sites and its subsequent activation (Russell and Morgan, 
2014).  
It was shown in the present work that INS-1E beta cells express all four Jaks, but 
that these are activated with differing kinetics following treatment with IL-4 and 
IL-13. The differing activation kinetics of the Jaks could explain the differences in 
pathways known to be activated by IL-13 stimulation (pSTAT3, pSTAT6 and 
PI3K/Akt ) (Russell et al., 2013). Importantly, each receptor monomer can recruit 
up to two different Jaks since they possess Box regions, which are used by the 
FERM domains in Jaks to bind to receptors (Ferrao and Lupardus, 2017, 
Usacheva et al., 2002, Noon-Song et al., 2011, Umeshita-Suyama et al., 2000). 
This work demonstrates that IL-13, as well as IL-4 stimulation of INS-1E cells, led 
to the phosphorylation of all four Jaks. It will be important in the future to ascertain 
if a particular Jak or Jaks is recruited to either the IL-4R or the IL13R1. This 
could be done either using co-immunoprecipitation assays, to determine which 
Jak is pulled down with each receptor or site directed mutagenesis by mutating 
specific residues in either the Box (receptor) or the FERM (Jaks) domains and 
examining if this alters the outcome of IL-13 or IL-4 treatment. Based on the 
experiments of Russell et al., (2013), the activation of STAT6 and the protection 
offered by IL-13 against cytotoxicity were reduced after Jak2 inhibition, 
implicating Jak2 in the signalling pathway. This correlated well with western blot 
analysis (Fig 4.9), which suggested that knockdown of Jak2 reduced STAT6 
activation in response to IL-13. Other studies suggest that IL-4 requires Jak3 
activation to mediate its protection (Kaminski et al., 2010).  
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In our previous experiments and reports by others, it was shown that both the 
PI3K/Akt and the Jak/STAT signalling pathways are activated by IL-4 and IL-13 
in beta cells (Russell et al., 2013, Kaminski et al., 2010, Rutti et al., 2016). 
However, using a PI3K/Akt inhibitor wortmannin, it was reported that IL-13 was 
still able to protect beta cells from serum withdrawal induced cell death (Russell 
et al., 2013), implying that the Jak/STAT signalling is more likely to be involved in 
cytoprotection than the PI-3K/Akt pathway, although other investigators have 
argued the contrary (Rütti et al., 2016). In future experiments, an alternative 
method to show that the contribution of the PI-3K/Akt to the protection afforded 
by IL-13 will be to perform a site directed mutagenesis or CRISPR on the IL-4R 
receptor at tyrosine 497 position reported to recruit IRS2 which activates the 
pathway (Nelms et al., 1999). 
 The use of a Jak/STAT specific PCR array panel to identify genes modulated 
during IL-13 stimulation identified a variety of genes with altered expression. A 
proportion of these were confirmed at both the RNA levels using gene specific 
primer qPCR assays and at the protein level, by Western blotting. Amongst these 
genes, the upregulation of signal regulatory protein alpha (SIRP) was 
demonstrated for the first time. This prompted an investigation into its role in beta 
cells. Encouragingly, MCL-1 and BCLXL and SOCS-1 were also upregulated at 
both the RNA and protein level and these have been previously shown to protect 
beta cells from cell death both in vitro and in vivo (Allagnat, 2010, Carrington et 
al., 2009). Additionally, It was shown that IL-13 and IL-4 upregulated the 
expression of STAT6 itself, implying the presence of a positive feedback loop. 
Taken together, this implies that pre-incubation of cells with IL-13 upregulates 
anti-apoptotic proteins such as SOCS1, BCLXL, and MCL-1 and these likely are 
involved in the cytoprotection observed. Other genes that were upregulated but 
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not directly studied in this work were GRB2, JunB, Jun, Crk, and SH2B1. These 
have also been shown to regulate beta cell health and might contribute to the 
cytoprotective effects of IL-13 (Gurzov et al., 2008, Chen et al., 2014, Scarim et 
al., 2003, Hügl et al., 1998, Lee et al., 2004). Further genes implicated in the 
regulation of inflammation and not directly studied here include PIAS1 and PIAS2. 
PIAS1 & 2 are known to inhibit STAT1 and STAT2 signalling by binding to the 
activated homo or heterodimers of STAT molecules to prevent DNA binding (Liu 
et al., 2015a). As aberrant STAT1 signalling has been observed in T1DM 
(Richardson et al., 2016), these molecules may warrant future attention. Figure 
7.1 details the current understanding of the IL-4 and IL-13 signalling in pancreatic 
beta cells. 
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Figure 7. 1: A schematic representation of the present understanding of Jak/STAT6 
signalling in beta cells 
Stimulation of beta cells with IL-4 or IL-13 recruits receptor components that leads to 
trans-phosphorylation of Jaks. Activated Jaks then phosphorylate tyrosine residues on 
the receptor cytoplasmic tail exposing docking sites wherein STAT6 is recruited and 
activated. Activated STAT6 then migrates to the nucleus where it regulates the 
expression of genes. 
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7.3 The role of STAT6 in IL-13 signalling  
The core of the thesis was to investigate the role of STAT6 in IL-13 mediated 
cytoprotection of beta cells. To achieve this, STAT6 expression and activity were 
either reduced or increased, through the use of small interference RNA or a 
STAT6 expression plasmid. Somewhat surprisingly, knockdown of STAT6 alone 
did not affect beta cell viability. Nevertheless, the data reveal that STAT6 
facilitates the IL-13 induced protection of beta cells since knockdown of STAT6 
attenuated the protective effect of IL-13 following stimulation with pro-
inflammatory cytokines, palmitate or serum withdrawal. Knockdown of STAT6 
also revealed that many of the genes that were upregulated in response to IL-13 
and IL-4 (SIRP, SOCS-1, MCL-1 and BCL2L1) were modulated by STAT6 
confirming the key role of STAT6 in IL-13 mediated protection. Given the results 
of knockdown studies, alternative validation of these findings using a STAT6 
expression vector was performed. Using site-directed mutagenesis, a STAT6 
expression vector was used to create a constitutively active and dominant 
negative form as described by Daniel et al. (2000). These variant forms behaved 
as expected when assayed using a luciferase reporter system. Their use in 
viability assays showed subtle protection from pro-inflammatory cytokines by 
constitutively active STAT6 but this did not achieve statistical significance. It was 
noticed, however, that the dominant form by itself was detrimental to beta cell 
survival. The low transfection efficiency of the INS-1E cells was a particular 
challenge and made it difficult to interpret results arising from the experiments 
with STAT6 variants. In an attempt to overcome this, co-transfection of the STAT6 
variants with a GFP construction was performed. The theory being that the GFP 
transfected cells are more likely to be transfected with STAT6 (co-transfection 
principle). However, we cannot guarantee that the identified cells are transfected 
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with both the GFP and the STAT6 plasmid and the results were not sufficiently 
clear to draw firm conclusions. In the future, it may be beneficial to generate 
stably transfected cells or use CRISPR technologies to generate cells containing 
variant forms of STAT6. 
This work also demonstrates that the loss of STAT6 leads to a decline in anti-
apoptotic proteins MCL-1 and BCLXL and an increase in the expression of the 
MHC class I subunit, B2M. These findings align with studies of pancreatic tissue 
from donors with T1DM in whom B2M expression is increased in insulin 
containing islets (Richardson et al., 2013, Richardson et al., 2016). Furthermore, 
immunohistochemical staining of pancreatic sections revealed a decrease in the 
expression of MCL-1 in certain islet cells in T1DM, when compared to individuals 
without diabetes (Richardson et al., 2013).  
Collectively, this work has demonstrated a role for STAT6 in the protection of 
rodent and human beta cells against cytotoxic stimuli. It was further shown that 
the loss of STAT6 can occur following exposure to cytotoxic stimuli and that the 
use of IL-13 and IL-4 could rescue such loss. Importantly, STAT6 expression is 
reduced in the islets of individuals with T1DM (Leslie et al., 2018), suggesting 
that the beta cells in these islets may be more susceptible to death induced by 
cytokines elaborated by infiltrating immune cells, potentially through reduced 
expression of anti-apoptotic molecules like MCL1. These cells may also have 
enhanced visibility to influential immune cells. The loss of STAT6 and its 
contribution to beta cell health is schematically represented in Figure 7.2. 
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CD8+ 
Figure 7. 2: Schematic showing how the Loss of STAT6 could contribute to beta cell 
loss in  T1DM 
Under stress, STAT6 expression is reduced, this leads to decreased MCL-1, BCLXL 
and SOCS1 expression but in contrast leads to increase B2M expression. The 
decrease in anti-apoptotic proteins enhances apoptosis, while increase in B2M leads 
to MHC class I expression and hence prompting immune cells which infiltrate and 
secrete more detrimental cytokines 
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7.4 The role of SIRP and its ligand CD47 in beta cells 
This work demonstrates for the first time that IL-13 and IL-4 lead to a significant 
and strong upregulation of SIRP expression in beta cells. As very little was 
known about the role of this protein in beta cell survival, additional investigations 
were carried out. It was shown that SIRP is expressed in rodent and human 
beta cell lines and in human islets by western blotting. Strikingly, knockdown of 
this protein with small interference RNA induced beta cell death directly. SIRP 
has only been previously described in a single study in pancreatic islets of rodent 
models, wherein pancreatic specific knockout affected insulin secretion 
(Kobayashi et al., 2008) but no information about its impact on beta cell viability 
was provided. Importantly, the study of SIRPin other cell systems has revealed 
that it sequesters a number of binding partners, including Grb2, PDK1, Jak2, 
STAT1 and SHP2. Intriguingly, all of these molecules have been associated in 
other studies with the control of beta cell viability (Shen et al., 2009, Zhang et al., 
2009, Shen et al., 2010). The increased expression of SIRP in beta cells 
exposed to IL-13 or IL-4 may therefore impact on the function of these molecules 
and subsequent downstream pathways. The ability of SIRP to bind to these 
molecules has not yet been studied in beta cells but may be important since an 
alteration in some of these interactions may facilitate either loss or improvement 
in cell viability. For example, reduced levels of SIRP could result in the inhibition 
of the SHP2, Grb2 and PDK1 mediated activation of the Akt cytoprotection 
pathway (Shen et al., 2009). Future study of these binding partners in beta cells 
might shed light on the mechanism of death caused by SIRP knockdown. 
 In the present study, a SIRP expression plasmid was used to artificially 
increase SIRP levels and study the impact on apoptosis induced by serum 
287 
 
withdrawal. This revealed that the upregulation of SIRP might play an important 
role in the protection of beta cells from cytotoxicity although the precise 
mechanism of cytoprotection remains to be determined. SIRP is known to signal 
by binding to its associated ligand CD47 thereby transmitting signals in a 
bidirectional manner, that impact upon both phagocytosis and apoptosis 
pathways in the recipient and donor cells (Oshima et al., 2002). It was shown in 
the present work that both human and rodent beta cells express CD47, and that 
CD47 is more abundantly expressed on beta cells compared to alpha cells in 
donors without diabetes. Surprisingly, the reverse was true in individuals with 
T1DM, with expression of CD47 being reduced in beta cells and increased in 
alpha cells.  
7.5 Therapeutic potential of the IL-4/IL-13 pathway 
The findings arising from this thesis have demonstrated that IL-13 and IL-4 can 
stimulate anti-apoptotic pathways in beta cells; hence, the Jak/STAT6 presents 
a potential therapeutic targetable pathway. The administration of IL-4 and IL-13 
in vivo to reduce the incidence of T1DM has been demonstrated in NOD mice 
models of the disease and shown to be effective at decreasing the disease 
incidence (Zaccone et al., 1999, Cameron et al., 1997). The administration of IL-
13 to humans has not been reported, and the direct administration of this cytokine 
would be challenging due to a potential side effect of inducing asthma (Yang et 
al., 2001). To avoid the direct administration of IL-4 or IL-13, molecules that 
induce the secretion of either IL-4 or IL-13 could be exploited. One molecule that 
has been considered in the context of diabetes and which is known to enhance 
IL-4 synthesis is calcitriol (Vitamin D or 1, 25(OH) 2D3) (Ysmail-Dahlouk et al., 
2016). In that study, PBMCs were isolated from individuals with T1DM and non-
diabetic controls and treated with calcitriol. In the untreated samples, IL-4 
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secretion was lower in T1DM and IFN- was higher. However, treatment of the 
PBMCs with calcitriol significantly enhanced IL-4 secretion and STAT6 activation 
and reversed the production of IFN- (Ysmail-Dahlouk et al., 2016). Additionally, 
the administration a synthetic glycolipid alpha-galactosylceramide (GalCer) is 
a potent activator of invariant NKT-cells that secrete IL-13 could be used, 
although, the activity of these cells has been reported to be dysregulated in T1DM 
individuals (Usero et al., 2016, Sullivan and Kronenberg, 2005).   
Alternatively, enhancing the activity of some proteins involved in the anti-
apoptotic pathway such as STAT6, SIRP, MCL-1, SOCS1, BCLXL and PIAS1 
could serve as potential therapeutic targets. One drug that might be repurposed 
for the treatment of T1DM which could exploit the pathway is valproic acid, a 
compound used for the treatment of epilepsy, migraines and bipolar disorder 
(Chateauvieux et al., 2010). Valproic acid has been shown to increase STAT6 
and PIAS1 expression in FBR cell lines (McGarry et al., 2004), and importantly, 
to reduce beta cell apoptosis in juvenile diabetic rats although the mechanism 
was attributed to histone deacetylase inhibition (Khan and Jena, 2016).  
7.6 Conclusion 
Taken together, the data presented in this thesis revealed that loss of STAT6 
leads to a reduction in the Jak/STAT6 signalling pathway in beta cell. This does 
not directly compromise viability but it makes the beta cells more vulnerable to 
cytotoxicity. In recently published data we show that STAT6 is reduced in T1DM 
individuals, possibly due to increased pro-inflammatory cytokines secretion 
(Leslie et al., 2018), highlighting this as a potentially important dysregulated 
pathway in T1DM.  
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This loss of STAT6 will cause a reduction in anti-apoptotic proteins such as MCL-
1 and BCLXL. STAT6 depletion is also associated with reduced levels of SOCS-
1, which is a negative regulator of IFN signalling (Li et al., 2015b, Allagnat et al., 
2010, Carrington et al., 2009). Interferon signalling pathways are dysregulated in 
T1DM (Qaisar et al., 2018) and have been suggested to initiate diabetes in NOD 
mice (Li et al., 2008). Loss of SOCS1 could contribute to potentiating IFN 
signalling hence exacerbating the disease. Importantly, in this thesis, I have 
reported that IL-13 and IL-4 upregulate SIRP in beta cells and shown that SIRP 
is able to protect the cells from cytotoxicity through a still to be defined 
mechanism. The depletion in STAT6 could imply an eventual loss in SIRP that 
would lead to beta cell death.  
Finally, the Jak/STAT6 pathway is shown to be critical for maintaining beta cell 
survival through a variety of mechanisms that involve the regulation of multiple 
genes, the most differentially expressed being SIRP whose loss might be 
deleterious to beta cell survival in T1DM. The updated schematic representation 
of this pathway is in Fig 7.3. 
Taken together, these data implicate STAT6 as an important regulator of beta 
cell viability.  
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Figure 7. 3: Jak/STAT6 pathway Schematic updated 
The pathway illustrates the upregulated genes upon stimulation with IL-13, some of which are anti-apoptotic MCL1, 
BCLXL, STAT6 and SIRPAlso upregulated is SOCS1, which negatively regulates STAT molecules. 
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7.7 Limitation of the study and future works 
7.7.1 Limitations  
The work presented here has focused on the role of STAT6 in beta cell 
cytoprotection afforded by IL-4 and IL-13. These cytokines are known to activate 
in addition to STAT6, both the PI-3K/Akt pathway and STAT3 Russell et al. 
(2013), which were not studied further.  
To study the role of STAT6 in controlling beta cell viability, experiments in which 
INS-1E cells were transfected with mutated forms of STAT6 with modified activity, 
did not take into account endogenously expressed STAT6, which could 
potentially skew or mask the results obtained. To resolve this, cell lines stably 
expressing these variant forms of STAT6 could be developed by cloning these 
versions into INS-1E cells using a Flp-InTM T-RExTM system or CRISPR gene 
editing technology. The Flp-InTM T-RExTM system is used to develop stable cell 
lines containing the gene of interest under the control of a tetracycline inducible 
promoter. These cells have a flippase (Flp) recombinase recognition target site 
at a transcriptionally active locus, which can be targeted to accommodate the 
gene of interest using a Flp-InTM expression vector (Senkel et al., 2009). While 
the CRISPR gene editing technology uses helicase and nuclease enzymes on 
the CRISPR associated system (CAS) protein and a guide RNA (target gene and 
tracerRNA) to specifically help edit the genome of interest to the desired 
sequence (Adli, 2018). 
The cytoprotective experiments performed in this thesis investigated on INS-1E 
cells and human derived EndoC H1 cell lines and it is not known whether these 
protective effects can occur with human islets. 
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 Immunohistochemical staining of tissue sections with anti-sera against SIRP 
did not perform as expected. There was no staining in pancreatic tissue sections 
when probed with anti-sera against SIRPThis challenge made it hard to 
validate the loss of STAT6 seen in tissue (Leslie et al., 2018), with a similar loss 
in SIRP. This could be attributed to the type of fixative used in our tissue 
samples, the antigen retrieval method or the conformation of the protein in tissue, 
which differs from the linear structures in western blotting (Ivell et al., 2014, 
Werner et al., 2000).  
7.7.2 Future works 
Future works arising from the findings in this thesis will include; 
  Further assessing the impact of STAT6 in beta cells by generating stable 
cell lines expressing the various forms of STAT6. This will validate the 
results obtained in this thesis.  
 IL-13 upregulated the expression of SIRP and in chapter 6 it was shown 
that knockdown of SIRP was detrimental to beta cells. Overexpressing 
SIRP protected INS-1E cells from serum withdrawal cytotoxicity. Hence, 
the role of SIRP in beta cell viability by overexpressing this protein in pro-
inflammatory cytokine treatments and measuring cell viability will be 
investigated. In doing this, the experiments will validate the findings that 
SIRP is one of the main mechanisms by which IL-13 protects beta cells 
from cytotoxicity. Since there is a lot of evidence implicating pro-
inflammatory cytokines (Allagnat et al., 2010, Choi et al., 2004, Collier et al., 
2011, Fatima et al., 2016, Souza et al., 2008) in beta cell loss, this could 
serve as a therapeutic target for treatment of T1DM. Additionally, the 
phosphorylation of tyrosine residues on the cytoplasmic tail of SIRP is 
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critical in modulating the activity of the protein will be studied to assess 
whether phosphorylation of these residues is important in the protective 
effects of SIRPin beta cells. SIRP activated tyrosine residues will be 
mutated by site directed mutagenesis and the viability experiments  
performed to determine the impact of each residue on beta cell survival. 
Also, these tyrosine residues can bind other proteins such as STAT1, SHP1 
and SHP2 which will be investigated using co-immunoprecipitation. The role 
of CD47 in the SIRP mediated protection will also be investigated by 
knockdown of CD47 prior to viability experiments with SIRP 
 Our PCR array detected a range of other genes, which were upregulated in 
response to IL-13 and IL-4, for example, PIAS1 and SOCS1. However, in 
this study, the impact of these proteins on beta cells survival and function 
has not been assessed. Thus additional studies to address whether some 
of these additional ‘hits’ might be important in the protective effects of IL-13 
in beta cells may well be warranted 
 A broad examination of the genes activated by IL-13 will be investigated 
using RNAseq. The results from RNAseq will be used to validate our 
findings and enable further research to understand and exploit beta cell 
protection by IL-13. 
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